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Abstract 
Protein therapeutics or biologics represent 30 % of current licensed pharmaceutical products. 
In general, biologics offer superior safety profiles compared to small molecules. However, 
significant clinical concerns have emerged in terms of development of anti-drug antibodies 
(ADAs), a phenomenon that is covered under the term, immunogenicity. Anti-drug antibodies 
can alter pharmacokinetics, reduce efficacy of the therapeutic and also can in some cases 
induce allergic reactions. Human recombinant interferon beta (IFN-β) is a biologic used for 
the treatment of multiple sclerosis (MS) – a chronic, inflammatory and demyelinating disease 
of the central nervous system. Long-term treatment with IFN-β has been shown to lead to the 
development of anti-IFN-β antibodies that can cause total loss or reduced efficacy. Anti-drug 
antibodies can be non-neutralising (N-NAb) and neutralising (NAb) depending on the site to 
which they bind.  
This study aimed to conduct a systematic review to determine factors affecting the formation 
of neutralising antibodies against three different formulations of IFN-β Avonex™, Rebif™ 
and Betaseron/Betaferon™. Findings from the systematic review highlight the relative 
differences in immunogenicity risk of different IFN-β formulations Avonex™, Rebif ™ and 
Betaseron/Betaferon™ with Avonex™ having the lowest risk, Rebif™ has moderate risk and 
Betaseron/Betaferon™ has high risk. Characterising the immunoglobulin profile of the IFN-β 
ADAs from the plasma of ADA positive MS patients revealed that IFN-β ADAs are 
predominantly of the IgG1 and IgG4 subclass. We also characterised the neutralising 
potential of the major ADA IgG4 subclass using a IFN-β bioactivity assay and show that 
IgG4 antibodies may likely contribute to the neutralisation activity. The potential of the 
neutralising ADAs to cross-react with endogenous IFN-β was investigated using an in vitro 
bioactivity assay. Findings from this set of experiments revealed varying degrees of 
neutralisation of endogenous IFN-β. We next explored the potential immunological 
consequence of ADA with regards to formation of immune complexes and activation of 
complement. The interaction of ADAs with the biologic can result in formation of immune 
complex. Immune complexes can activate the complement system. The data revealed IFN-β 
ADAs can form immune complexes with IFN-β and therefore activate complement. We also 
attempted to identify IFN-β linear epitopes that the ADAs had the ability to bind. However, a 
combination of multipin peptide technology and in vitro peptide competitive binding assay 
failed to reveal a definitive linear epitope although there was some evidence for the existence 
of potential linear epitopes. We also examined the involvement of T helper cells and T 
regulatory cells (Tregs) in ADA development. The data revealed no significant differences in 
the frequency of Tregs among IFN-β ADAs positive, negative and healthy donors. Attempts 
were also made to identify T helper epitopes within IFN-β that could potentially drive 
immunogenicity. Using T-cell epitope prediction tools (IEDB-AR and ProPred) and T-cell 
functional assays we identified an immunogenic sequence of 36 amino acids within IFN-β 
(position 130-166). Our data revealed that one IFN-β peptide within this sequence is a 
potential T-cell immunogenic epitope. In addition we identified a possible association of one 
IFN-β derived peptide with the DRB1*1501HLA haplotype.  
ix 
 
In summary, the results presented in this thesis have provided essential information on 
subclass profile of IFN-β ADAs, the possible involvement of T helper cells and potential 
antibody epitopes within IFN-β. Future studies should be aimed at providing greater detail on 
the evolution of the ADA response and test strategies to remove immunogenic determinants 
from IFN-β.   
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Chapter 1. General Introduction 
1.1 Adverse drug reactions 
1.1.1 Definition 
The World Health Organisation (WHO) states, ‘an adverse drug reaction is any response to a 
drug which is noxious, unintended and undesirable effect of the drug, which occurs at doses 
used in humans for prophylaxis, diagnosis or therapy’. Adverse drug reactions (ADR) are a 
major clinical problem and account for 2-6 % of all hospital admissions (Pirmohamed et al. 
1998). From a clinical perspective, ADR can be classified into five main groups Type A, B, 
C, D and E (Park, Pirmohamed & Kitteringham 1998). Type A reactions are predictable from 
the known pharmacology of the drug and represent an exaggeration of the pharmacological 
effect and are usually dose-dependent (for example excessive bleeding is associated with the 
use of anti-coagulants). Type B reactions are idiosyncratic and not predictable from the 
known pharmacology of the drug, have no simple dose-response and is host-dependent and 
(for example hepatitis associated with drug halothane). Type C reactions are toxicological 
and can be predicted from the chemistry of the medicine (for example hepatotoxicity with 
paracetamol). Type D reactions are delayed type reactions and include teratogenic effects 
such as congenital malformation syndromes (for example phocomelia, a birth defect is 
associated with drug thalidomide). Type E reactions are those that occur upon drug 
withdrawal (for example withdrawal seizures upon stopping phenytoin) (Park, Pirmohamed 
& Kitteringham 1998).  
The mechanisms of ADR can be due to its pharmacological (on-target) or non-
pharmacological (off-target) effects (Clarke 2010; Park 2009). On-target reactions are 
predictable from the known primary pharmacology (action of drug on its therapeutic target) 
and secondary pharmacology (action of drug on therapeutically unrelated target) (Valentin et 
al. 2009). In comparison, the off-target reactions are idiosyncratic and therefore cannot be 
predicted from the known pharmacology of the drug (Uetrecht 2008). Several off-target 
reactions are immune-mediated and represent a significant clinical problem (Kola & Landis 
2004; Lasser et al. 2002). Development of immune-mediated adverse drug reactions is 
clinically heterogeneous and accounts for 16 % of all ADRs (Hoigne et al. 1993). These 
reactions are common to both small molecule drugs and biologics. Small molecule drugs are 
chemically-derived and usually have molecular weight below 500 Daltons. Biologics are 
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biotechnology-derived proteins, peptides, antibodies, viruses and vaccines (a detailed 
description of biologics is given in Section 1.4). 
1.2 Overview of the human immune system 
This section provides a general overview of the human immune system.  
1.2.1 Introduction to human immune system  
The immune system is a complex network of cells, tissues and organs. This complex network 
works to protect an individual from external harmful microorganisms such as bacteria, 
parasites and fungi. It distinguishes self from non-self and can also have the potential to 
detect abnormally growing host cells and destroy them. 
The immune system comprises of primary lymphoid organs, which are the sites of 
lymphocytes birth and or maturation, and the secondary lymphoid organs, in which further 
differentiation of lymphocytes occurs. T lymphocytes or T-cells mature in the thymus 
whereas B lymphocytes or B-cells mature in the bone marrow. These two tissues constitute 
the primary lymphoid organs. The cervical, axillary, mesenteric, inguinal lymph nodes and 
spleen constitutes the secondary lymphoid organs. Mature, naive lymphocytes migrate 
throughout the body using the blood vessels, and encounter antigens in the secondary 
lymphoid organs. The antigen is a molecule that interacts with high affinity immunological 
receptors present on cells of the adaptive immune system (discussed later). Antigens can be 
classified into three groups, autoantigens, for example are a person’s own self antigens, 
alloantigens which are found in different members of the same species, for example red blood 
cell antigens and heterophile antigens are identical antigens which are found in the cells of 
different species. 
1.2.2 Functional elements of the human immune system  
The human immune responses are the result of the interdependent function of both innate and 
adaptive immune compartments. The salient features of innate and adaptive immune 
compartments are listed in Table 1.1 (Janeway & Medzhitov 2002). 
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 Innate (natural)  Adaptive (acquired)  
Receptors Fixed in genome 
Rearrangement is not 
necessary 
Encoded in gene segments 
Rearrangement necessary 
Distribution 
Recognition  
 
 
Self-non self discrimination 
Non-clonal 
Conserved molecular 
patterns such as LPS, LTA, 
mannans, glycans 
Perfect and selected over 
evolutionary time  
Clonal 
Proteins, peptides, 
carbohydrates 
 
Imperfect and selected in 
individual somatic cells 
Action time  Immediate activation of 
effectors  
Delayed activation of 
effectors 
Response  Co-stimulatory molecules 
Cytokines IL-1β, IL-6 
Chemokines IL-8  
Clonal expansion or anergy 
IL-2 
Effector cytokines IL-4, IFN-
γ 
   
Table 1.1: Illustrates the salient features of immune system compartments (adapted from 
(Janeway & Medzhitov 2002). 
1.2.2.1 Innate immune system 
Innate immunity is an antigen-non specific defence mechanism and can be divided into 
immediate and early induced innate immunity. Immediate innate immunity is activated 0-4 
hours after exposure to an infection and involves the action of antimicrobial enzymes, 
complement proteins, antimicrobial peptides, mechanical removal of microbes, anatomical 
barrier to infection, and bacterial antagonism by normal flora bacteria. Early induced innate 
immunity is activated 4-96 hours after exposure to an infection and involves recruitment of 
innate immune cells as a result of PAMP binding to PRR that are expressed on these cells 
(Janeway 1989). The cells of innate immune system include phagocytic cells (dendritic cells, 
neutrophils, eosinophils, macrophages and monocytes), cells that release inflammatory 
mediators (macrophages, mast cells, basophils and eosionophil) and NK cells (Akira & 
Takeda 2004; Cella et al. 1999; Medzhitov & Janeway 2002; Medzhitov, Preston-Hurlburt & 
Janeway 1997; Poltorak et al. 1998).  
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1.2.2.1.1 Complement system 
Complement system comprises of 30 soluble proteins circulating in the blood in inactive 
forms. Complement proteins are activated sequentially in response to recognition of 
molecular components associated with for example microorganisms. There are three 
complement pathways: the classical pathway, the lectin pathway and the alternative pathway 
(Sjoberg, Trouw & Blom 2009).  The ultimate product of these pathways is production of an 
enzyme C3 convertase (refer Figure 1.1). The classical complement pathway is activated by 
antibody bound to particulate antigen. However, many other substances, such as components 
of damaged cells, LPS and nucleic acids can initiate this pathway in antibody-dependent 
manner.   The classical complement pathway is initiated by activation of C1 (Morgan 2000). 
The classical complement pathway is activated when C1 (complement protein complex) 
interacts with Fc portion of the antibody molecules immunoglobulin G (IgG) or 
immunoglobulin M (IgM). The C1 protein complex consists of 3 complement proteins C1q, 
C1r and C1s. The C1q, portion of C1 complex binds to antibodies or the microbes. The 
binding activates C1r portion of C1 which in turn activates C1s. The activation of C1s 
cleaves complement protein C4 into C4a and C4b. The formation of C3 convertase cleaves 
C3 into C3a and C3b. C3b binds to C3 convertase that cleaves C5 into C5a and C5b. The 
lectin complement pathway is activated by interaction of lectins (microbial carbohydrates) 
with MBL found in body fluids. The alternative complement pathway is activated by C3b 
binding to microbial surfaces and antibody molecules.  
The three complement activation pathways converge on the activation of C3. This activation 
leads to the concluding common pathway with the assembly of C5-C9 forming 
transmembrane pore called membrane attack complex (MAC) on the cell surface and cause 
cell death by osmotic lysis (Parkin & Cohen 2001). The proteins produced by the 
complement pathways trigger inflammation, promote attachment of antigens to phagocytes, 
attract phagocytes to the infection site, cause lysis of gram-negative bacteria, serve second 
signal (discussed later) in activation of B-cells and remove harmful immune complexes.   
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Figure 1.1: Schematic representation of three pathways of complement activation 
modified from (Parkin & Cohen 2001).  
1.2.2.2 Antigens 
An antigen can be defined as a substance that reacts with antibody molecules and antigen 
specific receptors on lymphocytes. An immunogen is an antigen that stimulates an adaptive 
immune response. In principle, antigens can include a broad spectrum covering different 
classes of organic molecules ranging from simple chemical compounds to complex 
macromolecules (Rao 2001). The actual portion of an antigen that can react with antigenic 
receptors on B-cells and T-cells are called epitopes. The size of an epitope is generally 
thought to be equivalent to 5-15 amino acids and 3-4 sugar residues.  Protein antigens usually 
have several epitopes because proteins are composed of hundreds of amino acids and can 
form three-dimensional (3-D) shapes. The humoral response to protein antigens can comprise 
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of antibodies directed against the linear segments of sequence of amino acids presented as 
extended conformation or any possible secondary structural arrangements at the surface of 
the antigen (Colman 1988; Novotny 1987). 
1.2.2.3 Adaptive immune system 
The adaptive immunity is an antigen-specific defence mechanism and can be divided into 
humoral immunity and cell-mediated immunity. Humoral immunity involves production of 
antibodies in response to an antigen and is mediated by B-cells. Cell-mediated immunity 
involves production of cytotoxic T-cells, activated NK cells, activated macrophages and 
cytokines in response to an antigen and is mediated by T-cells. The process of adaptive 
immunity includes transportation of antigens by antigen presenting cells to lymphoid organs 
where the antigens are recognised by naive B-cells and T-cells (Romani & Schuler 1989). 
The activated B-cells and T-cells subsequently proliferate and differentiate into effector and 
memory cells.   
1.2.2.3.1 Cells and cell surface molecules of the adaptive immune system 
The cells and surface molecules important for adaptive immune responses include major 
histocompatibility complex (MHC) molecules (MHC class I, II and III), antigen presenting 
cells (APC) such as dendritic cells (DC), macrophages and B-cells and lymphocytes which 
include CD4
+
 and CD8
+  
T-cells.  
 Major histocompatibility comples (MHC) 
The human version of MHC molecules is called as human leukocyte antigen (HLA) 
complex coded by the HLA genes. The MHC consists of more than 200 genes located on 
chromosome 6. The genes are classified into three groups: MHC class I, MHC class II 
and MHC class III (Shiina, Inoko & Kulski 2004). 
 
The human MHC class I genes include HLA-A, HLA-B and HLA-C. The proteins are 
found on the surface of the cell and these proteins are bound to peptides and have been 
exported from within the cell. The MHC class I proteins exhibit these peptides to 
cytotoxic CD8
+ 
T-cells. The MHC class II proteins include HLA-DPA1, HLA-DPB1, 
HLA-DQA1, HLA-DQB1, HLA-DRA1 and HLA-DRB1. The MHC class II presents 
antigenic peptides to T-helper CD4
+
 T-cells. T-cell receptors can recognise epitopes when 
bound to MHC molecules. The HLA genes have several hundred variations referred to as 
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an allele. The HLA allele can be defined as a variant of a single genetic locus and each of 
which is given a number for example HLA-B27. The HLA-B27 consists of 40 different 
alleles and is designated as HLA-B*2701 to HLA-B*2740. Studies have established 
genetic associations between the susceptibility of disease and particular alleles of HLA 
genes. For example, HLA-B27 allele increases the risk of ankylosing spondylitis (Khan et 
al. 2007). 
 
Figure 1.2: Map of human major histocompatilibility complex (MHC). The 
establishment of MHC class I, II and III regions of human MHC are shown with 
estimated genetic distances specified in base pairs (kb). The additional genes are 
designated for MHC class I region E, F and G and are also referred to MHC class-I like genes 
or MHC class IB molecules, the additional MHC class II genes are referred to as 
pseudogenes. The genes also shown in MHC class III region code for C2, C4 (C4a and C4b) 
and factor B (Bf) complement proteins, tumour necrosis factors (TNF) and lympotoxins 
(LTA and LTB). The gene encoding 21-hydroxylase CYP 21Ban enzyme implicated in 
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steroid synthesis is also shown. Genes in grey colour and in italics are pseudogenes. The 
MHC class I genes are shown in red, the MHC class I related genes (MIC) shown in blue and 
are distinct from MHC class I like genes, the MHC class II genes are shown yellow. The 
genes which have immune functions but not related to MHC either class I or II are shown in 
purple. The figure was adapted and modified from (Janeway CA Jr 2001). 
 Antigen presenting cells (APC) 
The cells include dendritic cells (DC), macrophages and B-cells. The main function of 
antigen presenting cells (APC) is to engulf and degrade the protein antigens into peptide 
epitopes, bind those epitopes to MHC molecules and place them on their surface where 
they can be recognised by the T-cell receptors of T-cells. Antigen presenting cells (APC) 
express both MHC class I and MHC class II molecules and can perform two major 
functions. B-cells are involved in presentation of soluble antigens. The peptide fragments 
are exposed onto the MHC class II molecules of the B-cell surface immunoglobulin 
receptors (Lanzavecchia 1990). Upon up-regulation the antigen presenting B-cells 
activate the proliferation and differentiation of CD4
+
T-cells (Parker 1993).    
 
 Lymphocytes – Lymphocytes include B-cells which mediate humoral immunity and 
produce antibodies against specific antigen (discussed later), and T-cells which are 
responsible for cell-mediated immunity and regulate adaptive immune responses. Based 
on the cell surface markers, T-cells can be classified into CD4
+
 T-cells and CD8
+
 T-cells. 
The CD4
+
 T-cells have CD4 molecules and T-cell receptor for protein antigen recognition 
and regulate the adaptive immune responses through cytokine production. The activated 
CD4
+
 T-cells can differentiate into specific subtypes depending on the cytokine milieu of 
the microenvironment. The T-cells subsets include T helper 1, T helper 2, T helper 17, 
Tregs, follicular helper T-cell and T helper 9. The effector functions of T-cells subset are 
mediated by the cytokines secreted by the differentiated cells. The CD8
+
 T-cells have 
CD8 molecules and T-cell receptor for protein antigen recognition and upon activation 
the cells differentiate into cytotoxic T-cells.  
 
o CD4+ T-cells – The main functions of CD4+ T-cells include elimination of 
intracellular pathogens, mount immune response to extracellular parasites including 
helminthes, bacteria and fungi. These cells are also essential in maintenance of 
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immunologic tolerance to self and foreign antigens and mediate humoral immunity 
through interaction with B-cells.  
The antigen recognition receptors of T-cells are termed as T-cell antigen receptor 
(TcR). T-cell receptors are analogues to the B-cell receptor (BcR) and are composed 
of two highly variable glycoproteins either with αβ subunits or γδ subunits associated 
with invariable molecules andwhich constitutes the CD3 complex 
(Rudolph, Stanfield & Wilson 2006). Nearly 95 % of the conventional T-cells exhibit 
a TcR composed of αβ subunits. The remaining 5 % of T-cells exhibit γδ subunits.The 
TcR α chain is located on chromosome 14 and comprise of V (variable) and J 
(joining) genes. The β chain gene is located on the chromosome 7 with V, J and D 
(diversity) genes. The γ and δ chain gene are located on the chromosome 7 and 14 
respectively. The repertoire of TcR αβ is generated by gene rearrangement between 
V-J segments and V-D-J segments (Starr, Jameson & Hogquist 2003). The junctional 
diversity is expressed in complementary determining regions (CDR) and will form 
antigen-recognition site of the TcR (Cabaniols et al. 2001; Rock et al. 1994). The TcR 
recognises antigen in the form of peptide complexes bound to MHC molecules. The 
T-cells respond to short contiguous amino acid sequences in proteins.  
The TcR and CD4 molecule of naive T-cells detects the corresponding MHC class II 
peptide complex on mature DC and will send first signal for the activation of naive T-
cells. The second signal promotes survival of those T-cells through co-stimulatory 
molecules such as CD40, CD80 and CD86 on the DC which bind to CD40L and 
CD28 molecules on the T-cell. The DC produces cytokines such as IL-6, IL-2 and IL-
12 which contributes to proliferation and differentiation into effector of T-cells. The 
activated T-cells synthesise the cytokine IL-2 and high affinity IL-2 receptor. The 
binding of IL-2 to its high affinity receptor allows T-cell proliferation and formation 
of T-cell clones. The effector T-cells are classified based on the cytokines they 
produce and dominated by Th1, Th2, Th17, Tregs and T-follicular cells. The Th1 
cells coordinate immunity against intracellular bacteria and promote opsonisation. 
The opsonisation can be defined as a process of alteration to the surface of a pathogen 
or some particles so it can be ingested by phagocytosis. The antibody and complement 
opsonise extracellular bacteria for destruction by macrophages and neutrophils 
(Janeway CA Jr 2001). They also produce cytokines such as IFN-γ, IL-2, tumour 
necrosis factor-alpha (TNF-α). The T helper 2 cells coordinate immunity against 
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helminths and microbes. They also produce B-cell growth factors (IL-4, IL-5, IL-9 
and IL-13) and IL-22. The T helper 17 cells promote local inflammatory response and 
stimulate neutrophils and produce cytokines IL-6 and IL-17. T-follicular cells 
promote humoral immunity stimulating antibody production and antibody isotype 
switching by B-cells. They produce cytokines that are characteristics of both T helper 
1 and T helper 2 cells.   Regulatory T-cells suppress immune responses and produce 
inhibitory cytokines IL-10 and TGF-β that help limit immune responses and also 
prevent autoimmunity. 
 
o Regulatory T-cells – are distinct subset of T-cells which plays an important role in 
maintaining peripheral control of T-cell responses. Regulatory T-cells contribute to 
immunological tolerance and immune homeostasis and can suppress both innate and 
adaptive immune cells (Zhang et al. 2009). Sakaguchi et al described CD4+ T-cells 
expressing IL-2 receptor CD25 which is critical for maintaining peripheral 
immunological tolerance and it represents 5-10 % of all peripheral CD4+ T-cells. In 
vitro experiments suggest Tregs are anergic but such cells can expand in vivo through 
lymphopenia or antigen-driven proliferation (Hong et al. 2005; Wing & Sakaguchi 
2010). The immunological tolerance occurs when an immunocompetent host fails to 
respond to an immunogenic challenge with a specific antigen. The human immune 
system implements this tolerance mechanism in two different routes – central and 
peripheral. Central tolerance occurs during the lymphocyte development whereas the 
peripheral tolerance occurs after the lymphocytes leave the primary lymphoid organs. 
The tolerance can exist in T-cells, B-cells or both. In several experimental models the 
state of tolerance to variety of T-dependent and T-independent antigens has been 
demonstrated. Based on these studies it is clear that a number of factors such as 
physical form of antigen, route of administration, dosage, age of the recipient and 
others will contribute to determine whether an antigen will stimulate an immune 
response or induce tolerance.  
Naturally occurring CD4+ Tregs (nTreg) specifically express a transcriptional factor 
Foxp3 that plays critical role in their development and function. Foxp3 is an important 
biological marker and is currently the most specific and reliable molecular marker for 
nTregs. Evidence suggests that the Tregs can suppress the activation and expansion of 
autoreactive T-cells. Regulatory T-cells are divided into Foxp3 negative Tregs that is 
CD4+IL-10 producing T-cells or T regulatory type 1 cells (Tr1 cells) and Foxp3 
11 
 
positive Tregs that is CD4+IL-35 producing T-cells or T regulatory type 35 cells 
(Tr35 cells). Najafian et al reports Foxp3+Tregs are a subset of CD8+ T-cells 
(Najafian 2003). Young et al describes Foxp3+Tregs as CD3+CD4-CD8- double 
negative T-cells (Young & Zhang 2002). Natural killer T-cells are also potent 
suppressor T-cells in selected models. Foxp3+ Tregs include both CD4+ and CD8+ T-
cells. CD4+Foxp3+ Tregs have been extensively studied when compared to 
CD8+Foxp3+ Tregs. CD4+Foxp3+ Tregs plays important role in immune tolerance 
and therefore this subset has attracted more attention in translational research. 
CD4+Foxp3+ Tregs can express other surface markers such as CD25, CTLA-4, 
GITR, OX40, CD103, CD39 and CD73 (Kang, Tang & Bluestone 2007). 
Understanding the phenotypical and functional plasticity of such surface markers can 
provide the means for harnessing the cells into therapeutics. Futhermore, Tregs can 
also be divided into natural Tregs (nTregs) and induced Tregs (iTregs). Both of these 
Tregs express Foxp3 as a functional marker and express TcRs. TGF-β and IL-2 are 
the essential cytokines for induction of Tregs (Chen et al. 2003). CD4+ nTregs are 
dependent on IL-2 for their function and maintains a fine balance in suppressing 
autoreactive T-cells, normal intestinal immunity and also dampens anti-pathogen 
effector mechanisms. Retinoid acid (Benson et al. 2007), leukemia inhibitory factor 
(Gao et al. 2009), CTLA-4 and PD-1 enhance the induction of iTregs. But IL-4, IL-6, 
IFN-γ, OX-40, Tim-1 suppress the induction of iTregs (Degauque et al. 2007). 
Epigenetic differences between nTregs and iTregs might also contribute for Foxp3 
expression (Lal & Bromberg 2009). Epigenetics can be defined as mitotically or 
meiotically heritable changes in cellular phenotype or gene expression resulting in 
changes at a chromosome without altering the DNA sequence. Many of these factors 
might heavily contribute for the therapeutic manipulations of Tregs.   
 
T regulatory Type I cells produce large amounts of IL-10. It exhibits no Foxp3 
expression and the proliferation is poor in vitro (Groux et al. 1997). IL-10 is the 
effector cytokine for Tr1 cells (Levings, Sangregorio & Roncarolo 2001). IL-27 can 
induce aryl hydrocarbon receptor expression in T-cells which binds to c-Maf and then 
activate IL-10 gene in activated CD4+ T-cells to induce Tr1 differentiation (Apetoh et 
al. 2010). Tr1 cells can inhibit macrophage activation and therefore Tr1 cells are 
critical in suppressing innate immunity (Battaglia et al. 2006; Lindsay et al. 2001). It 
can also inhibit activation of CD4+ T-cells (Groux et al. 1997). Collison et al 
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described a subset of CD4+ T-cells expressing IL-35 and they do not express Foxp3 
transcriptional factor (Collison et al. 2007). But when compared to Foxp3+ Tregs, 
these IL-35 producing CD4+Foxp3- cells can also suppress proliferation in vitro and 
blocks the development of experimental autoimmune encephalomyelitis (EAE) in 
animal models. TGF-β, IL-10 and IL-35 are the key players in Treg suppressive 
mechanisms (Castellani et al. 2010; Collison et al. 2010).  
 
o CD8+ T-cells – The main function of CD8+ T-cells is to kill infected cells and tumour 
cells via apoptosis. Once activated the CD8
+
 T-cells proliferate and differentiate into 
cytotoxic T-cells. The CD8
+
 T-cells display surface molecule called CD8 and TcR. 
The TcR in cooperation with CD8 bind peptides from the endogenous antigens bound 
to MHC class I molecules.  
 
 B-cells – are responsible for production of antibody molecules during adaptive immunity. 
Naive B-cells are activated by both T-dependent antigens and T-independent antigens. In 
order for B-cells to proliferate, differentiate and mount an antibody response against T-
dependent antigens (for example proteins) the B-cells must interact with effector T-cells. 
The B-cells and T-cells encounter antigens in secondary lymphoid organs (lymph nodes 
and spleen). Here the antigens or microbes can bind to BcR on naive B-cells. The naive 
B-cells are activated and remain in the lymph nodes to proliferate and differentiate.  
 
The B-cell receptor (BcR) is a membrane bound, signal transducing protein that can bind 
directly to epitopes of peptides, proteins, polysaccharides, nucleic acids and lipid antigens 
(Cambier et al. 2007). The BcR are composed of membrane bound immunoglobulin (Ig) 
that functions as their binding substructure and a heterodimer of CD79a (Ig-α) and b (Ig-
β) that function as their transducer substructure. Post activation by antigen, B-cells 
secretes a soluble form of their receptors termed as antibody (Rao 2001). The antibody or 
immunoglobulin molecules are Y-shaped macromolecules composed of two different 
types of polypeptide chains. One is termed as heavy or H chain (50 kDa in size) and the 
other is termed as light or L chain (25 kDa in size). The two heavy chains are linked to 
each other by disulphide bonds and each heavy chain is linked to a light chain by a 
disulphide bond. In an immunoglobulin molecule the two heavy and two light chains are 
identical and therefore an antibody molecule has two identical antigen-binding sites 
(Janeway CA Jr 2001).  
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The activation of  B-cells can occur in association with T-cell help (Parker 1993). 
Following binding of antigen to the BcR triggers signal-transduction cascade for B-cell 
activation (Benschop & Cambier 1999). This leads to transcriptional activation of genes 
and so the BcR along with bound antigen is internalised and either degraded or trafficked 
to an intracellular compartment. In this compartment the MHC class II molecules and 
antigenic peptides bound to BcR form complexes. The antigen processing occurs and 
peptide-MHC complexes are transported to the cell surface. The T-helper cell recognises 
the complexes through the TcR leading to T-cell activation. In this stage, the activated T-
cells provide help to B-cells leading to antibody production. Once activated, the B-cells 
differentiates into plasma cells to produce antibodies (Reth & Wienands 1997). During 
the process of differentiation, rearrangement, recombination and mutation of 
Immunoglobulin V, D and J regions occurs to form functional VJ (light chain) and VDJ 
(heavy chain) genes. At this stage mature B-cells will produce IgD and some membrane 
IgM that will migrate to the cell surface that can act as antigen receptor. Once the 
antigenic stimulation happens, the B-cells will differentiate into plasma cell secreting 
IgM. The class switch happens in some cells due to the rearrangement of DNA placing 
VDJ gene next to IgG, IgE or IgA constant regions. In the process of repeating antigenic 
stimulation, these B-cells will differentiate into new plasma cells expressing new isotypes 
(Pierce 2002). In normal circumstances this results in switch from IgM to IgG.    
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Figure 1.3: Schematic representation of B-cell activation. The antigen binding cause 
(1) BcR to trigger signal transduction events (2) leads to transcriptional activation of 
genes (3) BcR internalised (4) or either degraded (5) and trafficked to intracellular 
compartment and form complexes in association with MHC that can recognise TcR (6) T-
cell activation occur (7) the activated T-cells help B-cell initiating B-cell activation (8) 
using cytokines and cell-cell interactions.  
 
B-cells also mount an antibody response to T-independent antigens (for e.g. 
carbohydrates and lipids) without the requirement of interaction with effector T-cells. The 
resulting antibody responses will be of IgM isotype and do not give rise to memory 
response. There are two different types of T-independent antigens. TI-1 antigens or 
PAMPs (for e.g. LPS) can elicit B-cell activation binding to toll-like receptors. TI-2 
antigens (for e.g. capsular carbohydrates) with multiple, repeating subunits activate B-
cells by simultaneously cross-linking a number of BcRs. Several reasons contribute for T-
cell independent antibody responses. These include large molecular weight, repeated 
antigenic sequence and ability to activate the complement cascade. In animal models the 
TI-2 antigens elicits robust and long lasting primary antibody responses (Garcia de 
Vinuesa et al. 1999). However, these antigens in general do not elicit a recall response 
(Hosokawa 1979; Hosokawa, Amagai & Muramatsu 1979). 
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1.2.2.3.2 Humoral immunity  
Humoral immunity refers to production of antibody molecules in response to an antigen. 
Antibodies, also referred to as immunoglobulins (Ig) are specific glycoprotein molecules 
produced from B-cells and plasma cells in response to specific antigen and capable of 
reacting to the antigen. Antibodies are of five classes or isotypes IgG, IgM, IgA, IgD and IgE 
(Alzari, Lascombe & Poljak 1988; Davies & Metzger 1983).  
 
Figure 1.4: Structure of an antibody molecule. It consists of two identical heavy and two 
identical light chains and both are attached to disulphide bonds. The light chain interacts with 
heavy chain to form Fab portion and Fc domain. The antigen binding sites are located at the 
tip of arms, which are tethered by a flexible hinge region. In the amino acid sequence of an 
antigen binding sites there are three complement determining regions (CDR) CDR1, CDR2 
and CDR3.  
The immunoglobulin monomer is composed of 4 glycoprotein chains – 2 identical heavy 
chains and 2 identical light chains. The two tips of Y-monomer are called as the antigen-
binding fragments or Fab portions. The bottom part of the Y, C terminal region and is called 
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as Fc portion. The Fc portion is responsible for the biological activities (for e.g. activating the 
complements). The IgM is a pentamer and consist of five linked antibody like molecules. The 
IgA is a dimer and consists of two antibodies like molecules.    
Immunoglobulin G is one of the most abundant proteins in the blood. It accounts for approx. 
75 % of the total immunoglobulin in the plasma and made up of 4 glycoprotein chains with 
the molecular weight of 150 kD (Alzari, Lascombe & Poljak 1988). The human IgG subclass 
is composed of immunoglobulin G1 (IgG1), immunoglobulin G2 (IgG2), immunoglobulin 
G3 (IgG3) and immunoglobulin G4 (IgG4). The relative concentrations are 
IgG1>IgG2>IgG3=IgG4 (French 1986). The stimulation of antibody responses towards 
certain antigens might result in selective increase in IgG subclasses antibodies. The 
distribution of IgG subclass depends in part on the nature of antigen. Protein antigens elicit 
IgG1 and IgG3 subclass antibodies and polysaccharide antigens elicits IgG2 subclass 
antibody (Ferrante, Beard & Feldman 1990; Siber et al. 1980). Long term antigenic 
stimulation may lead to increased IgG4 levels (Gibbs & Oger 2007). IgG antibodies exerts 
two important functions complement activation and opsonisation. IgG4 with IgG1 can 
amplify immune complex mediated complement activation. Deficiencies of IgG subclasses 
can lead to disturbed immune responses and are associated with prolonged or severe 
infections, autoimmunity and haemolytic diseases of the new born (Aucouturier et al. 1992). 
The physiochemical, biological properties of IgG subclasses and clinical outcome of IgG 
subclasses deficiency are illustrated in Table 1.2 (Grey & Kunkel 1964; Huizinga et al. 1989; 
Jefferis 1986; Schur 1987; Vlug et al. 1994).  
Properties IgG1 IgG2 IgG3 IgG4 
Heavy chain type gamma 1 gamma 2 gamma 3 gamma 4 
Molecular mass (Taylor et al.) 146 146 170 146 
Average serum concentration mg/ml 4.9-11.4 1.5-6.4 0.2-1.1 0.08-1.4 
Proportion of total IgG % 43-75 16-48 1.7-7.5 0.8-11.7 
Half life (days) 21-23 20-23 7-8 21-23 
Antibody responses: 
Proteins 
Carbohydrates 
Allergens 
 
++ 
+ 
+ 
 
+/- 
++ 
- 
 
++ 
- 
- 
 
+/- 
- 
++ 
Complement activation: C1q binding ++ +  +++ - 
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IgG subclass Clinical outcome of IgG subclass deficiency 
IgG1 Recurrent infections 
IgG3 deficiency 
Chronic fatigue syndrome 
IgG2 Recurrent RTI 
IgA and IgG4 deficiency 
IgG3 Recurrent infections 
Chronic lung disease 
IgG4 Recurrent RTI 
Autoimmune conditions 
HIV infected patients 
Table 1.2: Illustrates the properties of IgG subclass and the clinical outcomes of IgG subclass 
deficiency. Key: (-) indicates nil, (+) indicates low, (++) indicates moderate and (+++) 
indicates high.   
Generation of antibody diversity – Antibody diversity refers to the total variety of 
antibodies in the body of an individual and the mechanisms that generate this are described. 
The Fab portion is composed of a heavy and light protein chains. The variable heavy chain is 
coded for by a combination of 3 genes called VH (variable), DH (Diversity) and JH (joining). 
The variable light chain consists of either kappa or a lambda chain coded for a combination 
of two genes called VL (variable) and JL (joining). The DNA of each B-cell consists of 
multiple forms of each one of these variable determinant genes. The exact number of each 
genes varies from person and while a person inherits alleles for the various V(D)J genes from 
each parent an individual B-cell will only express an inherited allele set from one parent. 
Hence, this increases diversity of antibodies in that individual.  Random gene translocations 
give rise to different combinations of multiple forms of each gene resulting in thousands of 
possible gene combination.  
Affinity maturation – is defined as the gradual modification of the shape of the epitope 
binding site for BcR as a result of somatic hypermutation.  
Somatic hypermutation is a process which happens when B-cells respond to antigen along 
with activated T-cells signals. During this process, the rearranged VH and VL genes are 
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mutated and the pattern of nucleotide base changes in V region genes resulting in somatic 
hypermutation. The mutations alter the amino acid sequences in the V region of an antibody 
causing enhanced binding to antigen. In conclusion, somatic hypermutation cause point 
mutations into the rearranged V region genes of activated B-cells, creating diversity and 
enhanced antigen binding. The longer and more tightly the antigen binds to BcR, the greater 
the chance the B-cell has of surviving and replicating.  
Clonal selection and expansion – The cytokines produced from effector T-cells enable 
activated B-cells to proliferate producing clones of identical B-cells and this is referred to as 
clonal expansion. A single activated B-cell produces approximately 4000 antibody-secreting 
cells within seven days and B-memory cell also have these high affinity antibodies on their 
surface.  
The effector action of an antibody is influenced by the isotype of heavy chain C region. The 
heavy chain V region can become associated with C region of any isotype through the 
process of isotype switching. The first antibody to be produced is IgM which is referred as 
primary antibody response. However, the activated B-cells subsequently undergo isotype 
switching secreting antibodies of different isotypes IgG, IgA and IgE which is referred as 
secondary antibody response. The secondary response is characterised in the first few days by 
the production of small amounts of IgM and large amounts of IgG, with some IgA and IgE 
antibodies. Isotype switching occurs by recombination involving deletion of DNA between 
the rearranged V region and the selected C region. In animal models IL-4 has shown to 
induce switching to IgG1 and IgE, TGF-β induces switching to IgG2 and IgA. IL-5 induces 
switching to IgA. 
Memory response – During humoral immunity several circulating B-memory cells and T-
memory cells develop. The exposure to the same antigen results in rapid production of 
antibodies. The primary response to a new antigen generally peaks 5-10 days. IgM is made 
first and is later replaced by IgG. The secondary response peaks in 1-3 days where there is 
increase in amount of IgG. B-memory cells have a long life and replicate and produce 
antibodies periodically when they are exposed to persisting epitope remaining on the surface 
of follicular dendritic cells.  
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1.2.2.3.3 Cell-mediated immunity 
Cell-mediated immune response does not involve antibodies but rather involves activation of 
macrophages and NK-cells, production of antigen-specific T-cells and release of various 
cytokines. Cell-mediated immunity is mediated though T-cells. T-cells mature in the thymus 
into the naïve T-cells expressing T-cell receptors (TcRs) allowing them to interact with their 
cognate antigen.  
T-cell receptors are complex protein molecules consisting of a heterodimer of two 
glycoprotein chains αβ T-cell linked together by a disulphide bond which represents 95 % of 
T-cells. It is responsible for recognising the antigens bound to MHC molecules. The amino 
terminus of this TcR is extracellular with a hypervariable region which also represents the 
polymorphic antigen-interacting molecule. The CD4+ T-cells recognise the antigens bound to 
MHC class II molecules which are sourced from the extracellular environment through 
endocytic or lysosomal pathway. The CD8+ T-cells recognise the antigens bound to MHC 
class I molecules originating from the intracellular environment through proteasome 
degradation pathway. Two signals are required to stimulate T-cells.  
Signal 1 – antigen binding to MHC molecule 
The T-cells recognise the peptide fragments which are bound to MHC class I or class II 
molecules that display antigenic peptides on the surface of the APC (Germain 1994). 
Signal 2 – co-stimulation 
T-cell receptors interact with co-stimulatory molecules on the surface of APC (Janeway & 
Bottomly 1994). Important molecules include B7 molecules such as CD80 and CD86, ICOS 
inducible co-stimulator ligand and CD40 recognised through CD28, CTLA-4 cytotoxic T 
lymphocyte antigen, ICOS and CD40-ligand on T-cells. These signals are critical and 
contribute to the priming and differentiation of effector T-cells. It should also be noted that 
differences in these signals and TcR recognition of peptides lead to cell death which 
contributes for the tolerance towards self-antigens (Miller & Basten 1996; Ross et al. 2000a). 
T-cell activation causes release of cytokines and the activated T-cells rapidly proliferate to 
produce large clones of thousands of identical T-cells, a process called clonal expansion. 
These cells differentiate into effector T-cells.  
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1.2.2.4 Mechanisms underlying immunogenic responses to biologics 
The formation of anti-drug antibodies can be through T-cell dependent (Td) and T-cell 
independent (Ti) mechanisms (De Groot & Scott 2007).  
In the Td pathway the T-cells recognise the antigenic peptides which are derived from the 
biologic and are presented by APC via MHC class II molecules. The activated T-cells 
stimulate B-cells to generate antibodies against the biologic. It causes proliferation and 
expansion of epitope specific B-cells (Bachmann et al. 1994). It results in a robust antibody 
production which is long lasting, high affinity antibody titre response and is predominantly of 
the IgG isotype. The T-cell subset polarisation determines the profile of anti-drug antibodies 
generated. The Th1 mounts an IgG1 and IgG2 specific anti-drug antibodies. However, the 
Th2 response drives neutralising IgG4 specific anti-drug antibodies (Baker et al. 2010; 
Reding 2006; Reding et al. 2002). 
The T-cell independent pathway involves polyvalent antigens that bind to the B-cell receptor 
(BcR) and induce receptor clustering (Vos et al. 2000). The aggregated biologic displaying 
repeating epitopes can cluster BcRs and cause B-cell activation generating antibodies without 
the assistance of T-cells (Batista & Harwood 2009)(Batista and Harwood 2009). The 
generated anti-drug antibodies will be of IgM isotype or low-affinity IgG. While the 
immunological mechanisms of Td and Ti pathways are distinct, cross talk between Td and Ti 
pathways exists (Sethu et al. 2012). In Ti pathway the antigen laden marginal zone B-cells 
can function as APC which presents biologic to T-cells (Fehr et al. 1998). The other 
mechanism which represents interaction between Td and Ti pathways is B-cell epitope 
spreading. Epitope spreading perhaps plays an important role in evolution of anti-drug 
antibodies specificities.  
1.3 Immune-mediated adverse drug reactions 
The Food drug administration (FDA) defines immune-mediated adverse drug reactions as 
‘any adverse effect on the structure and function of the immune system or on other systems as 
a result of immune mediated dysfunction'. Based on underlying mechanisms, immune 
mediated adverse drug reactions to biologics (Pichler 2006) have been classified as; 
 Type α – high cytokine and cytokine release syndrome wherein immunostimulation leads 
to excessive cytokine release. For example, muromonab-CD3 used for the treatment of 
organ transplant rejections, can provoke release of several cytokines such as tumor 
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necrosis factor-α (TNF-α), interferon-γ (IFN-γ) and interleukins (IL) 2, 3 and 6 (Vasquez, 
Fabrega & Pollak 1995).    
 Type β – immunogenicity, anti-drug antibodies (ADA) formation and subsequent 
hypersensitivity reactions. Unwanted immune reactions with ADA production may 
neutralise the biological activity of the therapeutic protein and can also cross-react with 
endogenous protein counterpart (for example beta interferons in the treatment of multiple 
sclerosis) (Baert et al. 2003).  
 Type γ – immune or cytokine imbalance syndrome due to immune deviation. It is further 
classified into; 
o Impaired immune functions as in the case of the immunosuppressive effects of 
TNF inhibitors (used in treatment of rheumatoid  arthritis) (Chatenoud 1993) 
leading to reactivation of tuberculosis.  
o Immune or cytokine imbalance syndrome that leads to autoimmune reactions, 
inflammatory or allergic reactions as seen with autoimmunity associated with 
interferon alpha treatment (Rifkin et al. 2005). 
 Type δ – cross reactivity reactions may occur due to expression of same antigen on 
different cell types, for example cetuximab (epidermal growth factor receptor EFGR) 
antagonist which is used for the treatment of colorectal cancer) causing acneiforme 
eruptions due to cross-reactivity with EGFR on skin cells (Perez-Soler & Saltz 2005).  
 Type ε – non immunological mediated reactions with unclear/unknown mechanisms, 
example etanercept, an anti-tumour necrosis factor drug used in the treatment of 
autoimmune diseases which may cause heart insufficiency (Kwon et al. 2003). 
1.4 Biologics 
1.4.1 Definitions 
The FDA definition of biological products or biologics ‘is any virus, therapeutic serum, toxin, 
antitoxin or analogous product applicable to the prevention, treatment or cure of diseases or 
injuries in man’. This can include vaccines, blood and blood products, cells, tissues, genes, 
recombinant proteins and allergenics. The European medicines agency (EMA) has extended 
the breadth of biologics by defining it as ‘a medicinal product whose active substances is 
made by or derived from a living organism’.  
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Biologics consist of hormones, growth factors, cytokines, vaccines, enzymes, antibodies and 
fusion proteins (Giezen et al. 2008). Biologics are made using biological methods with or without 
recombinant DNA technology (Leach 2013). They differ from small molecule drugs in a number 
of features that are listed in Table 1.3. Biologics are derived from well-characterised cells using 
various types of expression systems which includes bacteria, yeast, insect, plants and mammalian 
cells and can be produced using cell cultures, animals or plants (ICH S6 1997). Biologics are 
made up of carbohydrates, proteins or nucleic acids and sometimes complex combinations of 
these substances (FDA 2012a).  
Since 1982 over 334 (according to FDA and EMA biologic product approvals) biologics have 
been approved in the United States (US) or European Union (EU) for the treatment of serious life 
threatening diseases and other disease conditions. The diseases include diabetes, cancer, 
autoimmune diseases, viral infections and hereditary deficiencies (Figure 1.5) (Giezen et al. 2008; 
Schellekens 2008). Biologics are classified into four different groups (I, II, III and IV) based on 
their function and therapeutic application (Leader, Baca & Golan 2008). The examples for each 
of this classification are provided in Table 1.4. A comprehensive list of approved biologics 
excluding blood and blood derived products has been obtained from FDA (listed in drugs@FDA 
page on the FDA website and tabulated in Appendix 1) 
 
Figure 1.5: Food and drug administration-approved biologics excluding blood and blood 
derived products by therapeutic areas (source Drugs@FDA page on the FDA website). 
Oncology related biologics contribute 31 % and rheumatology related biologics contribute 22 % 
of the global share in the biologics market. ‘Others’ include biologics for the treatment of renal, 
skin, ulcer and palpable cord disorders. 
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Small-molecule drugs 
 
 Low molecular weight (typically < 500 Daltons). 
 Manufactured with high consistency and using standard chemical processes. 
 The majority of these drugs are manufactured from chemical precursors. 
 The contents and purity of drug active agents can be analysed quickly and accurately. 
 The absorption of drug is determined by the drug’s physio-chemical properties, the 
formulation and mode of administration. Small molecules drugs tend to diffuse across the 
cell membrane from a region of high concentration (for e.g. GI) to one of low 
concentration (for e.g. blood) more rapidly. 
Biologics 
 
 Derived or synthesized from biological sources. 
 The molecular mass is typically >20,000 Daltons and has a complex structure.  
 They require rigorous biochemical analysis to assess quality and purity. 
 The characteristics are highly dependent on their method of manufacture.   
Table 1.3: The table illustrates characteristics of small-molecule drugs over biologics 
(Bernton 2007; Leach 2013; Vugmeyster et al. 2012). Abbreviations: GI, Gastrointestinal; 
e.g, example 
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Table 1.4: Biologics are classified into 4 groups. Group I – Biologics with enzymatic or regulatory activity; Group II – Biologics with special 
targeting activity; Group III – Protein vaccines and Group IV – Protein diagnostics. BMP – Bone morphogenetic protein; CD – Cluster of 
differentiation; EGFR – Epidermal growth factor receptor; GH – Growth hormone; GnRH – Gonadotropin-releasing hormone; GP – 
Glucoprotein; HIV – Human immunodeficiency virus;  IL – Interleukin; PDGF – Platelet-derived growth factor; PSA – Prostate specific antigen; 
TAG – Tumor-associated glycoprotein; TNF – Tumor necrosis factor; VEGF – Vascular endothelial growth factor 
 
Group I 
Biologics with  enzymatic 
or regulatory activity 
• Group Ia: Replacing a 
protein that is deficient or 
abnormal.  
• Examples: Insulin, GH, 
somatotropin, Factor VIII, 
Factor IX, Protein C, β-
glucocerbrosidase, α-1-
protienase, adenosine 
deaminase, human albumin. 
• Group Ib: Augmenting an 
existing pathway. 
• Examples: Erythropoietin, 
IL-11, Interferons, Factor 
VIIa, BMP7, GnRH, PDGF. 
• Group Ic: Providing a 
novel function or activity 
• Examples: Botulinum toxin, 
Collgenase, Hyaluroindase, 
L-asparaginase, 
Streptokinase. 
Group II 
Biologics with special 
targeting activity 
• Group IIa: Interfering with 
a molecule or organism. 
• Examples: monoclonal 
antibodies targeting VEGF, 
EGFR, CD3, CD52, TNF-α, 
IL1R, C5 and fusion 
proteins. 
• Group IIb: Delivering 
other compounds or 
proteins. 
• Examples: Diptheria toxin 
conjugated with IL-2, anti-
CD33 conjugated to 
calicheamicin. 
 
Group III 
Protein vaccines 
 
• Group IIIa: Protecting 
against a deleterious foreign 
agent. 
• Examples: Hepatitis B, 
HPV vaccines. 
• Group IIIb: Treating an 
autoimmune disease. 
• Example: anti Rh IgG. 
• Group IIIc: Treating 
cancer. 
• Examples: Vaccines for B 
cell non-Hodgins 
lymphoma. 
 
Group IV 
Protein diagnostics 
 
• Examples: Glucagon, 
GHRH, Secretin, Imaging 
agent labeled anti-PSA, 
anti-TAG-72, GPIIb/IIIa 
receptors, antibodies 
against HIV and Hepatitis 
C virus. 
2
4
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1.4.2 Adverse drug reactions associated with biologics 
Biologics in general, offer superior safety profiles when compared to small molecule drugs 
due to the lower risk of off-target reactions. However, in some patients unwanted immune 
responses to biologics may cause immunologically based adverse events such as infections, 
malignancy, CRS, anaphylaxis, serious skin reactions and immunogenicity (refer Appendix 
1) (Giezen et al. 2008; Leader, Baca & Golan 2008). The adverse drug reactions can be 
broadly classified into on-target or off-target effects. The adverse reactions due to on-target 
reactions (or exaggerated pharmacology) include malignancies, serious infections, CRS, 
autoimmunity and tumour lysis syndrome. Off-target adverse drug reactions can be further 
classified based on immune response-mediated (for example immunogenicity of interferon 
beta) and non-immune response mediated (for example Fc-mediated acute phase reaction 
associated with golimumab (anti-TNF drug) treatment). In this section the adverse drug 
reactions associated with biologics is discussed in detail.    
 Immune reactions  
Immune reactions include infusion reactions, immunogenicity, cytokine release syndrome 
(CRS) and hypersensitivity reactions (Presta 2006). An example of this is the acute 
anaphylactic (IgE mediated) and anaphylactoid reactions reported with rituximab (a chimeric 
CD20 specific mAb used for treatment of non-Hodgkin lymphoma and CLL) (Chung et al. 
2008; Coiffier 2002) (refer Appendix 1 for more examples). Immunogenicity of the biologic 
can result in formation of ADA and can lead to loss of therapeutic efficacy (discussed in 
detail in Section 1.5). Cytokine release syndrome often referred as cytokine storm is 
uncontrolled hypercytokinaemia that results in multiple organ damage (Carter 2001; 
Loertscher & Lavery 2002). Muromomab-CD3, a mouse mAb against human CD3 used in 
the treatment of renal transplantations can cause cytokine release syndrome (CRS) (Cohen et 
al. 2008; Ransohoff & Zamvil 2007).  
 Serious Infections 
Serious infections are major adverse drug reactions associated with biologics. Out of all the 
biologics mentioned in Appendix 1, twenty biologics have been associated with infections 
including reactivation of bacterial (such as mycobacterial, streptococcal, listerial or 
meningococcal), viral (such as hepatitis B or C virus), fungal (such as histoplasmosis) or 
sometimes opportunistic infections (such as JCV). An increased risk of tuberculosis has been 
reported with infliximab – TNF specific chimeric mAbs – for treatment of inflammatory 
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bowel disease(Theis & Rhodes 2008). PML, a fatal demyelinating disease of CNS is due to 
reactivation of latent John Cunnigham virus (JCV) infection and has been reported with using 
natalizumab (used for the treatment of RRMS) (Carson et al. 2009; Major 2010). 
Natalizumab causes reduced T-cell trafficking to the CNS and may compromise the immune 
surveillance and control of JCV in susceptible patients increasing the risk of PML 
(Bloomgren et al. 2012). 
 Platelet and thrombotic disorders 
Drug induced immune thrombocytopenia, characterised by decrease in the number of 
circulatory platelets has been reported with biologics such as alemtuzumab, a humanised 
mAb against CD52 (used for treatment of graft-versus-host disease). The mechanism behind 
this adverse event is due to direct cytolysis of blood cells (which is a mechanism of action of 
alemtuzumab) that can lead to severe multi-lineage haematopoietic cell depletion resulting in 
lymphopenia, neutropenia and thrombocytopenia (Cox et al. 2005; Lorenzi et al. 2008). 
 Autoimmunity 
The immunomodulatory functions of biologics can lead to immunosuppression and can cause 
various autoimmune diseases (Mongey & Hess 2008). The use of anti-TNF mAbs for 
treatment of rheumatic diseases has been linked with development of anti-nuclear antibodies 
and antibodies to double-stranded DNA and cause Lupus-like syndromes – a musculoskeletal 
disorder (Ramos-Casals et al. 2007). The potent immunosuppressive mAb alemtuzumab 
when used in treating multiple sclerosis developed autoantibodies to thyrotropin receptor due 
to potent immunosuppressive action causing antibody-mediated thyroid autoimmunity and 
developed autoimmune hyperthyroidism (Coles et al. 2006). 
 Cancer 
A review of 3,400 plus RA patients who received TNF-specific mAb demonstrated a dose-
dependent increase in risk of malignancy (Askling et al. 2005). However, the evidence for 
anti-TNF therapy as a cause for malignancy has continued to be questioned (Askling et al. 
2009; Dixon & Silman 2006; Scott 2006). 
The IL-12/23 specific mAbs are associated with theoretical concerns of potential 
tumorigenicity in patients suffering from moderate-to-severe plaque psoriasis and in CD. 
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Interleukin-12 has important role in anti-tumour immunity through its effects on tumour 
infiltrating cytotoxic T-cells (Longowski, J.L et al 2006).  
 Dermatitis 
Cetuximab, an EGFR specific chimeric mAb, and panitumumab, an EGFR specific 
humanised mAb is used for the treatment of mCRC (Jean & Shah 2008). Unfortunately these 
mAbs can cause skin rash on the face and upper torso, pruritus, dermatitis and erythema 
(Perez-Soler et al. 2005). The dermatitis is considered to be due to pharmacodynamic action 
as EGFR is widely expressed on epithelial cells (Bianchini et al. 2008). 
 Cardiotoxicity 
Trastuzumab, a humanised mAb against human HER2/neu, used in the treatment of 
HER2/neu positive metastatic breast cancer is associated with cardiotoxicity (Hudis 2007). 
Cardiac dysfunction was seen in 4 % of treated patients and this is characterised by impaired 
LVEF and tends to be reversible (Force, Krause & Van Etten 2007). The mechanism behind 
trastuzumab cardiotoxicity is due to blocking HER2/neu downstream signalling causing 
programmed cell death of heart muscle cells with impaired contractility and LV function 
(Kuramochi et al. 2006). 
1.5 Immunogenicity to Biologics 
Unwanted immunogenic responses have been described with the majority of biologics and is 
characterised by formation of anti-drug antibodies (refer Appendix 1). The development of 
ADA is one of the causes of clinical non-response due to neutralisation of the biological 
activity and also cross-react with endogenous protein (Koren 2002; Koren, Zuckerman & 
Mire-Sluis 2002). Patient specific factors, treatment specific factors and biologic specific 
factors may contribute to the formation of anti-drug antibodies. Immunogenicity to biologics 
is a major safety concern for manufacturers, regulatory bodies, healthcare professionals and 
the patients. 
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1.5.1 Clinical consequences 
The consequences of immunogenicity to biologics range from transient appearances of 
antibodies with or without any clinical significance to potentially severe life threatening 
conditions. Potential consequences are severe hypersensitive reactions for e.g. basiliximab 
(Han et al 2004), anaphylaxis for e.g. abciximab and alglucosidase alfa (Shopnick, Kazemi et 
al. 1996; Corona, Leon et al. 1999), a decrease in efficacy for e.g. interferon beta, induction 
of autoimmunity for e.g. alemtuzumab and interferon alpha (Li, Yang et al. 2001; Sorensen, 
Ross et al. 2003; Aarskog, Maroy et al. 2009; (Perez-Alvarez et al. 2013) and cross reactivity 
to endogenous proteins for e.g. interferon beta (Baker et al. 2010). The formation of ADA 
will vary among different biologics, the manufacturing processes, indication and the target 
patient population. Anti-drug antibodies can be binding antibodies (BAb) or neutralising 
antibodies (NAb) and results in clinically meaningful antibody induced alteration.  
1.5.1.1 Effects of anti-drug antibodies on therapeutic efficacy  
The formation of anti-drug antibodies (both binding and neutralising) limits the efficacy of 
the biologic. Binding antibodies alter the pharmacokinetics for example in the cases of 
bevacizumab and adalimumab (Wang 2005). High titre BAb can also mistarget the drug to Fc 
receptor (FcR) expressing cells and therefore reduces efficacy for e.g. as in the case of 
replacement lysosomal enzymes such as alglucerase and imiglucerase (Wang et al. 2008). 
Binding antibodies are also referred to as clearance antibodies. Neutralising antibodies can 
block the biologic efficacy and may cross-react with endogenous protein counterpart for e.g. 
interferon beta (van de Stadt et al. 2013). 
1.5.1.2 Effects of anti-drug antibodies on patient safety 
The major safety problems associated with immunogenicity include anaphylaxis for e.g. 
abciximab and alglucosidase alfa (Shopnick, Kazemi et al. 1996; Corona, Leon et al. 1999), 
infusion reactions for e.g. with alemtuzumab and denileukin diftitox (Baert et al. 2003), non-
acute reactions for example delayed hypersensitivity with rituximab (Han et al. 2003), 
immune responses secondary to immune complex formation for e.g. with alpha-glucosidase 
(Rojas et al. 2005) and cross-reactivity to endogenous proteins for e.g. with interferon beta 
(Rossert, Casadevall & Eckardt 2004). 
29 
 
1.5.2 Properties, functional effects and factors affecting formation of anti-drug 
antibodies 
The anti-drug antibodies formed against biologics can result in significant changes in the 
pharmacokinetics and efficacy. The formation of ADA can be due to overt immune response 
to an exogenous version of endogenous human proteins or failure of immune tolerance to 
self-antigens (Goodnow 2001; Schellekens 2003; Sethu et al. 2012). The generation of ADAs 
is influenced by the biologic structure, manufacturing process, formulation and route of 
administration. Biologics are complex macromolecules and so a small change in the 
particular region may result in major change in overall properties. For instance oxidation of 
recombinant protein IFN-α may lead to form aggregates (Hochuli 1997). The changes in 
primary amino acid sequence causes increased immune response for example insulin derived 
non-human sources (Schernthaner 1993). The potential for immunogenicity is also impacted 
by the manufacturing process. Changes in the manufacturing processes are likely to affect the 
biologic product quality and therefore can result in immunogenicity (Chirino & Mire-Sluis 
2004). The administration of biologics at high dosage or through a mucosal route can reduce 
immunogenicity through peripheral tolerance induction and is mediated by inducing 
tolerogenic DC and Tregs (Meritet, Maury & Tovey 2001). 
1.5.2.1 Binding antibodies (non-neutralising antibodies) 
Binding antibodies are also referred to as non-neutralising antibodies (Giannelli et al. 1994). 
They bind to epitopes that do not participate in the interaction between the biologic and its 
respective receptor or in other words these antibodies are capable of binding to a biologic but 
may or may not neutralise its biological effects (Wadhwa & Thorpe 2010). Binding 
antibodies can either expedite the clearance, called clearing antibodies or can prolong the 
bioavailability, called sustaining antibodies (Ponce et al. 2009). It is also been reported that 
the BAb titres can be higher than NAb and the BAb are produced much earlier during the 
course of treatment than NAb (Scagnolari et al. 2002b). Binding antibodies can also reside 
much longer than the NAb (Bellomi et al. 2003). 
1.5.2.2 Neutralising antibodies 
Neutralising antibodies neutralise the biological activity of the drug and could also alter the 
function of endogenous protein counterparts (Ponce et al. 2009). Significant correlations have 
been made between the NAb titres and the loss of clinical responses and this has been 
reported in several biologics such as interferon beta and natalizumab (Casato et al. 1991; Itri 
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et al. 1987; Lok, Lai & Leung 1990; Milella et al. 1993; Porres et al. 1989; von Wussow et al. 
1988; Wussow et al. 1991). It is also reported that the percentage of NAb positive patients 
varies depending upon the source of the product, the route and frquency of administration and 
also the type of assay used to detect NAb. The non-human origin of biologics, the degree of 
humanisation, the presence of impurities, the dosage and different routes of administration 
contribute to the formation of antibodies. Disis et al 2004 reported HER-2/neu peptide based 
vaccine BAb promote the generation of NAb through mechanism of epitope spreading (Disis 
et al. 2004). Epitope spreading can be defined as, ‘the development of immune responses to 
endogenous epitopes secondary to the release of self-antigens during a chronic autoimmune 
or inflammatory response’ (Vanderlugt & Miller 1996).  The full details of factors 
contributing to immunogenicity are described in Section 1.5.5. The cross reactivity of NAb 
with their endogenous proteins have also been reported (Antonelli et al. 1999; Bertolotto et 
al. 2000; Khan & Dhib-Jalbut 1998). In terms of timeline of NAb development, using a 
typical example of NAb formation to interferon beta (IFN-β), approximately 45 % (mean ~ 
25 %) of the patients develops or become NAb positive within 6-12 months of treatment. The 
NAb can also persists for a long time irrespective of the withdrawal of the drug (Gneiss et al. 
2004b; Malucchi et al. 2005; Petersen et al. 2006; Sorensen et al. 2005b).  
 
Figure 1.6: Dynamics and clinical consequences of NAb by time during treatment with 
IFN-β. The schematic represents the longitudinal clinical impact of NAb. The formation of 
NAb impacts IFN-β treatment and this reflects on routine magnetic resonance imaging (MRI) 
scans of the patient post treatment particularly during 12-36 months (Ross et al. 2006). The 
figure was adapted and modified from (Sorensen 2008). 
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1.5.3 Assays for immunogenicity  
A number of immunogenicity testing assays have already been or being developed that has 
reasonable predictivity. Some currently used assays for quantifying binding and neutralising 
antibodies are described in the following sections  
1.5.3.1 Binding antibody assays 
Several assays are available for measurement of binding antibodies BAb (Chirmule, Jawa & 
Meibohm 2012; Krieckaert, Rispens & Wolbink 2012) including Enzyme-linked immuno 
sorbent assay (ELISA), radioimmunoassay or affinity chromatography. The ELISA methods 
most commonly used are direct ELISA or capture ELISA. In order to measure anti-IFN-β 
antibodies in plasma samples; the direct ELISA involves coating the wells with IFN-β 
whereas in capture ELISA, the plate are coated with monoclonal capture antibody specific for 
human IFN-β. Radioimmunoassays are also used for anti-drug antibody measurements and in 
the case of ADAs to anti-TNF radiolabelled therapeutic anti-TNF antibodies are used to bind 
to free anti-drug antibodies in the plasma samples (Baert et al. 2003). 
1.5.3.2 Neutralising antibody assays 
Biologics in general can act on cellular targets in vivo and alter the expression of several 
genes within the target cells. The NAb assays quantify these changes in gene expression 
where in there is inhibition of gene changes in presence of NAb. Interferon beta, a 
recombinant protein, binds to the interferon alpha or beta receptor (IFNAR) receptor 
activating intracellular signalling casade leading to synthesis of gene products such as 
myxovirus A (MxA), neopterin, oligoadenylate synthetase (OAS), tumour necrosis factor 
apoptosis inducing ligand (TRAIL) and β2 microglobulin. The presence of NAb in the 
samples fails to bind and activate the receptors and thus these downstream gene expression 
effects are lost. Hence, IFN-β induced gene products can be used in assays to measure its 
bioactivity. The World Health Organisation (WHO) expert committee on biological 
standardisation 1985 recommends use of Cytopathic Effect assay (CPE) for measurement of 
IFN-β induced NAb. Cytopathic Effect assays use virus responsive cells and the ability of 
IFN-β to inhibit viral replication is measured.  
The guidelines issued from EFNS recommend cell based assays for measuring IFN-β induced 
MxA mRNA or protein (Sorensen et al. 2005a). Sandwich type ELISA, western blots (Kob et 
al. 2003), fluorescence activated cell sorting (FACS) (Pachner 2003; Pachner, Bertolotto & 
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Deisenhammer 2003; Pachner, Oger & Palace 2003) and polymerase chain reactions (PCR) 
can also be used for measurements of MxA mRNA or protein. The recent EMA guidelines on 
immunogenicity states use of competitive ligand binding (CLB) assays for assessing the 
neutralising capacity of antibodies induced against therapeutic mAb such as CD40.  
A potential source of artefact is from the ability of NAb to cause decrease or prevent binding 
of drug to reagents in the capture or detection methods. Several new assay formats are under 
research for example acid disassociation to detect anti-drug antibodies and drug (Patton et al. 
2005) and affinity capture elution assay to detect anti-drug antibodies to therapeutic mAb in 
presence of high levels of drug (Kelley et al. 2013). 
1.5.4 Immunoglobulin isotypes involved in immunogenicity 
Studying immunoglobulin isotypes involved in immune response against biologics may 
provide further insights into evolution of immune responses. Several of biologics specific 
anti-drug antibodies are mainly of IgG isotype, although some IgA, IgM and IgE isotype have 
been reported (Candon et al. 2006; Kosmac et al. 2011; Vultaggio et al. 2010). The presence 
of high-affinity IgG and formation of IgG1 and IgG4 anti-drug antibodies indicates the 
presence of T-cell help (Baker et al. 2010). Infliximab and adalimumab IgG anti-drug 
antibodies are predominantly of IgG1 and IgG4 subclasses. Interferon beta anti-drug 
antibodies are predominantly of IgG1 and IgG3 within the first 6 months while IgG4 
antibodies peaked later after 24 months (Gibbs & Oger 2007). The formation of IgG4 anti-
drug antibodies are suggestive of repeated antigenic exposure (Aalberse, van der Gaag & van 
Leeuwen 1983).  
1.5.5 Factors contributing to immunogenicity to biologics 
Several different factors are thought to contribute the immunogenicity of biologics. The 
factors could be patient specific, treatment specific or biologic specific. 
1.5.5.1 Patient specific factors 
 Patient age  
The immune response against a biologic can be an age-related phenomenon. For example 
children might have different immune response compared to adults and therefore age 
factor is considered crucial for immunogenicity (according to the guidelines issued from 
European and US Federal agencies). Ageing is associated with a decline in the immune 
system function and increases the risk of infections (Dorshkind & Swain 2009). 
33 
 
 Genetic status 
Genetic factors such as human leukocyte antigen (HLA) haplotypes can modulate 
immune responses to biologic. Definite HLA types have been discovered in the anti-drug 
antibodies response to several biologics (Sethu et al. 2012). HLA-DRB1*0401, HLA-
DRB1*1601, HLA-DRB1*0408 (Buck et al. 2011; Hoffmann et al. 2008), HLA-
DRB1*0701 (Barbosa et al. 2006), HLA-DR2, HLA-DQ6, DQB1*0602, HLA-DR15 
(Stickler et al. 2004) for interferon beta, HLA-DQA1*0102, HLA-DR4.1, DQ4, 
DQA1*0301 (Ohta et al. 1999; Simonney et al. 1985), HLA-DRA-DRB1*1104 (Ettinger 
et al. 2010) for factor VIII and HLA-DRB1*09-DQB1*0309 for erythropoietin 
(Praditpornsilpa et al. 2009). Human leukocyte antigen mapping studies may define 
subsets of populations at risk. 
 Immunological status and competence of the patient  
Patients suffering from immune suppression may have lower risk of mounting immune 
response to biologics when compared to healthy donors with intact immune system. 
Neutralising antibodies was detected in 95 % of immune-competent cancer patients 
treated using recombinant GM-CSF compared to only 10 % of immune-compromised 
cancer patients (Ragnhammar et al. 1994).  
1.5.5.2 Treatment specific factors 
 Treatment regime (route of administration, dosage and frequency of administration) 
Route of administration can influence the risk of sensitisation. Intradermal, SC and 
inhalational route of administration are more immunogenic when compared to 
intravenous route of administration. Research suggests SC administration is relatively 
hostile to an already immunogenic biologic however SC route of administration by itself 
cannot render non-immunogenic biologics, immunogenic (Schellekens 2005). Hence, the 
strength of immune response to an antigen can be subcutaneous > intramuscular > 
intravenous. For obvious reasons SC route of administration is the most convenient route 
for at least when self-administration is made by patients. In conjunction to route of 
administration, the dose, frequency and duration also contribute to immunogenicity 
(Rosenberg and Worobec 2004). For instance long term treatment with high dose factor 
VIII induced tolerance, while intravenous abatacept (a fusion protein) has shows only a 
mild increase in immunogenicity. High dose infliximab and pre-treatment with high doses 
of non-antigen-binding variant of the therapeutic antibody with alemtuzumab have shown 
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decreased immunogenicity and induce immunological tolerance using the mechanism of 
exhaustion of the immune response (Maini et al. 1998; Sathish et al. 2013). 
 Combination therapy 
Immunomodulators when given in combination with biologics have been described to 
inhibit formation of anti-drug antibodies (Rojas et al. 2005). For example co-
administration of anti-TNF agents with azathioprine, mercaptopurine, steroids or 
methotrexate is associated with decreased frequency of anti-drug antibodies formation 
(Jani M et al 2013).  
1.5.5.3 Biologic specific factors  
 Target binding capability 
The influence of target binding capacity on ADA formation is exemplified in a study 
where 20 patients initially received nonbinding form and binding form of alemtuzumab 
followed by therapeutic alemtuzumab. The percentage of anti-drug antibodies patients 
were found to be lower in the group who were treated with target-binding form of 
alemtuzumab (Khono, T et al 2007).  
 Molecular structure or amino acid sequence differences between native and therapeutic 
protein  
Different degrees of humanisation of the biologic can lead to different degrees/types of 
immunogenicity for e.g. a fully humanised IgG1 monoclonal antibody which is derived 
from by CDR grafting can elicits a human anti-human antibody response (Nechansky 
2010). Dalum et al have shown non-human epitopes can elicit T-cell response and 
therefore facilitate epitope spreading to generate ADAs (Dalum et al. 1997). 
 T-cell epitopes 
When the biologic is taken up by antigen presenting cells, the protein is digested into 
peptides and these can be loaded on to MHC molecules. The MHC-antigen complexes are 
transported to the surface where they bind to T-cell receptors (TcR) and induce 
proliferation of antigen specific T-cells. T-cells can recognise linear epitopes from 
proteins that are processed by antigen presenting cells. The antigenic proteins are broken 
down by proteolytic enzymes in the antigen presenting cells. During this process large 
numbers of peptides are formed. Nearly, 2 % of the peptides generated contain right 
amino acid sequence that allow them to bind in the MHC grove and are presented on the 
surface of antigen presenting cells. One of the important aspects to consider in terms of 
immunogenicity is the binding strength of T-cell receptor to MHC molecules (Lazarski et 
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al. 2005). The nature of T-cell, TcR and the MHC-peptide complexes determine the 
overall effect of T-cell responses. Various methods such as in silico prediction tools and 
in vitro proliferation assays have been used to investigate the role of T-cell epitopes in 
immunogenicity. In order to aid the identification of T-cells epitopes computer algorithms 
such as Immune Epitope Database and ProPred have developed to map the locations for 
MHC class I and II restricted T-cell epitopes within proteins. Insilico prediction tools 
have already been applied to design vaccines and also in selection of epitopes in 
autoimmunity studies (De Groot & Scott 2007). MHC class II predictions methods can be 
useful for evaluation of T-cell dependent immunogenicity. MHC class II restricted T-cells 
provide help to B-cells leading to formation of anti-drug antibodies.    
 B-cell epitopes 
Some biologics contain multivalent antigenic determinants and hence can induce T-cell 
independent anti-drug antibodies formation. Mapping of binding regions of anti-drug 
antibodies on biologics may enable to identify B-cell epitopes involved in 
immunogenicity. B-cell epitopes are important component of anti-drug antibody 
response. The B-cell epitopes of recombinant factor VIII has been extensively studied. 
The precise amino acids which are required for antibody binding have been identified on 
various factor VIII domains (Fulcher et al. 1985; Scandella et al. 1995). This 
identification had led to development of factor VIII variants with reduced 
immunogenicity (Parker et al. 2004). 
 Protein aggregates  
Studies have also shown that the aggregated forms of biologics can stimulate humoral 
immune responses (Braun et al. 1997). Protein aggregates are made up of either intact 
native protein or degraded or denatured protein. Subvisible particulates of protein 
aggregates in the size 0.1-10 microns have strong potential to elicit an immune response 
(Berkowitz 2006; Gamble 1966; Gross & Zeppezauer 2010; Roda et al. 2009). The 
mechanisms of aggregate induced ADA generation include the following – cross linking 
of B-cell receptors and causing B-cell activation (Bachmann et al. 1993; Dintzis et al. 
1989), increased antigen uptake, processing and presentation (Seong & Matzinger 2004), 
followed by recruiting T-cells and B-cells to produce high-affinity IgG antibody 
(Bachmann & Zinkernagel 1997). 
 Post translational modifications (glycosylation or pegylation) 
Glycosylation in general enhances solubility and diminishes aggregation and antibodies 
formation. Glycosylation can alter protein immunogenicity by shielding immunogenic 
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epitopes from immune system (Cole et al. 2004; Wei et al. 2003). Pegylation can also 
diminish antibodies formation via similar mechanisms (Harris, Martin & Modi 2001; 
Inada et al. 1995). However, immune response to polyethylene glycol (PEG) itself has 
been recently identified (Liu et al. 2011). 
 Impurities with adjuvant activity 
Microbial impurities in the biologic formulations can potentially contribute towards 
immunogenicity. These impurities exert immune enhancing activity and prompts antigen 
presenting cells to stimulate B-cells to produce antibodies (Verthelyi & Wang 2010). 
 Formulation 
Large protein excipients in the formulation for example HSA may form protein adducts 
under abnormal storage conditions and can predispose ADA generation (Braun & Alsenz 
1997).  
 Manufacturing process 
Proteins can denature and form aggregates during the manufacturing process wherein 
they may be exposed to heat, light and mechanical agitation.  
1.6 Multiple sclerosis 
Multiple sclerosis (MS) is a chronic inflammatory and demyelinating disease of the central 
nervous system (CNS). Multiple sclerosis is documented all over the world, with 
approximately 2.5 million people affected worldwide, around 400,000 people in the US and 
100,000 people in the UK (Coles 2009; Noonan, Kathman & White 2002; Rosati 2001). The 
highest incidence is found in Caucasian woman, people of Northern European descent and 
those living in northern latitudes (International et al. 2009). Diagnosis is established between 
the ages of 20 and 40 and it affects women almost twice as much as men (Alonso et al. 2007; 
Koch-Henriksen 1999). The overall life expectancy is lowered by about seven years 
(Ragonese et al. 2008). 
1.6.1 Causes and molecular pathology 
The cause of this disease includes environmental exposure and genetic susceptibility. 
Environmental factors – The disease is common in regions populated by northern 
Europeans. Epstein-Barr virus infection in young adults increases the risk of developing 
multiple sclerosis (Levin et al. 2003).The patients suffering from this disease also exhibit 
infections such as measles, mumps and  rubella (Martyn, Cruddas & Compston 1993).  
Two different mechanisms have been proposed  
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 Molecular mimicry – activation of autoreactive cells by cross-reactivity between self-
antigens and antigens from microbes. It involves reactivity of T-cell and B-cells with 
peptides or antigenic determinants shared by infectious agents and self-antigens. It leads 
to activation and migration of cells across the blood brain barrier (BBB), CNS infiltration, 
tissue damage and disease onset. 
 Bystander activation – The autoreactive cells are activated due to nonspecific 
inflammatory events during infections. It involves TcR independent bystander activation 
of autoreactive T-cells through inflammatory cytokines, superantigens and Toll-like 
receptor (TLR) activation.  
Genetic factors – The familial re-occurrence rate of multiple sclerosis is about 20 %, a  
genetic association exists between this disease and MHC alleles DRB1*1501, DRB5*0101, 
DQA1*0102 and DQB2*0602 (Olerup & Hillert 1991). The association was again strongest 
in northern Europeans but is seen in all populations with DR4 (DRB1*0405 – DQA1*301 – 
DQB1*0302) MHC alleles (Marrosu et al. 1992).  
Disease mechanisms – 
The hallmark of this disease is formation of sclerotic plague in the CNS, which are 
characterised by inflammation, demyelination and remyelination, oligodendrocyte depletion 
and astrocytosis, and neuronal and axon degeneration (Hohlfeld & Wekerle 2004). The 
lesions can develop in any part of the CNS; however tendency exists to accumulate near 
periventricular and exterior surfaces of brain and spinal cord. The lesions are round to oval 
shaped and are centered to one or numerous medium sized vessels (Hohlfeld et al. 2006). 
The pathogenesis of this disease begins with increased migration of autoreactive CD4
+
 T-
cells across the BBB. The activated T-cells produce a range of pro-inflammatory cytokines 
which stimulate other T-cells, B-cells, macrophages, natural killer cells and microglia to 
augment and perpetuate inflammatory process. The cytokines cause increased permeability of 
the BBB, alter adhesion molecule expression, produce antibodies and recruit other immune 
cells into the CNS. The advent of T helper 17 cells has led to further understanding of T-cell 
regulation. The evidence suggests these cells secrete IL-17 with IL-6 and TNF-α and plays a 
crucial role in inflammation (Bowman, Chackerian & Cua 2006). Damage to axons can be 
mediated by cytotoxic T-cells, macrophages, antibodies, loss of trophic support and oxidative 
stress (Sospedra & Martin 2005). Loss of trophic support for axons and exposure to lethal 
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metabolites also leads to degeneration of axons. The redistribution of ion channels, 
mitochondrial failure and calcium mediated toxicities all contribute to axonal degeneration 
(Waxman 2006a, 2006b). 
1.6.2 Clinical picture 
The clinical manifestations of multiple sclerosis can include impairment in the variety of 
cognitive functions, loss of vision or abnormalities of eye movements, fatigue, spasticity, 
imbalance, in-coordination and sensory loss. There is no cure for multiple sclerosis once this 
condition is detected and it remains rest of the life. There are treatment options that can 
relieve symptoms and relapses. These can be divided into three main categories. 
Treatment for acute relapses – corticosteroids are thought to suppress the immune system and 
hence reduce the inflammation and increase the duration between relapses but have no impact 
on the progression of the disease. The mechanism of action of corticosteroids in the treatment 
of relapses is still unclear. But, the potential mechanism of action includes reducing oedema, 
stabilising blood-brain barrier, diminishing pro-inflammatory cytokines and causing T-cell 
apoptosis (Gold, Buttgereit & Toyka 2001). The complications associated with 
corticosteroids such as avascular bone necrosis, diabetes, exacerbation of infections, 
hypertension, reduced bone density, weight gain has to be considered before the treatment 
(Pozzilli, Romano & Cannoni 2002). 
Treatment for specific symptoms – is a critical component of general management of 
multiple sclerosis disease. Symptomatic treatment is intended at elimination or reduction of 
symptoms impairing the functional abilities associated with the disease. The Multiple 
Sclerosis Therapy Consensus Group (MSTCG) and the German Multiple Sclerosis Society 
consensus publication contain suggestions for the treatment of common symptoms (Henze et 
al. 2006). 
Treatment to slow the progression of multiple sclerosis using disease modifying drugs 
(DMD) – this includes immunomodulatory drugs such as azathioprine, interferon beta, 
cyclophosphamide, glatiramer acetate, intravenous immunolgobulin, methotrexate, 
mitoxantrone and natalizumab (Clegg, Bryant & Milne 2000). Research into long term effects 
of these drugs are limited but they can reduce the number and severity of relapses and may 
also help to slow the progression of the disease.  
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1.7 Interferon beta IFN-β 
Interferons are naturally occurring proteins which stimulate intracellular and intercellular 
responses that regulate resistance to viral infections, enhance immune responses and 
modulate cell survival and death (De Maeyer & De Maeyer-Guignard 1982). In 1975 Isaacs 
and Lindenmann introduced interferons as antiviral agents (Isaacs & Lindenmann 1957) 
Three types of interferons have been identified with Type I IFN being composed of 16 
members which includes 12 IFN-α, IFN-β, IFN-ε, IFN-κ and IFN-ω. Interferon alpha and 
beta share 32-40 % of the amino acid sequence. Both are encoded in chromosome 9 and act 
on a common cell surface receptor (Lin 1998). Interferon beta exists in humans and is 
produced primarily by virus-infected fibroblasts. It is also produced in the glial cells in the 
CNS. Human IFN-β is a 23-kD glycoprotein and consists of 166 amino acids and 20 % 
carbohydrates. 
Type II IFN includes IFN-γ which exhibits antiviral activities and is produced from immune 
T-cells.  
Type III IFN or IFN-λ family includes IFN-λ1 (also known as IL-29), IFN-λ2 (also known as 
IL-28A) and IFN-λ3 (also known as IL-28B). Recent evidence suggests type III IFN is 
similar to members of interleukin-10 (IL-10) family. These interferons also exhibit antiviral 
responses and activate IFN-stimulated genes (Gad et al. 2009).  
 
Type I IFN proteins were developed as therapeutic proteins for the treatment of multiple 
sclerosis because of its anti-viral properties as the patients suffering from this disease 
exhibited viral infections (Borden et al. 2007). Type I IFN proteins also exhibit numerous 
immunomodulatory functions and alter T helper 1 and T helper 2 balance (Hussien et al. 
2001), antagonise proinflammatory cytokines such as IFN-γ, IL-12 and TNF-α, down 
regulate MHC class II expression which affects antigen presentation (Yong 2002), possess 
anti-proliferative properties on T-cells and also can cause T-cell apoptosis (Sharief et al. 
2001; Yong 2002). The evidence also suggests that Type I IFN inhibits transmigration of 
immune cells across the BBB (Leppert et al. 1996). 
Interferon alpha and beta exert their biological effect, by binding to the same high affinity 
cell surface receptor (Type I IFN receptor) and initiating a signalling cascade. The Type I 
IFN receptor consists of two subunits (interferon alpha or beta receptor) IFNAR1 and 
IFNAR2 which are associated with two cytoplasmic tyrosine kinases Janus Kinase 1 (Jak1) 
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and Tyk2 (Muller et al. 1993; Novick, Cohen & Rubinstein 1994; Uze, Lutfalla & Gresser 
1990). The interferon molecule binds to IFNAR2 which recruits IFNAR1 and induces 
phosphorylation of Jak1 and signal transduction and activators of transcription (STAT). The 
further processes include transactivation from interferon stimulated response elements (ISRE) 
contained in the promoter regions of several genes (Platanias 2005). 
Interferon beta triggers the synthesis of host cell proteins contributing to its several 
immunomodulatory properties. The induction of host cell proteins such as 2’, 5’-
oligoadenylate synthetase, myxovirus (Mx) protein, double-stranded RNA-dependent protein 
kinases and inducible nitrous oxide (NO) can inhibit viral replication (Baron et al. 1991; 
Borden et al. 1988). Interferon beta exhibits potent T-cell anti-proliferative properties (Bekisz 
et al. 2010). It might also affect T-cell function via inhibition of T helper 1 cytokines such as 
IFN-γ, IL-12 and TNF, and  promotes T helper 2 cytokine secretion such as IL-10 (Dayal et 
al. 1995; Noronha, Toscas & Jensen 1993; Rudick et al. 1996). Prolongation of cell cycle and 
depletion of metabolites might cause anti-proliferative effects in tumor cells (Borden 1992; 
Shearer & Taylor-Papadimitriou 1987). Interferon beta also increases the expression of HLA 
class I molecules and this also might contribute to antiviral effects (Spear et al. 1987). It 
inhibits HLA class II molecules induced from IFN-γ and so inhibits the antigen presentation 
(Jiang et al. 1995; Johnson & Panitch 1989; Joseph et al. 1988; Ling, Warren & Vogel 1985; 
Noronha, Toscas & Jensen 1992; Ransohoff et al. 1991).  
Jacobs et al found the beneficial effect of IFN-β in patients suffering from multiple sclerosis 
(Jacobs & Johnson 1994; Jacobs et al. 1982a; Jacobs et al. 1982b). Interferon beta treatment 
dampens the plaque formation, decreases relapses and eventually improves disease prognosis. 
In 1993 IFN-β-1b was approved for the treatment of RRMS (Hoyer 1993; Paty & Li 1993). 
Since then, two recombinant forms of IFN-β products IFN-β-1a and IFN-β-1b have been 
approved for the treatment of multiple sclerosis. Four different preparations are currently 
available: IFN-β-1a (Avonex™ from Biogen), IFN-β-1a (Rebif™ from Merck Serona), IFN-
β-1b (Betaseron™ from Bayer) and IFN-β-1b (Extavia™ from Novartis). IFN-β-1a 
(Avonex™ and Rebif™) is a 166 amino acid glycosylated protein produced in Chinese 
hamster ovary (CHO) cells (Revel 2003). IFN-β-1b (Betaseron™ and Extavia™) is a 165 
amino acid non-glycosylated protein produced in Escherichia Coli (E Coli) and lacks 
glycosylation and contains serine residue substitution for cysteine at position 17 (Lin 1998). 
The majority of multiple sclerosis patients exhibit improvement to this treatment (PRISMS et 
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al 1998). It reduces relapses and also slows down the disease progression (Killestein & 
Polman 2011). 
1.7.1 Structure of interferon beta  
In 1992, the first structure of murine IFN-β was elucidated (Senda et al. 1992). In 1997, the 
crystal structure of human IFN-β was elucidated (Karpusas et al. 1997). Interferon beta is 
roughly cylindrical in shape and belongs to family of long-chain helical cytokines. It contains 
166 amino acid residues and consists of five α-helices designated as helix A (amino acid 
residues 2-22), helix B (amino acid residues 51-71), helix C (amino acid 80-107), helix D 
(amino acid 118-136) and helix E (amino acid 139-162). The helices are connected by a long 
AB loop and 3 short loops BC, CD and DE. The AB loop is further divided into 3 segments 
AB1 (amino acid residues 23-35), AB2 (amino acid residues 36-40) and AB3 (amino acid 
residues 36-40). The structure also consists of several hydrophobic residues Phe-70, Phe-154, 
Trp-79 and Trp-143 which are involved in interaction with each other that stabilise the core 
of the molecule. 
A glycosylation site exists at residue Asn-80. The studies suggest that the glycosylation of 
IFN-β plays a critical role in protein solubility and stability. Non-glycosylated forms of IFN-
β are more susceptible to form aggregates and lead to immunogenicity. The limited number 
of studies suggests similar effects of both IFN-α and IFN-β on the relapse rates (Durelli et al. 
1996; Hughes 1997; Myhr et al. 1999).  
The subunit of IFN receptor IFN-α-R1 interacts with exposed helix C residues and exposed 
residues of helix A and helix C side (residues Lys83 and Tyr89) of IFN-β. IFN-α-R2 interacts 
with AB loop, helix D, DE loop and helix E. Residues Arg33/35, Arg144/147, Glul 46/149 
and Arg 149/151 are highly conserved and are involved in direct binding (Radhakrishnan et 
al. 1996). 
The structure-function analysis of the IFN-β can provide critical information on the INFAR 
binding receptors, neutralising antibody binding sites, identification of T-cell and B-cell 
antigenic determinants. The potential overlapping between sequences of amino acids can be 
identified.  
1.7.2 Side effects of interferon beta 
Nearly 80 % of the patients experience flu-like symptoms within 24 hours of IFN-β 
injections. The increase in temperatures can be due to up-regulation of inflammatory 
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cytokines such as IL-6 and IFN-γ. Skin reactions occur in 50 % of patients. Skin necrosis has 
been reported in 5 % of patients (Lublin et al. 1996; Walther & Hohlfeld 1999). Formation of 
anti-drug antibodies have been reported with all the 4 different IFN-β preparations 
('Randomised double-blind placebo-controlled study of interferon beta-1a in 
relapsing/remitting multiple sclerosis. PRISMS (Prevention of Relapses and Disability by 
Interferon beta-1a Subcutaneously in Multiple Sclerosis) Study Group'  1998; 'PRISMS-4: 
Long-term efficacy of interferon-beta-1a in relapsing MS'  2001; Rudick et al. 1998; UBC 
1996). The formation of neutralising antibodies impacts clinical safety and efficacy (the 
details of this aspect will be discussed in more detail in the systematic review described in 
chapter 2). 
1.8 Thesis aim and hypotheses 
The aim of the research presented in this thesis was to understand immunogenicity, anti-drug 
antibody formation and the immunological consequence of NAb against therapeutic protein 
IFN-β-1a Rebif™.     
This thesis set about addressing the following hypotheses: 
 IFN-β-1a Rebif™ IgG subclass antibodies exhibit differential neutralising capabilities 
and neutralise endogenous IFN-β.  
 IFN-β-1a Rebif™ IgG antibodies form immune complex with IFN-β-1a Rebif™ and 
activate complement. 
 IFN-β-1a Rebif™ IgG antibodies are associated with specific B-cell epitopes. 
 IFN-β-1a Rebif™ IgG antibodies are associated with specific T–cell epitopes. 
 Defect in the regulatory T-cells leads to IFN-β-1a Rebif™ immunogenicity. 
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Chapter 2: Influence and clinical significance of interferon beta neutralising antibodies 
in multiple sclerosis – a systematic review and meta-analysis 
2.1 Introduction 
Multiple sclerosis is a chronic inflammatory and neurodegenerative immune-mediated 
disorder of the CNS and is characterised by inflammation, demyelination and primary or 
secondary axonal degeneration (Compston & Coles 2008).   
Type I interferons which include IFN-β are used in the treatment of relapsing forms of 
multiple sclerosis and shown to be beneficial ('The IFNB Multiple Sclerosis Study Group'  
1993; Paty & Li 1993; Yong et al. 1998). There are two forms of IFN-β, namely IFN-β-1a 
and IFN-β-1b, which are prescribed for the treatment of multiple sclerosis (refer to Table 
2.1). IFN-β-1a is produced in CHO cells and is identical to the human form of IFN-β. 
Interferon beta-1b is produced in E.coli and consists of 165 amino acids due to lack of N 
terminal methionine and cysteine is substituted with serine at position 17. There are four 
different formulations of IFN-β: IM IFN-β-1a Avonex™ from Biogen-Idec, SC IFN-β-1a 
Rebif™ from Merck-Serono, SC IFN-β-1b Betaferon/Betaseron™ from Bayer-Schering and 
SC IFN-β-1b Extavia™ from Novartis (refer Figure 2.1 for amino acid sequences). Studies 
indicate IFN-β decreases the annualised relapse rate by approximately one-third (Napier 
1997). Overall IFN-β is welltolerated in the management of multiple sclerosis.  
A 
MTNKCLLQI ALLLCFSTTA LS 
   MSYNLLGFLQ RSSNFQCQKL LWQLNGRLEY CLKDRMNFDI PEEIKQLQQF QKEDAALTIY 
EMLQNIFAIF RQDSSSTGWN ETIVENLLAN VYHQINHLKT VLEEKLEKED  FTRGKLMSSL 
HLKRYYGRIL HYLKAKEYSH CAWTIVRVEI LRNFYFINRL TGYLRN 
 B 
MSYNLLGFLQ RSSNFQCQKL LWQLNGRLEY CLKDRMNFDI PEEIKQLQQF QKEDAALTIY 
EMLQNIFAIF RQDSSSTGWN ETIVENLLAN VYHQINHLKT VLEEKLEKED FTRGKLMSSL 
HLKRYYGRIL HYLKAKEYSH CAWTIVRVEI LRNFYFINRL TGYLRN   
C 
 SYNLLGFLQ  RSSNFQSQKL   LWQLNGRLEY CLKDRMNFDI PEEIKQLQQF QKEDAALTIY 
EMLQNIFAIF RQDSSSTGWN ETIVENLLAN VYHQINHLKT VLEEKLEKED FTRGKLMSSL 
HLKRYYGRIL HYLKAKEYSH CAWTIVRVEI LRNFYFINRL TGYLRN   
Figure 2.1: The amino acid sequences. The Figure A represents the amino acid sequence of 
human endogenous IFN-β molecule with 187 amino acids which includes 1-21 signal peptide 
and 22-187 interferon beta molecule. The Figure B represents the amino acid sequence of 
IFN-β-1a molecule with 166 amino acids and Figure C represents the amino acid sequence of 
IFN-β-1b molecule with 165 amino acids.                       
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IFN-β is the most commonly prescribed treatment for multiple sclerosis. However, IFN-β 
induces formation of neutralising antibodies which may abrogate the efficacy of the 
treatment.  Immunogenicity of IFN-β is the major complication associated with treatment. 
The formation of neutralising antibodies against biologics including IFN-β is due to several 
factors (Schellekens 2005) –  
o Patient specific factors for example patient age, genetic status, immunological status and 
competence of the patient 
o Treatment specific factors for examples treatment regime, route of administration, dosage 
and frequency of administration  
o Biologic specific factors for examples molecular structure or differences in the amino 
acid sequence, degree of humanisation, T-cell epitopes, B-cell epitopes, protein 
aggregates, post-translational modifications, impurities, formulation, manufacturing 
process. 
Up to 45 % (mean approx. 25 %) of patients develop neutralising antibodies to different 
formulations of IFN-β (Creeke & Farrell 2013). Neutralising antibodies are more frequently 
produced with IFN-β-1b than with IFN-β-1a (Bertolotto et al. 2003; Cook et al. 2001; 
Malucchi et al. 2004; Panitch et al. 2002). Research also suggests that SC IFN-β-1a is more 
immunogenic than with the IM route of administration (Giovannoni, Munschauer & 
Deisenhammer 2002). The causes for the formation of neutralising antibodies are unclear. 
Patients with neutralising antibodies exhibit higher relapse rates, prominent lesion activity on 
MRI and increased rate of disease progression (Sorensen 2008).   
This chapter describes a systematic review which aimed to determine factors affecting the 
formation of neutralising antibodies against different formulations of IFN-β in the treatment 
of multiple sclerosis. The review aimed to define the reasons for variability in the reported 
incidences of neutralising antibodies, and furthermore assess the methodological recording 
and reporting of clinical risk factors which contribute to the formation of neutralising 
antibodies against IFN-β.  
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Interferon beta formulations Produced 
in  
Protein 
modification 
Federal 
approval 
Molecular 
target 
Molecular 
structure 
Licensed 
for  
Route  Frequency Distributor 
Avonex™ Interferon 
beta-1a 
Recombinant 
form of 
native 
protein  
CHO cells Glycosylated 1996 Type 1 
interferon 
receptors 
Recombinant 
human 
physiologic 
protein 
molecular 
weight 22.5 
kDa 
RRMS IM QW Biogen Idec 
Rebif™ Interferon 
beta-1a 
Recombinant 
form of 
native 
protein  
CHO cells Glycosylated 2002 Type 1 
interferon 
receptors 
Recombinant 
human 
physiologic 
protein 
molecular 
weight 22.5 
kDa 
RRMS SC TIW Merck 
Serono, 
Pfizer 
Betaseron/ 
Betaferon™ 
Interferon 
beta-1b 
Recombinant 
form 
E.coli Not 
glycosylated 
1993 Type 1 
interferon 
receptors 
Recombinant 
human 
physiologic 
protein 
molecular 
weight 18.5 
kDa 
RRMS SC EOD Bayer 
Extavia™ 2009 Novartis 
 
Table 2.1: Characteristics of different interferon beta formulations (source Drugs@FDA page on the FDA website). Abbreviations: CHO, 
Chinese Hamster Ovary; E.coli, Escherichia coli; kDa, Kilodalton; RRMS, relapsing remitting multiple sclerosis; IM, intramuscular; SC, 
subcutaneous; QW, once a week; QIW, 3 times a week; EOD, every other day.  
4
5
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2.2 Methods 
2.2.1 Search strategy 
The databases used in the review included MEDLINE OVID (1950 to February Week 4 
2013), EMBASE OVID (1980 to February Week 4 2013), CENTRAL on The Cochrane 
Library (2011, Issue 4) and the Clinicaltrials.gov (1997 to February Week 4 2013). Search 
strategies were developed specifically for each database and are presented in Appendix 2. 
The reference lists of identified review articles and of all included trials were searched to find 
other potentially eligible studies. 
2.2.2 Criteria for considering studies in this review 
Randomised controlled trials (RCTs) and non-randomised controlled studies (NRS) 
comparing the efficacy of different formulations of IFN-β such as IFN-β-1a Avonex™, IFN-
β-1a Rebif™, IFN-β-1b Betaferon/Betaseron™, and IFN-β-1b Extavia™ in patients with 
multiple sclerosis were included. Men and women (aged 18 or more) were eligible. Trials in 
which IFN-β were used to treat or control other disease conditions were excluded. Studies 
were only considered for inclusion if they were published in English.    
2.2.3 Types of outcome measure 
The primary outcome of interest extracted in each study was the frequency of IFN-β 
neutralising antibodies.   
2.2.4 Study selection 
2.2.4.1 Inspection of citations 
After duplicate citations were removed, all titles and abstracts were independently reviewed 
by two reviewers with reference to the inclusion or exclusion criteria (refer appendix 3 - 
Study Eligibility Screening Form) and a decision was made about whether to retrieve the full 
report of the study.  The number of titles or abstracts identified, selected and rejected was 
recorded.   
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2.2.4.2 Inspection of retrieved reports 
Once the full reports were retrieved, they were inspected for relevance to the review and the 
inclusion and exclusion criteria were applied.  Studies not meeting the pre-determined criteria 
were excluded.  If there was any disagreement about whether to include any of the studies, a 
third reviewer assessed them and, together with the other reviewers made a consensus 
decision about whether to include or exclude.  A record was made of the number of full 
reports retrieved and the number excluded.   
2.2.5 Data collection 
A formal data extraction form was designed, piloted independently on a small selection of 
studies and adjusted as necessary (refer appendices 3 and 4). For each study, information 
regarding the participants, comparison groups, treatments and outcomes were tabulated. 
Where they were recorded or provided by the author, the following data were extracted for 
each randomised study: 
1. Study characteristics: number of participants, number of participants in each treatment 
group, year completed, setting, inclusion criteria, definition of neutralising antibody 
positivity and length of follow up. 
2. Participant characteristics: age, gender, underlying disease and indication for IFN-β 
treatment. 
3. Treatments: number of treatment groups, treatment details (Avonex™ and/or Rebif™ 
and/or Betaferon/Betaseron™ and/or Extavia™), dosage, route of administration and 
frequency of treatment. 
4. Outcomes reported: status of neutralising antibodies and the method used to detect 
neutralising antibodies.  
Where they were recorded or provided by the author, the following data were extracted for 
each non-randomised study: 
1. Study characteristics: number of participants, number of participants in each intervention 
group, year completed, setting, inclusion criteria, definition of neutralising antibody 
positivity and length of follow up. 
2. Participant characteristics: age, gender, underlying disease and indication for IFN-β 
treatment. 
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3. Treatment characteristics: Avonex™ and/or Rebif™ and/or Betaferon/Betaseron™ and/or 
Extavia™, dosage, route of administration and frequency of treatment. 
4. Status of neutralising antibodies and the method used to detect neutralising antibodies.  
2.2.6 Quality assessment 
The methodological quality of frequency of neutralising antibodies recording and reporting 
was assessed for both randomised and non-randomised studies using selected elements of the 
McMaster Quality Assessment Scale of Harms for primary studies (the McHarm scale) 
http://hiru.mcmaster.ca/epc/mcharm.pdf. The elements used were selected based on an 
evaluation of their relevance to our research question and what they aimed to evaluate: the 
quality and appropriateness of study design and reporting, the applicability of the study 
findings to the population and measures taken to reduce bias (refer appendix 6).  
Both data collection and quality assessment of studies were undertaken from one reviewer 
(Karthik Govindappa), with three randomised and three non-randomised studies assessed by a 
second reviewer (Dr Jamie Kirkham) to check for consistency.   
2.2.7 Statistical analysis and synthesis 
Statistical analyses were performed using RevMan (version 5.2 software). As the frequency 
of IFN-β neutralising antibodies data is dichotomous (i.e. the data from outcomes have two 
possible values for example yes or no), the data were analysed by calculating the Odds Ratio 
(OR) with corresponding 95% confidence intervals using the method of Mantel-Haenszel. 
Data from randomised controlled trials were analysed separately from the non-randomised 
study data.    
2.2.7.1 Meta-analysis 
We aimed to conduct two primary meta-analyses. For RCTs, the frequency of neutralising 
antibodies against IFN-β-1a Avonex™, IFN-β-1a Rebif™, IFN-β-1b Betaferon/Betaseron™ 
or IFN-β-1b Extavia™ in patients with multiple sclerosis was determined. For NRS, the 
frequency of neutralising antibodies against IFN-β-1a Avonex™, IFN-β-1a Rebif™, IFN-β-
1b Betaferon/Betaseron™ or IFN-β-1b Extavia™ in patients with multiple sclerosis was 
determined.  
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2.2.7.2 Heterogeneity and sub group analyses 
If clinical heterogeneity was too great, studies were not pooled in a meta-analysis and 
narrative synthesis was used to compare studies. A chi-squared test for statistical 
heterogeneity was undertaken and the I
2 
statistic was calculated. Where the necessary data 
were available, the following analyses were also planned: 
o Comparison of neutralising antibodies against IFN-β-1a Avonex™ 30 µg and 60 µg; 
o Comparison of neutralising antibodies against IFN-β-1a Rebif™ 22 µg and 44 µg and 
o Comparison of neutralising antibodies against IFN-β-1a and IFN-β-1b 
2.2.7.3 Publication bias 
Publication bias for the randomised trials included in the meta-analyses was assessed by 
visual inspection of a funnel plot providing a sufficient number of studies were included in 
the analysis. All study authors were contacted where ever possible for missing outcome data.  
2.3 Results 
2.3.1 Search results 
The database searches undertaken in February Week 4 2013, identified 249 abstracts for 
screening. After review of abstracts, 80 full text articles were reviewed. Of these, 40 articles 
were found to be not relevant, duplicates, one article was in Spanish language (Fernandez et 
al. 1999), two articles did not meet set inclusion criteria >20 patients (Chiu et al. 2007; Reske 
et al. 2004) and another two studies focused on neutralising antibody positive patients 
(Malucchi et al. 2005; Petersen et al. 2006). The remaining 35 articles were found to be 
eligible for this review (see Figure 2.2).       
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Figure 2.2: PRISMA flow diagram illustrating search strategy. Abbreviations: PRISMA 
– Preferred Reporting Items for Systematic Reviews and Meta-Analyses; NAbs – neutralising 
antibodies; RCT – randomised control trials; NRS – non randomised studies.   
2.3.2 Included studies 
The characteristics of the studies included in this review such as the intervention, 
formulation, dosage, route of administration, frequency, number of patients, neutralising 
antibodies definition, method used for detection of neutralising antibodies and the follow up 
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duration in months of all the RCTs and NRS are shown in Tables 2.2, 2.3 and 2.4. The Table 
2.2 list the characteristics of RCTs (n = 8) included in the meta-analysis (Barbero et al. 2006; 
Clanet et al. 2002; Francis et al. 2005; Freedman et al. 2005; Kappos et al. 2005; Li et al. 
2001a; Schwid & Panitch 2007; Sorensen et al. 2003). Table 2.3 list the characteristics of 
RCTs (n = 6) not included in the meta-analysis ('North American Study Group'  2004; 
Goodin et al. 2012; Polman et al. 2003; Rudick et al. 1998; Shahkarami et al. 2013; UBC 
1996) and Table 2.4 list the characteristics of NRS (n = 21) (Bellomi et al. 2003; Bertolotto et 
al. 2002; Durelli et al. 2008; Durelli et al. 2009; Farrell et al. 2008; Frank et al. 2004; Gilli et 
al. 2007; Giovannoni et al. 2007; Gottesman & Friedman-Urevich 2006; Hartung et al. 2011; 
Hegen et al. 2012a; Knobler et al. 1993; Malucchi et al. 2005; Minagar, Murray & 
Investigators 2008; Pachner et al. 2009a; Petkau et al. 2004; Phillips et al. 2004; Ross et al. 
2000b; Scagnolari et al. 2002a; Sorensen et al. 2005d) and Clinical trial NCT00367484 2011.  
The meta-analysis included 4146 patients with multiple sclerosis randomised to receive either 
IFN-β or placebo. Of those 1963 received IFN-β-1a Avonex™, 1694 received IFN-β-1a 
Rebif™ and 256 received IFN-β-1b Betaseron/Betaferon™. The comparison was established 
between these studies. The six RCTs where no comparison was able to establish the 
neutralising antibodies against different IFN-β formulations are described descriptively. 
However, a total of 3575 patients with multiple sclerosis received either IFN-β or placebo. Of 
those 408 received IFN-β-1a Avonex™, none received IFN-β-1a Rebif™ and 2489 received 
IFN-β-1b Betaseron/Betaferon™.  
Of the 21 non randomised studies, the comparison was established in seven studies consisting 
of 1763 patients with multiple sclerosis to receive IFN-β. Of those 497 received IFN-β-1a 
Avonex™, 768 received IFN-β-1a Rebif™ and 498 received IFN-β-1b 
Betaseron/Betaferon™. The remaining 14 non randomised studies where no comparison was 
able to establish the neutralising antibodies against different IFN-β formulations are 
described descriptively. However, a total of 2409 patients with multiple sclerosis received 
either IFN-β. Of those 294 received IFN-β-1a Avonex™, 969 received IFN-β-1a Rebif™ and 
1146 received IFN-β-1b Betaseron/Betaferon™. 
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Characteristics of the RCTs included in the meta-analysis 
   
Study Year Intervention Formulation Dosage Route Frequency 
 
Patients 
 
NAbs 
define 
NAbs 
detection 
method 
Follow up 
duration 
(months) 
Li 2001 
IFN-β-1a  Rebif™  22 µg SC TIW 303 
≥ 20 CPE 
36 
months IFN-β-1a  Rebif™  44 µg SC TIW 297 
Clanet 2002 
IFN-β-1a  Avonex™ 30 µg IM QW 402 
≥ 20 CPE 
36  
months IFN-β-1a  Avonex™ 60 µg IM QW 400 
Sorenson 2003 
IFN-β-1a  Rebif™  22 µg SC QW 103 
≥ 20 CPE 
Up to 60 
months 
IFN-β-1a  Rebif™  22 µg SC TIW 162 
IFN-β-1a  Avonex™ 30 µg IM TIW 82 
IFN-β-1b 
Betaseron/ 
Betaferon™ 
250 µg SC EOD 194 
  Placebo 
   
233 
Francis 2005 
IFN-β-1a  Rebif™  22 ug SC TIW 186 
≥ 20 CPE 
Up to 48 
months IFN-β-1a  Rebif™  44 ug SC TIW 182 
Freedman 2005 
IFN-β-1a  Rebif™  22 µg SC QW 95 
≥ 20 
Not 
reported 
Up to 24 
months IFN-β-1a  Rebif™  44 µg SC QW 98 
Kappos 2005 
IFN-β-1a  Avonex™ 30 µg IM QW 400 
≥ 20 CPE 
Up to 48 
months IFN-β-1a  Avonex™ 60 µg IM QW 395 
Barbero  2006 
IFN-β-1a  Avonex™ 30 µg IM QW 65 
≥ 20 
Not 
reported 
24  
months IFN-β-1b 
Betaseron/ 
Betaferon™ 
250 µg SC EOD 62 
Schwid 2007 
IFN-β-1a  Rebif™  44 µg SC TIW 268 
≥ 20 
Not 
reported 
Up to 16 
months IFN-β-1a  Avonex™ 30 µg IM QW 219 
 Table 2.2: Characteristics of RCTs included in the meta-analysis. Abbreviations: IFN-β, 
interferon beta; µg, microgram; SC, subcutaneous; IM, intramuscular; NAbs, neutralising antibodies; 
TIW, 3 times a week; QW, once a week; EOD, every other day; CPE, Cytopathic effect assay; MxA, 
Myxovirus A protein assay.  
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Characteristics of the RCTs not included in the meta-analysis 
Study Year Intervention Formulation Dosage Route Frequency Patients 
NAbs 
define 
NAbs 
detection 
method 
Follow up 
duration 
(months) 
UBC  1996 IFN-β-1b 
Betaseron/ 
Betaferon™ 250 µg SC EOD 
91 
≥ 20 CPE 
60  
months 
Placebo 87 
Rudick 1998 
IFN-β-1a or  
1b 
Avonex™ or 
Betaseron™ 
30 or 
250 µg 
IM or 
SC 
QW or  
EOD 
23 
103 ≥ 20 CPE 
Up to 60 
months 
IFN-β-1a  Avonex™ 30 µg IM QW 301 24 months 
Polman 2003 IFN-β-1b 
Betaseron/ 
Betaferon™ 250 µg SC EOD 
360 
≥ 20 
CPE and  
MxA 
36  
months 
Placebo 358 
N American 2004 IFN-β-1b 
Betaseron/ 
Betaferon™ 250 µg SC EOD 
238 
≥ 20 MxA 
36  
months 
Placebo 233 
Goodin 2012 IFN-β-1b 
Betaseron/ 
Betaferon™ 
250 µg 
SC EOD 
861 
≥ 20 MxA 
Up to  
42 months 500 ug 836 
Shahkarami 2013 IFN-β-1a  
Avonex™ 
30 µg IM QW 
42 
≥ 20 
CPE and  24  
months Cinnovex™ 42 Luciferase 
 Table 2.3: Characteristics of RCTs not included in the meta-analysis. Abbreviations: UBC, 
University of British Columbia; IFN-β, interferon beta; Cinnovex, is avonex biosimilar; µg, 
microgram; SC, subcutaneous; IM, intramuscular; NAbs, neutralising antibodies; TIW, 3 times a 
week; QW, once a week; EOD, every other day; CPE, Cytopathic effect assay; MxA, Myxovirus A 
protein assay.   
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Characteristics of non-randomised studies 
Study Year Intervention Formulation Dosage Route Frequency Patients 
NAbs 
define 
NAbs 
detection 
method 
 
Follow up 
duration 
(months) 
 
Knobler 1993 IFN-β-1b 
Betaseron/ 
Betaferon™ 
Various SC TIW 24 ≥ 20 CPE 
Up to  
72 
months 
Ross 2000 
IFN-β-1a  Avonex™ 30 µg IM QW 140 
Not  
reported 
CPE 
24  
months 
IFN-β-1a  Rebif™  
22 µg SC QW 143 
22 µg SC TIW 160 
IFN-β-1b 
Betaseron/ 
Betaferon™ 
250 µg SC EOD 311 
Bertolotto 2002 
IFN-β-1a  Avonex™ 30 µg IM QW 44 
≥ 20 CPE 
Up to  
18 
months 
IFN-β-1a  Rebif™  
22 µg SC TIW 36 
22 µg IM QW  16 
IFN-β-1b 
Betaseron/ 
Betaferon™ 
250 µg SC EOD 29 
Scagnolaric 2002 
IFN-β-1a  
Rebif™  
Avonex™ 
22 µg SC TIW 27 
Not  
reported 
CPE 
12  
months 
30 µg IM QW 32 
IFN-β-1b 
Betaseron/ 
Betaferon™ 
250 µg SC EOD 32 
Bellomi 2003 
IFN-β-1a  Rebif™  33 µg SC TIW 13 
Not  
reported 
CPE 
Up to 
72 
months 
IFN-β-1b 
Betaseron/ 
Betaferon™ 
250 µg SC TIW 29 
Frank 2004 IFN-β-1b 
Betaseron/ 
Betaferon™ 
250 µg SC EOD 30 ≥ 20 MxA 
Up to  
26 
months 
Malucchi 2004 
IFN-β-1a  Avonex™ 30 µg IM QW 33 
≥ 20 CPE  
Up to  
36 
months 
IFN-β-1a  Rebif™  22 µg SC TIW 25 
IFN-β-1b 
Betaseron/ 
Betaferon™ 
250 µg SC EOD 20 
Phillips 2004 IFN-β-1a  Avonex™ 30 µg IM QW 153 ≥ 20 CPE 
Up to  
24 
months 
Petkau 2004 IFN-β-1b 
Betaseron/ 
Betaferon™ 
50 µg 
SC EOD 
125 
≥ 20 
CPE and 
MxA 
36  
months 250 µg 124 
Sorenson 2005 
IFN-β-1a  Avonex™ 30 µg IM QW 70 
Not  
reported 
CPE 
Up to  
78 
months 
IFN-β-1a  Rebif™  
22 or  
44 µg 
SC TIW 170 
IFN-β-1b 
Betaseron/ 
Betaferon™ 
250 µg SC TIW 191 
Gottesman 2006 IFN-β-1b 
Betaseron/ 
Betaferon™ 
250 µg SC EOD 20 ≥ 20 MxA 
6  
months 
Giovannoni 2007 IFN-β-1a  Rebif™  44 µg SC TIW 259 ≥ 20 CPE 
Up to  
22 
months 
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Durelli 2008 IFN-β-1b 
Betaseron/ 
Betaferon™ 
250 µg SC EOD 88 ≥ 20 MxA 
48 
months 
Gilli 2007 
IFN-β-1a  Avonex™ 30 µg IM QW 60 
≥ 20 MxA 
Not  
reported 
IFN-β-1a  Rebif™  
22 µg 
SC TIW 
95 
44 µg 50 
IFN-β-1b 
Betaseron/ 
Betaferon™ 
250 µg SC TIW 51 
Farrell 2008 
IFN-β-1a  Avonex™ 30 µg IM QW 119 
≥ 20 Luciferase 
36  
months 
IFN-β-1a  Rebif™  
22 or  
44 µg 
SC TIW 149 
IFN-β-1b 
Betaseron/ 
Betaferon™ 
250 µg SC EOD 55 
Minager 2008 
IFN-β-1a  Avonex™ 30 µg IM QW 69 
Not  
reported 
Not 
reported 
Up to 
24 
months 
IFN-β-1a  Rebif™  44 µg SC TIW 67 
Durelli 2009 IFN-β-1b 
Betaseron/ 
Betaferon™ 
250 µg 
SC EOD 145 ≥ 20 MxA 
48  
months 375 µg 
Pachner 2009 IFN-β-1b 
Betaseron/ 
Betaferon™ 
250 µg SC EOD 30 ≥ 20 
CPE and 
MxA 
Not  
reported 
Hartung 2011 IFN-β-1b 
Betaseron/ 
Betaferon™ 
250 µg SC EOD 277 ≥ 20 MxA 
60  
months 
Hegan 2011 
IFN-β-1a  Avonex™ 
Not 
reported 
IM 
Not  
reported 
71 
≥ 20 MxA 
96  
months 
IFN-β-1a  Rebif™  
22 or  
44 µg 
SC 69 
IFN-β-1b 
Betaseron/ 
Betaferon™ 
Not 
reported 
  63 
Clinical trial 
NCT00367484 
2011 IFN-β-1a 
Rebif™ 
Clone 484-
39 
44 µg SC TIW 458 
Not 
reported 
Not 
reported 
12 
months 
 Table 2.4: Characteristics of non-randomised studies. Abbreviations: IFN-β, interferon beta; 
Various, 25, 125,  250, 500 µg; µg, microgram; SC, subcutaneous; IM, intramuscular; NAbs, 
neutralising antibodies; TIW, 3 times a week; QW, once a week; EOD, every other day; CPE, 
Cytopathic effect assay; MxA, Myxovirus A protein assay.  
2.3.3 Evaluating risk of bias 
The results of McHarm scale assessment for both RCTs and NRS were as follows: twenty- eight 
studies defined neutralising antibodies cut-off titres ≥ 20 NU/mL, all studies actively collected 
the neutralising antibodies data using a pre-defined lab diagnostic test, fourteen studies specified 
the baseline, timing and frequency of neutralising antibodies data, thirteen studies mentioned the 
Kawade method to report neutralising antibodies and fourteen studies clearly mentioned the 
protocol or methods for detection of neutralising antibodies (refer Table 2.5 and 2.6).     
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Evaluating  risk of bias in RCTs  
Studies Elements 
adopted from 
McHarm Scale 
Was NAb 
positivity 
pre-defined 
using 
standard or 
precise 
definitions? 
Was the 
mode of 
NAb data 
collection 
specified 
as active?  
Did the study 
specify the 
baseline, 
timing and 
frequency of 
NAb data 
collection?  
Did the 
authors use 
standard 
scales or 
checklist in 
NAb data 
collection?  
Is there a 
possibility 
of 
selective 
outcome 
reporting?  
1 UBC 1996 Yes Yes No baseline Unclear No 
2 Rudick 1998 Yes Yes Yes Yes Yes 
3 Li 2001 Yes Yes No baseline Unclear No 
4 Clanet 2002 Yes Yes Yes Unclear No 
5 Polman 2003 Yes Yes No baseline Unclear No 
6 Sorenson 2003 No Yes No baseline Unclear Yes 
7 N American 
2004 
Yes Yes No baseline Unclear No 
8 Francis 2005 Yes Yes No baseline Yes Yes 
9 Freedman 2005 Yes Yes No baseline Unclear No 
10 Kappos 2005 Yes Yes Yes Yes Yes 
11 Barbero 2006 Yes Yes  Yes Unclear No 
12 Schwid 2007 Yes Yes No baseline Unclear No 
13 Goodin 2012 Yes Yes Yes Unclear No 
14 Shahkarami 
2013 
Yes Yes Yes Yes No 
 
Table 2.5: Risk of bias for RCTs using McHarm Scale. The purpose of McHarm scale is to 
evaluate the harms associated in the studies and it provides the quality assessment checklist to 
harms in studies included for analysis.  
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Evaluating  risk of bias in NRS 
Studies Elements 
adopted from 
McHarm Scale 
Was NAb 
positivity 
pre-defined 
using 
standard or 
precise 
definitions? 
Was the 
mode of 
NAb data 
collection 
specified 
as active?  
Did the study 
specify the 
baseline, 
timing and 
frequency of 
NAb data 
collection?  
Did the 
authors use 
standard 
scales or 
checklist in 
NAb data 
collection?  
Is there a 
possibility 
of 
selective 
outcome 
reporting?  
1 Knobler 1993 Yes Yes No Unclear No 
2 Ross 2000 No Yes No frequency Yes Yes 
3 Bertolotto 2002 Yes Yes Yes Yes Yes 
4 Scagnolaric 
2002 
No Yes No baseline 
and timing 
Yes Yes 
5 Bellomi 2003 No Yes No baseline 
and timing 
Yes Yes 
6 Frank 2004 Yes Yes No baseline Unclear No 
7 Maluccchi 2004 Yes Yes Yes Yes Yes 
8 Phillips 2004 Yes Yes Yes Yes Unclear 
9 Petkau 2004 Yes Yes No baseline  Unclear No 
10 Sorenson 2005 No Yes No baseline Unclear Yes 
11 Gottesman 
2006 
Yes Yes Yes Unclear No 
12 Giovannoni 
2007 
Yes Yes Yes Unclear  No 
13 Gilli 2007 Yes Yes Yes Yes Yes 
14 Durelli 2008 Yes Yes No baseline Unclear No 
15 Farrell 2008 Yes Yes  No baseline 
and timing 
Yes Yes 
16 Minager 2008 No Yes Yes Unclear No 
17 Durelli 2009 Yes Yes  No baseline Unclear Yes 
18 Pachner 2009 Yes Yes Yes Unclear No 
19 Hartung 2011 Yes Yes No baseline 
and timing 
Yes No 
20 Hegan 2011 Yes Yes No baseline 
and timing 
Unclear Yes 
21 Clinical trial 
NCT00367484 
2011 
No Yes No baseline 
and timing 
Unclear No 
 
Table 2.6: Risk of bias for NRS using McHarm Scale. The purpose of McHarm scale is to 
evaluate the harms associated in the studies and it provides the quality assessment checklist to 
harms in studies included for analysis.  
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2.4 Randomised controlled trials comparing formation of neutralising antibodies 
against    
2.4.1 IFN-β-1a Avonex™ and Rebif™ 
Two studies involving 834 participants published in 2003 and 2007 (Schwid & Panitch 2007; 
Sorensen et al. 2003) provided data for this comparison. Sorensen et al followed patients for 
up to 60 months, while Schwid et al followed patients for up to 24 months. The primary 
outcome of Sorensen et al was to follow the formation of neutralising antibody against 
Avonex™ and Rebif™ and Schwid et al was to compare the clinical efficacy of Avonex™ 
and Rebif™. In Sorenson’s study, patients received Avonex™ 30 µg once a week 
administered IM and Rebif™ 22 µg either once or three times a week administered SC. The 
neutralising antibody was measured using the CPE (Cytopathic effect) assay using different 
assay sensitivities and was measured every 12 months. In Schwid’s study, patients received 
Avonex™ 30 µg once a week administered IM and Rebif™ 44 µg either three times a week 
administered SC. Neutralising antibody formation was assessed every 6 months but no 
information was provided on the detection method. The neutralising antibody cut-off positive 
titre was defined at ≥ 20 neutralising units (NU)/mL and was measured using Kawade 
titration method (TRU/ mL = ten times reduction units per mL). The frequency of 
neutralising antibodies was 22 out of 301 (7.30 %) for Avonex™ and 152 out of 533 (28.51 
%) for Rebif™. The pooled estimate significantly favoured Avonex™ (fixed effect, OR 0.22, 
95 % CI 0.13, 0.35) and the results showed little heterogeneity, I
2
 = 0 % (refer Figure 2.3). 
 
Figure 2.3: Forest plot. Individual and pooled OR for the outcome formation of neutralising 
antibodies in the studies considering two formulations of IFN-β Avonex™ and Rebif™.  
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2.4.2 IFN-β-1a Rebif™ and IFN-β-1b Betaseron/Betaferon™ 
Only one study involving 459 participants provided data for this comparison (Sorensen et al. 
2003). Sorensen el al followed patients for up to 60 months and the primary outcome of the 
study was to follow the formation of neutralising antibodies against Rebif™ and 
Betaseron/Betaferon™. Patients received Rebif™ 22 µg either once or three times a week 
administered SC and Betaseron/Betaferon™ 250 µg every other day administered SC. 
Neutralising antibody was measured using the CPE assay using different assay sensitivities 
and was measured every 12 months. The frequency of neutralising antibodies in this study 
was 89 out of 265 (33.58 %) for Rebif™ and 88 out of 194 (45.36 %) for 
Betaseron/Betaferon™. The pooled estimate was significant favouring Rebif™ (fixed effect, 
OR 0.61, 95 % CI 0.42, 0.89). 
2.4.3 IFN-β-1a Avonex™ and IFN-β-1b Betaseron/Betaferon™ 
Two studies involving 403 participants provided data for this comparison (Barbero et al. 
2006; Sorensen et al. 2003). Sorensen et al followed patients for up to 60 months, while 
Barbero et al followed patients for 24 months. The primary outcome of Sorenson et al was 
the formation of neutralising antibody against Avonex™ and Betaseron/Betaferon™ and 
Barbero et al was the efficacy of Avonex™ and Betaseron/Betaferon™. In Sorenson’s study, 
patients received Avonex™ 30 µg once a week administered IM and Betaseron/Betaferon™ 
250 µg every other day administered SC. Neutralising antibody was measured using CPE 
assay using different assay sensitivities and was measured every 12 months. In Barbero’s 
study, patients received Avonex™ 30 µg once a week administered IM and 
Betaseron/Betaferon™ 250 µg every other day administered SC. No information was 
provided on the neutralising antibody detection method but this was measured every 6 
months. The neutralising antibody cut-off positive for titre was defined a ≥ 20 neutralising 
units (NU)/mL and was measured using Kawade titration method (TRU/ mL = ten times 
reduction units per mL). The frequency of neutralising antibodies in these studies was 11 out 
of 147 (7.48 %) for Avonex™ and 110 out of 256 (42.96 %) for Betaseron/Betaferon™. The 
pooled estimate significantly favoured Avonex™ (fixed effect, OR 0.11, 95 % CI 0.06, 0.22) 
and the results showed little heterogeneity, I
2 
= 0 % (refer Figure 2.4).   
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Figure 2.4: Forest plot.  Individual and pooled OR for the outcome formation of neutralising 
antibodies in the studies considering two formulations of IFN-β Avonex™ and 
Betaseron/Betaferon™. 
2.5 Subgroup meta-analysis  
2.5.1 IFN-β-1a Avonex™ 30 µg and 60 µg 
Two studies involving 1597 participants provided data for this comparison (Clanet et al. 
2002; Kappos et al. 2005). Clanet et al followed patients for 36 months, while Kappos et al 
followed patients for up to 48 months. The primary outcome for Clanet et al was to compare 
the clinical efficacy of IFN-β-1a Avonex™ 30 µg IM and 60 µg IM decreasing disease 
progression and Kappos et al was to determine the incidence and significance of neutralising 
antibodies against IFN-β-1a Avonex™ 30 µg IM and 60 µg IM. Both studies used the CPE 
assay to detect neutralising antibody every 3 months (Kappos et al. 2005) and 6 months 
(Clanet et al. 2002) respectively. The neutralising antibody cut-off positive titre was defined 
at ≥ 20 neutralising units (NU)/mL and was measured using Kawade titration method (TRU/ 
mL = ten times reduction units per mL).The frequency of neutralising antibodies in these 
studies was 16 out of 802 (1.99 %) for Avonex™ 30 µg IM and 42 out of 795 (5.49 %) for 
Avonex™ 60 µg IM. The pooled estimate was significant favouring Avonex™ 30 µg IM 
(fixed effect, OR 0.36, 95 % 0.20, 0.65) and the results showed little heterogeneity, I
2 
= 0 % 
(refer Figure 2.5). 
 
Figure 2.5: Forest plot. Individual and pooled OR for the outcome of neutralising antibodies 
in the studies considering Avonex™ 30 µg and 60 µg.  
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2.5.2 IFN-β-1a Rebif™ 22 µg and 44 µg 
These three studies involving 1161 participants were published in 2001 and 2005 (Francis et 
al. 2005; Freedman et al. 2005; Li et al. 2001a). Li et al followed patients for 36 months; 
Francis et al followed patients for up to 48 months and Freedman et al followed patients for 
up to 24 months. The primary outcome of Li et al was to investigate the change in the MRI 
during IFN-β-1a Rebif™ treatment. The primary outcome of Francis et al was to examine the 
role of neutralising antibodies on the efficacy of IFN-β-1a Rebif™. The primary outcome of 
Freedman et al was to demonstrate the efficacy of once weekly IFN-β-1a Rebif™ on the 
treatment of relapses. Li et al and Francis et al used the CPE assay to detect neutralising 
antibodies. However, Freedman et al did not mention the method used for detection of 
neutralising antibodies. Freedman et al and Li et al measured the neutralising antibodies 
every 3 and 6 months respectively. Francis et al did not mention the timing of neutralising 
antibody measurements. The neutralising antibody cut off positive titre was defined at ≥ 20 
neutralising units (NU)/mL. The frequency of neutralising antibodies in these studies was 128 
out of 584 (21.01 %) for Rebif™ 22 µg SC and 97 out of 577 (16.81 %) for Rebif™ 44 µg 
SC. The pooled estimate favoured Rebif™ 44 µg SC although the difference did not reach 
statistical significance (random effect, OR 1.27, 95 % CI 0.75, 2.14), the results show 
heterogeneity, I
2
 = 63 % (refer Figure 2.6). 
 
Figure 2.6: Forest plot. Individual and pooled OR for the outcome of neutralising antibodies 
in the studies considering Rebif™ 22 µg and 44 µg.  
2.5.3 IFN-β-1a and IFN-β-1b 
These two studies involved 586 participants provided data for this comparison (Barbero et al. 
2006; Sorensen et al. 2003).  Sorensen et al followed patients for up to 60 months, while 
Barbero et al followed patients for 24 months. The primary outcome of Sorenson et al was 
the formation of neutralising antibodies against IFN-β-1a and IFN-β-1b. The primary 
outcome of Barbero et al was the number of patients with at least one active MRI lesion using 
IFN-β-1a and IFN-β-1b. In Sorenson’s study, patients received IFN-β-1a 30 µg once a week 
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administered IM or 22 µg once or three times a week SC and IFN-β-1b 250 µg every other 
day administered SC. The neutralising antibody was measured using CPE assay using 
different assay sensitivities every 12 months. In Barbero’s study, patients received IFN-β-1a 
30 µg once a week administered IM and IFN-β-1b 250 µg every other day administered SC. 
No information was provided on the neutralising antibody detection method but this was 
measured every 6 months. The neutralising antibody cut-off positive titre was defined at ≥ 20 
neutralising units (NU)/mL and was measured using Kawade titration method (TRU/ mL = 
ten times reduction units per mL). The frequency of neutralising antibodies in these studies 
reported was 100 out of 330 (30.30 %) for IFN-β-1a and 110 out of 256 (42.96 %) for IFN-β-
1b. The pooled estimate favoured IFN-β-1a although the difference did not reach statistical 
significance (random effect, OR 0.31, 95 % CI 0.06, 1.72) and the results showed 
heterogeneity, I
2
 = 88% (refer Figure 2.7). 
 
Figure 2.7: Forest plot. Individual and pooled OR for the outcome of neutralising antibodies 
in the studies considering IFN-β-1a and 1b.   
2.6 Randomised controlled trails which were not included in meta-analysis 
These six studies involved 3575 participants and were published between 1996 and 2013.                         
('North American Study Group'  2004; Goodin et al. 2012; Polman et al. 2003; Rudick et al. 
1998; Shahkarami et al. 2013; UBC 1996) (UBC – University of British Columbia). The 
follow up of patients in all these studies varied from 24 months up to 60 months (refer Table 
2.3).  
The primary outcome of University of British Columbia (UBC) study was to validate the 
accuracy of neutralising antibodies against Betaseron/Betaferon™ during the trial and to 
discuss the clinical implications of neutralising antibodies. The primary outcome of Ruddick 
et al was to define the incidence and significance of neutralising antibodies against Avonex™ 
30 µg QW IM and Betaseron/Betaferon™. The primary outcome of Polman et al was to 
explore the relationship between neutralising antibodies against Betaseron/Betaferon™ and 
clinical measures of the disease. The primary outcome of N American et al was to evaluate 
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the clinical efficacy and safety of Betaseron/Betaferon™. The primary outcome of Goodin et 
al was to assess neutralising antibodies against Betaseron/Betaferon™ 250 µg or 500 µg 
EOD SC in the trial. The primary outcome of Shahkarami et al was to evaluate the 
immunogenetic profile of Avonex™ 30 µg QW IM and Cinnovex™ (biosimilar) 30 µg QW 
IM. University of British Columbia study and Ruddick et al used the CPE assay to detect 
neutralising antibodies. Polman et al used both CPE and Myxovirus A protein (MxA) assay, 
N American et al used the MxA assay, Goodin et al used the MxA assay and Shahkarami et 
al used both CPE and the Luciferase assay to detect neutralising antibodies. The neutralising 
antibody cut-off positive titre was defined at ≥ 20 neutralising units (NU)/mL and was 
measured every 3 months (Goodin et al. 2012; Rudick et al. 1998; Shahkarami et al. 2013) or 
6 months ('North American Study Group'  2004; Polman et al. 2003; Rudick et al. 1998; UBC 
1996) (UBC – University of British Columbia) using Kawade titration method (TRU/ mL = 
ten times reduction units per mL).. The frequency of neutralising antibodies in Rudick’s 
study was 57 out of 301 (18.93 %) for Avonex™ 30 µg QW IM. The frequency of 
neutralising antibodies in Goodin’s study was 319 out of 861 (37.04 %) for 
Betaseron/Betaferon™ 250 µg and 340 out of 836 (40.66 %) for Betaseron/Betaferon™ 500 
µg and for Shahkarami’s study was 2 out of 42 (4.76 %) and 1 out of 42 (2.38 %) for 
Avonex™ and Cinnovex™ respectively. In all other studies where patients received 
Betaseron/Betaferon™ 250 µg EOD ('North American Study Group'  2004; Polman et al. 
2003; Rudick et al. 1998; UBC 1996) (UBC – University of British Columbia), the frequency 
of neutralising antibodies was 195 out of 712 (27.38 %) for Betaseron/Betaferon™ and 5 out 
of 781 (0.64 %) for placebo. 
2.7 Non-randomised controlled trials comparing formation of neutralising antibodies 
against:    
2.7.1 IFN-β-1a Avonex™ and Rebif™ 
These five studies involved 763 participants and were published between 2002 and 2008 
(Bertolotto et al. 2002; Farrell et al. 2008; Gilli et al. 2007; Malucchi et al. 2004; Minagar, 
Murray & Investigators 2008). They comprised a follow up study (Bertolotto et al. 2002), 
open label study (Malucchi et al. 2004), assess the frequency of neutralising antibodies using 
Luciferase assay (Farrell et al. 2008), correlation study (Gilli et al. 2007) and prospective and 
retrospective observational study (Minagar, Murray & Investigators 2008). The period of 
follow up in these studies ranged between 18 – 36 months and two studies reported that the 
CPE assay was used to detect neutralising antibodies (Bertolotto et al. 2002; Malucchi et al. 
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2004). However, Gilli et al did not report the follow up duration but used the MxA assay to 
detect neutralising antibodies. Farrell et al used the luciferase assay to detect neutralising 
antibodies (Farrell et al. 2008). Minager et al did not report the method used for detection of 
neutralising antibodies. The primary outcome of Bertolotto et al was to determine the 
incidence and prevalence of neutralising antibodies against three IFN-β formulations. The 
primary outcome of Malucchi et al was to investigate the impact of neutralising antibodies on 
clinical efficacy. The primary outcome of Farrell et al was the incidence of neutralising 
antibodies using the Luciferase assay. The primary outcome of Gilli et al was to correlate 
neutralising antibodies in both in vitro and in vivo bioactivity. The primary outcome of 
Minager et al was to compare the efficacy and tolerability of IFN-β-1a formulations. Four 
studies reported the neutralising antibody cut-off titre which was defined at ≥20 NU/mL and 
was measured using Kawade titration method (TRU/ mL = ten times reduction units per mL) 
(Bertolotto et al. 2002; Farrell et al. 2008; Gilli et al. 2007; Malucchi et al. 2004). The 
frequency of neutralising antibodies in all of these studies was 42 out of 325 (12.92 %) for 
Avonex™ and 144 out of 438 (32.87 %) for Rebif™. The pooled estimate favoured 
Avonex™ although the difference did not quite reach statistical significance (random effect, 
OR 0.22, 95 % CI 0.05, 1.05) and the results showed heterogeneity, I
2
 = 88 % (refer Figure 
2.8).  
 
Figure 2.8: Forest plot. Individual and pooled OR for the outcome of formation of 
neutralising antibodies in the studies considering two formulations of IFN-β Avonex™ and 
Rebif™. 
2.7.2 IFN-β-1a Rebif™ and IFN-β-1b Betaseron/Betaferon™  
These five studies involved 617 participants and were published between 2002 and 2007 
(Bertolotto et al. 2002; Farrell et al. 2008; Gilli et al. 2007; Malucchi et al. 2004; Scagnolari 
et al. 2002a). The details of four studies are mentioned in Section 2.3.2.9 (Bertolotto et al. 
2002; Farrell et al. 2008; Gilli et al. 2007; Malucchi et al. 2004). The period of follow up 
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ranged between 12 – 36 months. The primary outcome of Scagnolaric et al was to quantitate 
the relative immunogenicity profile of various IFN-β formulations (Scagnolari et al. 2002a). 
The CPE assay was used to detect neutralising antibodies. However, no information on the 
cut-off used for positive titre was reported. The frequency of neutralising antibodies in all of 
these studies reported 143 out of 430 (33.25 %) for Rebif™ and 58 out of 187 (31.01 %) for 
Betaseron/Betaferon™. The pooled estimate was non-significant (random effect, OR 0.97, 95 
% CI 0.41, 2.30) and the results showed heterogeneity, I
2 
= 75 % (refer Figure 2.9).        
 
Figure 2.9: Forest plot. Individual and pooled OR for the outcome of formation of 
neutralising antibodies in the studies considering two formulations of IFN-β Rebif™ and 
Betaseron/Betaferon™.  
2.7.3 IFN-β-1a Avonex™ and IFN-β-1b Betaseron/Betaferon™  
These five studies involved 862 participants and were published between 2000 and 2007 
(Bertolotto et al. 2002; Farrell et al. 2008; Gilli et al. 2007; Malucchi et al. 2004; Ross et al. 
2000b). The details of these four studies are mentioned in Section 2.3.2.9. The period of 
follow up ranged between 18 – 36 months (Bertolotto et al. 2002; Farrell et al. 2008; Gilli et 
al. 2007; Malucchi et al. 2004). The primary outcome of Ross et al was to measure anti-drug 
antibodies and to assess the influence of IFN-β preparations, dosage, frequency and route of 
administration (Ross et al. 2000b). The CPE assay was used to detect neutralising antibodies. 
However, no information on cut off positive titres was reported. The frequency of 
neutralising antibodies in all of these studies was 77 out of 396 (19.44 %) for Avonex™ and 
274 out of 466 (58.79 %) for Betaseron/Betaferon™. The pooled estimate was significant 
favouring Avonex™ (random effect, OR 0.22, 95 % CI 0.11, 0.44) but the results showed 
heterogeneity I
2
 = 63 % (refer Figure 2.10). 
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Figure 2.10: Forest plot. Individual and pooled OR for the outcome of formation of 
neutralising antibodies in the studies considering two formulations of IFN-β Avonex™ and 
Betaseron/Betaferon™. 
2.8 Non-randomised controlled trails which were not included in the analysis  
These 14 studies included 1951 participants and were published between 1993 and 2011 
(Bellomi et al. 2003; Durelli et al. 2008; Durelli et al. 2009; Frank et al. 2004; Giovannoni et 
al. 2007; Gottesman & Friedman-Urevich 2006; Hartung et al. 2011; Hegen et al. 2012a; 
Knobler et al. 1993; Pachner et al. 2009a; Petkau et al. 2004; Phillips et al. 2004; Sorensen et 
al. 2005d) and Clinical trial NCT00367484 2011. They comprised seven open label studies 
(Durelli et al. 2009; Frank et al. 2004; Giovannoni et al. 2007; Gottesman & Friedman-
Urevich 2006; Hartung et al. 2011; Phillips et al. 2004) and Clinical trial NCT00367484 
2011, three longitudinal studies (Bellomi et al. 2003; Hegen et al. 2012a; Petkau et al. 2004), 
two observational studies (Durelli et al. 2009; Pachner et al. 2009a), one pilot study (Knobler 
et al. 1993) and one population based study (Sorensen et al. 2005d). The period of follow up 
in these studies ranged from 6 – 96 months, five used the CPE assay (Bellomi et al. 2003; 
Giovannoni et al. 2007; Knobler et al. 1993; Phillips et al. 2004; Sorensen et al. 2005d), six 
used the MxA assay (Durelli et al. 2008; Durelli et al. 2009; Frank et al. 2004; Gottesman & 
Friedman-Urevich 2006; Hartung et al. 2011; Hegen et al. 2012a) and two used both the CPE 
and MxA assays (Pachner et al. 2009a; Petkau et al. 2004) to detect neutralising antibodies. 
Pachner et al did not report the follow up period (Pachner et al. 2009a) while the Clinical trial 
NCT00367484 2011 did not report the method used for detection of neutralising antibodies. 
Of 14 studies, 12 defined neutralising antibody cut-off titre as ≥20 NU/mL and was measured 
using Kawade titration method (TRU/ mL = ten times reduction units per mL) (Durelli et al. 
2008; Durelli et al. 2009; Frank et al. 2004; Giovannoni et al. 2007; Gottesman & Friedman-
Urevich 2006; Hartung et al. 2011; Hegen et al. 2012a; Knobler et al. 1993; Pachner et al. 
2009a; Petkau et al. 2004; Phillips et al. 2004) and Clinical trial NCT00367484 2011. 
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Bellomi et al and Sorenson et al have not reported the cut off neutralising antibody titres 
(Bellomi et al. 2003; Sorensen et al. 2005d). The primary outcomes of these studies are 
shown in the Table 2.7.  
Primary outcomes of NRS not included in the analysis 
Studies Primary outcomes 
Knobler 1993 Evaluation of safety and side effect of IFN-β-1b  
Bellomi 2003 Evaluate neutralising antibodies in long term IFN-β treatment  
Frank 2004 Determine the effect of IFN-β-1b on clinical measures  
Phillips 2004 Determine the safety and immunogenicity of IFN-β-1a Avonex™  
Petkau 2004 Impact of neutralising antibodies on efficacy of  IFN-β-1b  
Sorenson 2005 
Investigate the appearance and persistence of neutralising 
antibodies to various IFN-β preparations  
Gottesman 2006 
Dose escalation of IFN-β-1b Betaseron/Betaferon™ and adverse 
effects management  
Giovannoni 2007 Immunogenicity and tolerability analyses of IFN-β-1a  
Durelli 2008 
Investigate magnetic resonance imaging (MRI) and neutralising 
antibodies occurrence to IFN-β-1b  
Durelli 2009 Optimise IFN-β-1b dosage 250 µg and 375 µg  
Pachner 2009 Assess neutralising antibodies on IFN-β-1b therapeutic efficacy  
Hartung 2011 
Evaluate frequency and implications of neutralising antibodies 
against IFN-β-1b  
Hegan 2011 
Investigate the significance of various IFN-β formulations specific 
neutralising antibodies cut-off titres  
Clinical trial 
NCT00367484 
2011 
Evaluate the safety and immunogenicity of IFN-β-1a Rebif clone 
484-39  
 
Table 2.7: Primary outcomes of NRS not included in the analysis.  
The Figure 2.11 represents the percentage of frequency of neutralising antibodies 
development against different IFN-β formulations in eleven NRS (Bellomi et al. 2003; 
Durelli et al. 2008; Durelli et al. 2009; Frank et al. 2004; Giovannoni et al. 2007; Gottesman 
& Friedman-Urevich 2006; Hartung et al. 2011; Hegen et al. 2012a; Knobler et al. 1993; 
Pachner et al. 2009a; Petkau et al. 2004; Phillips et al. 2004; Sorensen et al. 2005d) and 
Clinical trial NCT00367484 2011. The mean with 95 % CI was calculated. The remaining 
three studies (Bellomi et al. 2003; Hegen et al. 2012; Sorensen et al. 2005) were not included 
because of inconsistency in reporting the frequency of neutralising antibodies to each IFN-β 
formulations.          
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Figure 2.11: The frequency of neutralising antibodies of 11 NRS.The figure represents the 
% of frequency of development of neutralising antibodies in three different IFN-β 
formulations in eleven NRS.  
2.9 Discussion  
In this systematic review the development of neutralising antibodies against three different 
formulations of IFN-β Avonex™, Rebif™ and Betaseron/Betaferon™ were compared to 
each other in the treatment of relapsing forms of multiple sclerosis for the first time using 
meta-analysis. The results from the meta-analysis of RCTs demonstrated Avonex™ has 78 % 
less risk against Rebif™ (refer Figure 2.2), Rebif™ has 39 % less risk against 
Betaseron/Betaferon™ and Avonex™ has 89 % less risk against Betaseron/Betaferon™ 
(refer Figure 2.3) in the development of neutralising antibodies. The subgroup meta-analysis 
of Avonex™ 30 µg and 60 µg revealed 30 µg has 64 % less risk against 60 µg (refer Figure 
2.4), meta-analysis of Rebif 22 µg and 44 µg revealed 22 µg has 27 % high risk against 44 µg 
(refer Figure 2.5) and meta-analysis of IFN-β-1a and 1b revealed IFN-β-1a has 69 % less risk 
against IFN-β-1a (refer Figure 2.6) in the development of neutralising antibodies. The 
comparison was also established in NRS and results demonstrate Avonex™ has 79 % less 
risk against Rebif™ (refer Figure 2.7), the comparison of Rebif™ against 
Betaseron/Betaferon™ was non-significant (refer Figure 2.8) and Avonex™ has 78 % less 
risk against Betaseron/Betaferon™ (refer Figure 2.9). Overall our results from all the studies 
included in this review suggest 1.22 % to 19.44 % of patients developed NAbs to Avonex™, 
15.20 % to 33.25 % of patients developed NAbs to Rebif™ and 27.38 % to 58.79 % of 
patients developed NAbs to Betaseron/Betaferon™.  
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The results presented in this review summarises the incidence of NAbs against different IFN-
β formulations. Several problems exist in comparison of relative immunogenicity among 
different IFN-β formulations and this can be due to differences in the studies, NAbs detection 
methods, laboratories, the duration of treatment and criteria for definition of NAbs positive 
titres. The differences between natural IFN-β and IFN-β-1b contribute for greater 
development of neutralising antibodies to Betaseron/Betaferon™ compared to Rebif™ and 
Avonex™. Betaseron/Betaferon™ is produced in E.coli and is not glycosylated. Furthermore, 
Betaseron/Betaferon™ has difference in the amino acid sequence compared to natural IFN-β, 
it consists of 165 amino acids due to lack of N terminal methionine and cysteine is substituted 
with serine at position 17. However, Rebif™ and Avonex™ are produced in CHO cells and 
have identical amino acid sequence to that of natural IFN-β and are glycosylated similar to 
natural IFN-β. The recent studies on recombinant therapeutic proteins which are produced in 
non-human mammalian cells can synthesise non-human sialic acid (Neu5Gc). The biologic 
cetuximab contains Neu5Gc, and forms immune complexes with anti-Neu5Gc antibodies that 
pre-exist in human plasma (Ghaderi et al. 2010). The studies also shown the galactose-alpha-
1, 3-galactose (alpha-Gal) epitope on cetuzimab induce anaphylaxis in patients with pre-
existing anti-Gal autoantibodies. The characteristics of different IFN-β formulations are 
provided in Table 2.1. The protein without carbohydrate (as in case with 
Betaseron/Betaferon™) has a tendency to form aggregates. The formulations for example 
large protein excipients like human serum albumin used in the IFN-β formulations can give 
rise to aggregates. The studies also suggest Avonex™ form less aggregates when compared 
to Rebif™ and Betaseron/Betaferon™ (Barnard, Babcock & Carpenter 2013). The 
posttranslational modifications, manufacturing, purification and storage also contribute for 
immunogenicity.  The development of neutralising antibodies is also dependent on dosing 
regimen. Our meta-analysis data on comparison of Avonex™ 30 µg versus 60 µg and 
Rebif™ 22 µg versus 44 µg revealed Avonex 30 µg and Rebif 44 µg developed less 
neutralising antibodies compared to Avonex 60 µg and Rebif 22 µg. The paradox still exists 
on low dose and high dose administration of therapeutic proteins. It has also been shown 
higher doses of remicade in treatment of rheumatoid arthritis might be less immunogenic 
when given in higher doses possibly because of high zone tolerance. Therefore, optimising 
dosage can be an important factor to consider in terms of immunogenicity. The IV route of 
administration was found less immunogenic than SC and IM because route of administration 
can influence the risk of sensitisation because immune-competent cells are mainly found in 
areas such as skin and mucosa. In addition, the frequency of administration also contributes 
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for immunogenicity. The IM IFN-β-1a Avonex™ 30 µg is given once a week basis. 
However, SC IFN-β-1a Rebif™ and SC IFN-β-1b Betaseron/Betaferon™ is given three times 
a week and every other day basis. In this review, because of limited number of studies and 
variability in reporting we could not find a pattern.  
The mechanism for development of anti-drug antibodies can be T-cell dependent and T-cell 
independent. In T-cell dependent the T-cells recognise the immunogenic peptides and are 
presented to antigen presenting cells via MHC class II molecules. However, in T-cell 
independent mechanism the antigen binds to BcR and cause B cell activation without help of 
T-cells. The generation of anti-drug antibodies will be of IgM isotype converting to IgG 
isotype. In the following experimental chapters we have characterised anti-IFN-β antibodies 
in a cohort of IFN-β treated patients and have explored the neutralising capabilities of anti-
IFN-β subclass specific anti-drug antibodies and  we also addressed the role of T helper cells 
in anti-drug antibodies to IFN-β (refer chapters 4 and 5).       
Our systematic review has number of limitations. First of all, we included only English 
language studies introducing potential for language bias and limited our search to studies 
identified through MEDLINE on Ovid, EMBASE on Ovid, CENTRAL on The Cochrane 
Library, Clinicaltrials.gov and bibliographic searches. Second, some relevant trials were 
excluded as we did not include unpublished articles, thesis or conference proceedings. Third, 
the variations on the quality of studies such as inconsistent sample size, disproportionate 
group size across different treatments and high drop-out rates after randomisation. Clear 
heterogeneity was observed in the NRS included for analysis. Possibly including all different 
languages articles limits the potential for language bias. Searching all databases, tertiary 
sources and restricted interface search engines for examples 1. Agency for Health and 
Research Quality http://www.ahrq.gov/ 2. BioSciences Information Service of Biological 
Abstracts Citation Index via webofknowledge.com 3. British Library Direct 
http://www.bldss.bl.uk/BLDSS/ 4. Current Controlled trials http://www.controlled-trials.com/ 
4. Database of Abstracts of Reviews of Effectiveness http://www.crd.york.ac.uk/CRDWeb/ 5. 
Iowa Drug Information Service http://www.uiowa.edu/idis/ 6. Medscape 
http://www.medscape.com/ 7. Science Citation Index via http://www.ebscohost.com/ 8. 
Scirus http://www.scirus.com/ 9. Toxicology Information Online – US National Library of 
Medicine via http://www.proquest.com 10. TRIP database http://www.tripdatabase.com/ 11. 
UK Clinical Research Network Portfolio Database http://public.ukcrn.org.uk/search/ 12. US 
Food and Drug Administration http://www.fda.gov/ can reveal all the possible relevant 
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studies. The pooling of the data systematicaly from all the identified studies and making 
contacts with the authors can avoid missing data.   
This systematic review shows the relative differences in immunogenicity of different IFN-β 
formulations Avonex™, Rebif ™ and Betaseron/Betaferon™. In conclusion Avonex™ has 
less risk, Rebif™ has moderate risk and Betaseron/Betaferon™ has high risk for development 
of neutralising antibodies. The observed differences in development of neutralising 
antibodies among the three IFN-β formulations are likely due to differences in the molecular 
structure or post translational modifications; but the dosing regimen may also contribute. 
2.10 Conclusions 
o The risk of development of neutralising antibodies was less in IFN-β-1a Avonex™, 
moderate in IFN-β-1a Rebif™ and high in IFN-β-1b Betaseron/Betaferon™. 
o Based on our findings IFN-β-1a Avonex™ 30 µg IM should be the drug of choice in 
patients with relapsing forms of multiple sclerosis.  
o Clinical testing for anti-IFN-β antibodies both binding and neutralising antibodies have to 
be incorporated in the clinical practice and nationwide procedures for detection of anti-
IFN-β antibodies have to be implemented. 
o Treatment with IFN-β should be discontinued with high titres of neutralising antibodies 
and therapeutic options should be re-evaluated. The sequential step wise treatment 
strategies (the present drug of choice is glatiramer acetate) have to be followed in case of 
treatment failures. 
Inconsistencies in methodology and in reporting data in the studies included in this review 
has limited the extent of our analyses. Longitudinal studies can help achieve time to first 
event analysis and can also characterise the kinetics of development of neutralising 
antibodies. Future clinical trials that include harmonised methodology and incorporate 
baseline testing for anti-IFN-β antibodies are required for a more robust meta-analysis to be 
conducted.       
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Chapter 3: Characterisation of anti-drug antibodies against therapeutic Interferon beta 
in multiple sclerosis patients  
3.1 Introduction 
The therapeutic protein interferon beta (IFN-β), available under the trade names Avonex™, 
Rebif™, Betaferon/Betaseron™ and Extavia™, is used for the treatment of multiple 
sclerosis. IFN-β exhibits anti-viral properties and numerous immunomodulatory functions. In 
terms of disease progression, treatment with IFN-β has been shown to dampen plaque 
formation, decrease relapses and eventually improve disease prognosis (Killestein & Polman 
2011).  
IFN-β is well-tolerated in the treatment of multiple sclerosis. However, a relatively common 
adverse effect of protein therapeutics is the development of anti-drug antibodies (De Groot & 
Scott 2007; Porter 2001; Strayer & Carter 2012). Development of anti-drug antibodies can be 
non-neutralising (N-NAb) or neutralising antibodies (NAb) depending on the site at which 
they bind. Nearly 50-80 % of patients develop N-NAb to different formulations of IFN-β. 
The presence of N-NAb in the absence of NAb has no significant clinical problem in terms of 
clinical efficacy (Francis et al. 2005; Pachner et al. 2009a; Pachner et al. 2009b; Rudick et al. 
1998; Zang et al. 2000). Formation of NAb blocks the bioactivity of IFN-β by binding to 
IFNAR receptor which is crucial for drug-target interactions (Giovannoni & Goodman 2005).  
Up to 45 % (mean approx. 25 %) of patients develop NAb to different formulations of IFN-β. 
The presence of anti-IFN-β antibodies has been associated with total loss or reduced efficacy 
of the drug, altered pharmacokinetics, infusion reactions and cross reactions with endogenous 
protein counterparts (Bendtzen 2010). Immunogenicity is the major complication associated 
with protein therapeutics and has become the key focus from drug development to post-
marketing studies. Detection and quantification of anti-drug antibodies has been implemented 
into routine clinical practice (Bertolotto 2009; van der Voort et al. 2009). The European 
National Neurological Societies (EFNS) task force recommends measurements of N-NAb 
before performing a NAb assay, with N-NAb positive samples further analysed for NAb. To 
date, there is no recommended assay available for the detection of N-NAb. However, the task 
force insists different N-NAb assays should be considered, evaluated and compared using 
large sample sets to identify the best sensitivity and specificity for further NAb detection 
(Sorensen et al. 2005a). The task force also recommends the use of a human lung 
adenocarcinoma epithelial cell line stimulated with a fixed amount of the same formulation of 
IFN-β used in the patients (Sorensen et al. 2005a) for the detection of NAb.  
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The anti-IFN-β antibodies are reported to be predominantly of the immunoglobulin G (IgG) 
class. Studies on distribution of IFN-β specific NAb IgG subclasses (IgG1-4) in multiple 
sclerosis patients following IFN-β treatment are limited (Deisenhammer, Reindl & Berger 
2001; Gibbs & Oger 2007). Type I interferons are crucial in the regulation of host immune 
responses and play an important role in first line of defence against viral infections. However, 
the potential for neutralisation of endogenous IFN-β by anti-IFN-β antibodies is unclear. The 
interaction of anti-drug antibodies with the therapeutic can result in formation of immune 
complex. Immune complexes can activate the complement system, which comprises 30 
soluble proteins circulating in the blood in inactive forms and plays an important role in 
innate and adaptive immunity (Carroll 2004). The evidence also suggests a role for activated 
complement in antigen processing and presentation (Strainic et al. 2008; Weaver et al. 2010). 
Hence, increased complement activation can enhance antigen processing and presentation 
which may contribute to progression of immunogenic responses against biologics. The 
identification of the relevant epitopes for anti-IFN-β antibodies is crucial for understanding 
drug-target interactions (Gneiss et al. 2004). Hence, an attempt has also been made to identify 
specific binding patterns of anti-IFN-β antibodies on the IFN-β molecule using continuous B-
cell epitope mapping using multipin peptide technology and in vitro competitive binding 
assay approach.               
The aim of this study was to characterise the anti-IFN-β antibody response in a cohort of 
IFN-β (Rebif™; Merck-Serono) treated patients and to determine the relative contribution of 
anti-IFN-β antibodies in neutralising IFN-β bioactivity. Furthermore, the study sought to 
establish whether NAb cross react with Type I interferons, to investigate the ability of 
immune complexes to activate the complement cascade and to identify the antibody binding 
regions on IFN-β-1a Rebif™ molecule. 
3.2 Methods 
The flow diagram of the methods employed in this chapter is shown in Figures 3.1 and 3.2.  
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Figure 3.1: The schematic representation of methods employed in this 
chapter using plasma samples. Abbreviations: IgG – Immunoglobulin 
G; IgM – Immunoglobulin M; IFN – Interferon; MxA – Myxovirus A 
protein, ELISA – Enzyme-linked immuno sorbent assay.  
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Figure 3.2: The schematic representation of methods employed in this chapter using serum 
samples. Abbreviations: IFN – Interferon; C1q – Complement 1, Q Subcomponent; ELISA – 
Enzyme-linked immuno sorbent assay, C3a – Complement 3a, C5a – Complement 5a.   
3.2.1 Chemicals and reagents 
Nunclon cell culture flasks, dishes and multi-well plates were obtained from Nalgene-Nunc 
International (VWR International, Lutterworth, UK). Protein assay dye reagents, Precision 
Plus protein Kaleidoscope standards, non-fat dry milk and the GS-710 calibrated imaging 
densitometer were from Bio-Rad (Hemel Hemstead, UK). NuPAGE Novox 4-12 % Bis 
Trisgels, NuPAGE lithium dodecyl sulfate (LDS) sample buffer, sample reducing agent and 
antioxidant, the XCell Surelock mini-cell were from Invitrogen (Paisley, UK). The THP-1 
cell line was a kind gift from Dr Dominic Williams, Department of Molecular and Clinical 
Pharmacology, University of Liverpool, UK. Western Lightening chemiluminescence 
reagents were from PerkinElmer, Beaconfield, UK. Hyperfilm enhanced chemiluminescence 
(ECL) was from Amersham (Little Chalfont, UK). Tetanus toxoid was purchased from 
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Staten’s Serum Institute, Denmark. IFN-β-1a Rebif™ was from Merck Serono; London, UK. 
Fetal bovine serum (FBS) was from Gibco, UK. Gammacell 1000 containing Caesium-137 
(
137
Cs) emitting gamma radiation was from Field Emission; Berkshire, UK. Pooled Human 
AB Serum was from Innovative research Inc; MI, USA. Roswell Park Memorial Institute 
medium-1640 (RPMI-1640), hydroxyethyl piperazineethanesulfonic acid (HEPES), 2-
Mercaptoethanol (2-ME), Lipopolysaccharide (LPS), Polyinosinic:polycytidylic acid (Poly 
I:C), phytohaemagglutinin (PHA), Cyclosporin-A (CSA), Penicillin-streptomycin solution, 
Trypan blue solution, Dimethyl sulfoxide (DMSO), Hank's Balanced Salt Solution (HBSS), 
(Bovine serum albumin) BSA, 3-(N-morpholino)propanesulfonic acid (MOPS), Radio-
Immunoprecipitation assay (RIPA) buffer, 3,3',5,5'-Tetramethylbenzidine (TMB), Kodak 
BioMax MS intensifying screen, Kodak developer and fixer solutions, Ponceau S solution, 
Tween 20, Phosphate Buffered Saline (PBS) tablets, paraformaldehyde were from Sigma-
Aldrich (Poole, UK). All other reagents unless otherwise mentioned were of analytical or 
molecular grade, and were from Sigma-Aldrich. 
3.2.2 Whole blood samples 
Whole venous blood samples to isolate plasma, serum and peripheral blood mononuclear 
cells (PBMCs) for the study were obtained from The Walton Neurological Centre, NHS 
Foundation Trust, Liverpool, UK. A total of 20 multiple sclerosis patients and 10 healthy 
volunteers were recruited (refer Table 3.1).  Ten patients were on IFN-β-1a Rebif™ therapy 
previously. They had been withdrawn from IFN-β-1a Rebif™ therapy due to development of 
neutralising antibodies (NAb) and are on alternative therapy. The determination of NAb 
status was established at Walton Neurological Centre as part of periodic or routine screening. 
The other 10 patients are still on FN-β-1a Rebif™ therapy and have not been reported to have 
developed NAb at the time of recruitment. Interferon beta therapy involves IFN-β-1a Rebif™ 
22 or 44 µg subcutaneous (SC) injections three times per week. The blood samples were 
collected on 3 different occasions. The total volume of 10 mL, 100 mL and 100 mL were 
obtained in the 3 different visits respectively. The first 10 mL blood sample was taken to 
confirm the IFN-β-1a Rebif™ antibody status. The next 2 blood samples were taken 3 weeks 
apart and not more than 3 months apart. In addition to patients, 10 healthy donors were also 
recruited from the population based within the staff and student body of Department of 
Molecular and Clinical Pharmacology, University of Liverpool, UK. The total volume of 100 
mL of blood was collected in a single visit for healthy donors. The study was approved by 
Liverpool local research ethics committee (reference No. 09 – H1005 – 84). 
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Donor 
Identity 
Age Sex Group IFN-β-1a 
therapy status 
Rebif  (s.c) 
Dose (g) 
Duration (months**) 
Therapy  |  Since WD 
P1 57 F RRMS WD 22 46 72 
N2 55 F RRMS WD 22 43 5 
P3 46 M RRMS WD 22 24 57 
N4 47 M RRMS ON 22 48 N.A 
N5 57 M RRMS ON 44 32 N.A 
N6 30 F RRMS ON 44 >120 N.A 
P7 54 M RRMS WD 22 36 44 
N8 43 M RRMS ON 22 >120 N.A 
H9 24 F Healthy N.A N.A N.A N.A 
P10 30 M RRMS WD 22 84 48 
H11 42 M Healthy N.A N.A N.A N.A 
N12 32 F RRMS ON 44 141 N.A 
P13 49 M RRMS WD 22 15 34 
P14 43 F RRMS WD 22 12 13 
P15 43 M RRMS WD 22 72 53 
N16 56 F RRMS ON 22 >120 N.A 
N17 37 F RRMS ON 44 96 N.A 
H18 47 F Healthy N.A N.A N.A N.A 
H19 30 F Healthy N.A N.A N.A N.A 
H20 43 F Healthy N.A N.A N.A N.A 
H21 33 F Healthy N.A N.A N.A N.A 
H22 43 M Healthy N.A N.A N.A N.A 
H23 30 F Healthy N.A N.A N.A N.A 
H24 27 M Healthy N.A N.A N.A N.A 
H25 32 F Healthy N.A N.A N.A N.A 
N26 50 F RRMS ON 22 60 N.A 
N27 45 F RRMS ON 22 120 N.A 
P28 46 F RRMS WD 22 48 31 
P29 53 F RRMS WD 22 36 57 
P30 41 F RRMS WD 22 18 54 
Table 3.1: Demographic and clinical features of 20 MS Patients and 10 Healthy controls 
involved in this study. The total of 20 RRMS patients were recruited in which 10 patients 
were IFN-β-1a Rebif™ NAb positive designated P1-P10 and 10 patients were IFN-β-1a 
Rebif™ NAb negative N1-N10. Patient P1 was discontinued from the study due to ill health. 
In addition to patients, 10 healthy donors designated as H1-H10 were also recruited as 
controls. Abbreviations: RRMS; Relapsing-Remitting Multiple Sclerosis; Rebif, IFN-β-1a; 
s.c, subcutaneous; WD, withdrawn/withdrawal; ON, ongoing; N.A,  not applicable; F, 
female; M,  male; ** treatment duration in months. 
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3.2.3 Separation of Peripheral blood mononuclear cells and Plasma 
Peripheral blood mononuclear cells and plasma were isolated from venous blood using 
density gradient centrifugation. Heparinised whole venous blood was gently layered on 
lymphoprep (specific gravity = 1.077, Axis-Shield; Cheshire, UK) and was centrifuged for 25 
minutes at 720 g without brake. Granulocytes and erythrocytes have a higher density than 
mononuclear cells and therefore sediment through the lymphoprep layer during 
centrifugation. Using a sterile Pasteur pipette the topmost layer containing plasma was 
collected into a new sterile tube and stored at – 80 °C until further use. The layer of cells 
(PBMCs) at the interface between the layered blood and lymphoprep was collected in another 
new sterile tube. The isolated cells were washed with HBSS and centrifuged for 10 minutes at 
580g. The obtained cells were counted using trypan blue and frozen (cryopreservation in 
Fetal bovine serum + 10% Dimethyl sulfoxide) at – 150 °C until further use.  
3.2.4 Separation of Serum 
Whole venous blood samples were collected in clotting activated silicon-coated blood 
collecting tubes (Vacuette; Gloucestershire, UK). The clotting of blood was allowed to take 
place at room temperature (around 20 °C) for 30 – 60 minutes. The initial centrifugation was 
carried out in a centrifuge at 2000 g for 10 minutes. The serum was removed and centrifuged 
again at 8000 g for 5 minutes to remove all cell debris. Isolated serum was aliquoted and 
frozen at – 80 °C until future use. 
3.2.5 Detection and quantification of total and Interferon beta 1a Rebif™ specific 
immunoglobulins 
Total IgM, IgG and IgE and IFN-β-1a Rebif™ specific IgM, IgG and IgE in the plasma were 
quantified using human IgM, IgG and IgE sandwich type ELISA quantitation kits (Bethyl 
Laboratories, Inc. USA). Total IgG subclass levels in the plasma were quantified by ELISA 
using human IgG subclass profile kit (Invitrogen – Life Technologies, UK). IFN-β-1a 
Rebif™ specificIgG subclasses were measured by ELISA using human IgG subclass 
screening kit (Cygnus Technologies, Inc. USA) according to the manufacturer’s protocol 
(please refer Table 3.3 for ELISA steps and Figure 3.3 for schematic representation.  
For quantification of total IgM, IgG and IgE immunoglobulins in plasma samples the affinity 
purified human IgM, IgG and IgE coating antibodies were diluted in coating buffer (0.05 M 
Carbonate-Bicarbonate, pH 9.6). The plates were coated with 100 µl of 1:100 diluted affinity 
purified coating antibodies and incubated for 16 hours at 4 °C. The plates were washed using 
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wash buffer (50 mM Tris, 0.14 M Nacl, 0.05% Tween 20, pH 8.0) 200 µL per well five times 
and blocked using blocking solution (50 mM Tris, 0.14 M Nacl, 1 % BSA, pH 8.0) for 1 hour 
at room temperature. The plates were washed again and 100 µl of plasma samples in 1:10000 
for IgM, 1:100000 for IgG and 1:200 for IgE dilutions were added and respective standards 
was incubated for 1 hour at room temperature. The plates were washed again and 100 µl of 
HRP-conjugated anti-human IgM, IgG and IgE detection antibodies were added at 1:50000, 
1:100000 and 1:50000 dilutions respectively and incubated for 1 hour at room temperature. 
The plates were washed and 100 µl of freshly prepared TMB substrate was added and 
incubated in the dark for 15 minutes. The reaction was stopped by addition of 100 µl of 0.18 
M H2SO4 and absorbance was measured at 450 nm. For measuring IFN-β-1a Rebif™ specific 
immunoglobulins IgM, IgG, and IgE a similar method was used. However, the plates were 
coated with 100 µl per well of IFN-β-1a (1.5 µg/mL Rebif™) instead of coating antibodies 
for 16 hours at 4 °C and the plasma dilutions used were 1:2 for IgM, 1:20 for IgG and neat 
samples was used for IgE detection. The absolute concentrations for total immunoglobulins 
types and IFN-β-1a Rebif™ specific immunoglobulins types were calculated based on the 
standards provided in the kit. 
For quantification of total IgG subclass, the plasma samples were diluted at 1:2500. Fifty 
microliters of diluted plasma samples, standards and human serum control was added into 
IgG antibody-coated microtiter plates. The plate was incubated at room temperature for 30 
minutes. The plate was washed using 200 µl of wash buffer three times. 100 µl of 1:50 
diluted peroxidase anti-human IgG secondary antibody was added into the plates and 
incubated at room temperature for 30 minutes. The plate was washed again using 200 µl of 
wash buffer three times. 100 µl of TMB solution was added into each well and the plate was 
incubated at room temperature for 30 minutes. 100 µl of stop solution was added into each 
well and the absorbance was measured on a plate reader at 450 nm. For measuring IFN-β-1a 
Rebif™ specific subclasses the plates were coated with 100 µl per well of IFN-β-1a Rebif™ 
(1.5 µg/mL) and incubated for 16 hours at 4 °C. The plates were washed using wash buffer 
200 µL per well five times and blocked using blocking solution for 1 hour at room 
temperature. The plates were washed again and 100 µl of 1:20 diluted plasma samples were 
added and incubated for 1 hour at room temperature. The plates were washed again and 100 
µl of HRP-conjugated IgG subclass (IgG1-IgG4) specific detection antibodies were added at 
1:100 dilutions respectively and incubated for 1 hour at room temperature. The plates were 
washed and 100 µl of freshly prepared TMB substrate was added and incubated in the dark 
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for 15 minutes. The reaction was stopped by addition of 100 µl of 0.18 M H2SO4 and 
absorbance was measured at 450 nm. The absolute concentrations for total IgG subclass were 
calculated based on the standards provided in the kit. However, IFN-β-1a Rebif™ specific 
IgG subclass was based on optical density values as no standards for quantification was 
available.  
ELISA Total immunoglobulins IFN-β-1a Rebif™ specific 
immunoglobulins 
Step 1 The plates coated with coating 
antibodies and incubated for 16 hours at 
4 °C 
The plates coated IFN-β-1a Rebif™ for 
16 hours at 4 °C 
Step 2 Diluted plasma samples were added and 
incubated for 1 hour at room 
temperature 
The plasma samples were added and 
incubated for 1 hour at room 
temperature 
Step 3 HRP-conjugated human detection 
antibodies were added and incubated for 
1 hour at room temperature 
HRP-conjugated human detection 
antibodies were added and incubated for 
1 hour at room temperature 
Step 4 TMB substrate was added and incubated 
in dark for 15 minutes 
TMB substrate was added and incubated 
in dark for 15 minutes 
Step 5 Stop solution was added and absorbance 
was measured using 450 nm 
Stop solution was added and absorbance 
was measured using 450 nm 
Table 3.2: Enzyme linked immuno-sorbent assay (ELISA) steps involved in detection and 
quantification of total and IFN-β-1a Rebif™ specific immunoglobulins. 
 
Figure 3.3: The schematic representation of total immunoglobulins and IFN-β-1a 
Rebif™ specific immunoglobulins ELISA. The details of the experiments are provided in 
Section 3.2.5.  
3.2.6 Neutralisation assay: Interferon beta 1a induced MxA bioassay 
Myxovirus resistance protein A (MxA) expression is an established biomarker for IFN-β 
bioactivity (Pachner et al. 2005). The neutralising potential of anti-IFN-β antibodies was 
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determined utilising IFN-β induced MxA protein expression in THP-1 cells, using western 
blotting.  
3.2.6.1 THP-1 cell culture 
The monocytic cell line THP-1 (Tsuchiya et al. 1980), was maintained in culture medium 
RPMI-1640 supplemented with 10 % FBS, 100 U/mL penicillin, 100 µg/mL streptomycin 
and L-glutamine 2 mM. Cells were maintained in a humidified incubator, at 37 °C, in 5 % 
carbon dioxide (CO2) atmosphere. Cells were grown in 75 cm
2
 Nunclon culture flasks and 
routinely passaged every alternate day, at around 80% confluency. For the analysis of 
Myxovirus A (MxA) protein, cells were seeded onto 24-well culture dishes, at 3 x 10
6
 cells 
per well, in a total volume of 800 µL culture medium.  
3.2.6.2 Incubation of plasma, IFN-β-1a Rebif™ and THP-1 cells 
Under sterile conditions, in a U-bottom 96-well plate, 100 U of IFN-β-1a Rebif™ was 
incubated with varying dilutions of plasma samples (1:10, 1:100, 1:1000, 1:10000, 1:100000 
and 1:1000000).  The plasma samples were obtained from IFN-β-1a Rebif™ treated NAb 
positive and NAb negative RRMS patients and a total volume of 200 µL in RPMI-1640 
culture medium. Healthy donor plasma samples were used as controls. The mixture was 
incubated at 37 °C, in a 5 % CO2 atmosphere for an hour. Two hundred microliters ofIFN-β-
1a Rebif™ incubated plasma samples were then added to THP-1 cells and incubated for 18 
hours at 37 °C, in a 5 % CO2. 
3.2.6.3 Preparation of cell lysates 
The incubated THP-1 cells were harvested and the cells were pelleted by centrifuging at 300 
g for 5 minutes at 4 °C. The supernatant was discarded and the cell pellet was resuspended in 
200 µL of ice cold RIPA lysis buffer. Cells were allowed to lyse on ice for 30 minutes, 
vortexing every 10 minutes. Cellular debris was removed by centrifugation at 8000 g for 10 
minutes at 4 °C. The supernatants (cell lysates) obtained were stored at – 80 °C prior to 
analysis by Western blot. 
3.2.6.4 Determination of protein content 
The total protein content of cell lysates was determined using Bradford Protein assay 
(Bradford 1976). This method involves the binding of Coomassie Brilliant Blue G-250 dye to 
basic and aromatic amino acids, an event that results in a change in colour of the dye (red to 
blue), and a consequent change in absorbance maximum from 465 to 595 nm. Hence, the 
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increase in absorbance at 570 nm, is proportional to the amount of bound dye, and thus to the 
amount of protein present. 
In brief, a standard curve 0, 0.5, 1, 2.5, 3.5, 5, 7.5, 10 µg of bovine serum albumin (BSA) was 
prepared using stock concentration of 0.1 mg/mL. The cell lysates were diluted at 1:200. One 
hundred microliters of Bradford detection reagent (Coomassie Brilliant Blue G, ethanol, 
phosphoric acid and deionised water) was added and the samples were vortexed and 
incubated for 5 minutes at room temperature. Two hundred microliters of samples and 
standards were transferred to 96 – well flat bottom plate for spectrophotometric analysis and 
measured using a MRX microplate reader (Dynatech Labs; Billingshort, UK).  
3.2.6.5 Western blot analysis 
10 µg of protein was denatured via the addition of loading buffer (70 % (v/v) NuPAGE 
sample loading buffer, 30 % (v/v) NuPAGE reducing agent) and incubated at 99 °C for 5 
minutes. The pre-cast 4 – 12 % NuPAGE Novex bis-tris polyacrylamide gels or 10 % SDS-
polyacrylamide electrophoresis (SDS-PAGE) gels (resolving gel made of deionised water, 30 
% acrylamide, 1.5 M Tris pH 8.8, 10 % SDS, 10 % APS, TEMED and stacking gel was made 
of deionised water, 30 % acrylamide, 1 M Tris pH 6.8, 10 % SDS, 10 % APS, TEMED) was 
used for loading the samples alongside PrecisionPlus protein Kaleidoscope standards. 
Samples were resolved by electrophoresis in a XCell Surelock mini-cell, using a 3-(N-
morpholino) propanesulphonic acid (MOPS) running buffer (50 mM MOPS, 50 mM Tris 
base, 3.5 mM SDS, 1 mM EDTA, 0.25 % (v/v) NuPAGE antioxidant or 25 mM Tris base, 
250 mM glycine pH 8.3, 0.1 % SDS at 90 V for 10 minutes, followed by 120 minutes at 130 
V for pre-cast gels and 10 % SDS-PAGE gels respectively). Separated proteins were 
transferred to polyvinylidene difluoride (PVDF) membrane using transfer buffer (12 mM 
Tris, 96 mM Glycine, 20 % Methanol) for 60 minutes keeping current constant (at 0.30 A). 
The PVDF membranes were pretreated with 100 % methanol and washed with deionised 
water prior to transferring proteins. To confirm whether the transfer process was successful, 
membranes were stained for 10 seconds with Ponceau S staining solution. Ponceau S is used 
for the detection of total proteins on PVDF membranes. Membranes were blocked for 60 
minutes, on an orbital shaker, in 5 % tris-buffered saline (TBS; 0.15 M NaCl, 25 mM Tris 
base, 3 mM KCL, pH 7.0) containing 0.1 % (v/v) Tween 20 and 5 % (weight/volume; w/v) 
non-fat dry milk. Blocked membranes were probed for 16 hours at 4 °C with rabbit anti-MxA 
primary antibody from Santa Cruz biotechnology, Middlesex, UK (1:500 in TBS-Tween 
containing 5 % (w/v) non-fat dry milk). Following 3 washes in TBS-Tween, membranes were 
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then probed for 1 hour with goat anti-rabbit (1:5000 in TBS-Tween containing 5 % (w/v) 
non-fat dry milk) horseradish peroxidase (HRP) – conjugated secondary antibody (New 
England Biolabs, Hertfordshire, UK). Immunoblots were visualized with Western Lightening 
chemiluminescence reagents and exposed to Hyperfilm ECL under darkroom conditions, 
using a Kodak BioMax MS intensifying screen. Blots were developed using Kodak developer 
and fixer solutions. In order to determine equal loading of samples, membranes were probed 
with mouse anti-β-actin primary antibody from abcam, Cambridge, UK (1:20000 in TBS-
Tween containing 5 % (w/v) non-fat dry milk) and rabbit anti-mouse (1:20000 in TBS-Tween 
containing 5 % (w/v) non-fat dry milk) HRP – conjugated secondary antibody (New England 
Biolabs, Hertfordshire, UK). Films were scanned using a GS-710 calibrated imaging 
densitometer and analysis was performed using TotalLab software. 
3.2.7 IgG4 depletion 
The human IgG4 affinity matrix (Capture select, BAC BV, The Netherlands) is a unique resin 
containing 12 kDa Llama antibody fragments which recognises human IgG4. The affinity 
matrix is directed towards a particular domain on the Fc portion of the human IgG4 that 
enables binding of human IgG4 without cross reacting with other human IgG subclasses. The 
amount of resin required for the IgG4 depletion in the total plasma was calculated as 
described below. The anti-IFN-β antibodies positive plasma samples contained 0.1 – 0.8 
mg/mL of total IgG4. The recommended ratio indicated for use is 1 mL of resin to 6 mg/mL 
of total IgG4. Hence, 200 µL of resin was used for every mL of plasma samples. The total 
IgG4 levels in anti-IFN-β-1a Rebif™ antibodies plasma samples were quantified using 
human IgG subclass profile kit (Invitrogen – Life Technologies, UK).  
The Mobicol “F” spin columns (MoBiTec GmbH, Germany) was used for depleting IgG4 in 
plasma samples. The columns are designed for wide range of applications which includes 
fractionation and purification of antibodies when used with affinity matrix. The matrix and 
the plasma samples of interest were incubated in these columns.    
The columns were equilibrated using equilibration buffer (100 mM Sodium Citrate, 150 mM 
NaCl pH 6.5-7.0) using gravity flow-through mode. Two milliliters of human IgG4 affinity 
matrix resin was centrifuged for 2 minutes at 500 g and supernatants were discarded. 1 mL of 
equilibration buffer was added and was centrifuged and supernatants were discarded. This 
equilibration step was repeated 3 times. 1 mL of neat plasma was incubated with the resin for 
3 minutes at room temperature in a Mobicol “F” spin column. The IgG4 depleted plasma 
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samples were collected using quick spin on a mini centrifuge. The flow-through plasma 
samples obtained was depleted of total IgG4 (80-99 %). The depletion percentage of total 
IgG4 was quantified by ELISA using human IgG subclass profile kit (Invitrogen – Life 
Technologies, UK) according to manufacturer’s instructions. 
3.2.8 Cross reactivity of anti-Interferon beta 1a Rebif™ antibodies to endogenous 
interferon beta 
Lipopolysaccharide (LPS) and Polyinosinic: polycytidylic acid (Poly I:C) are Toll-like 
receptor (TLR) TLR-4 and TLR-3 ligands respectively and are able to induce endogenous 
production of IFN-β in many cell types including THP-1 cells. In this experiment, LPS and 
Poly I:C were used to stimulate the THP-1 cells to produce endogenous IFN-β and the 
production of IFN-β was determined using MxA protein expression (refer Figure 3.4). The 
addition of anti-IFN-β-1a Rebif™ antibodies reacts with endogenous IFN-β and hence 
reduces the MxA protein expression. 
 
Figure 3.4: Schematic representation of the rationale and strategy for the cross 
reactivity assessment of anti-IFN-β-1a Rebif™ antibodies to endogenous IFN-β. In order 
to assess the potential of anti-IFN-β-1a Rebif™ antibody cross reactivity – LPS 1 µg/mL and 
Poly I:C 10 µg/mL was used to trigger endogenous IFN-β secretion in THP-1 cells and 
subsequent MxA protein expression due to autocrine effect of secreted IFN-β on THP-1 cells. 
Cross reactivity of anti-IFN-β-1a Rebif™ antibodies was assessed by co-incubating anti-IFN-
β-1a Rebif™ antibodies positive patient plasma at 1:1000 dilutions with LPS and Poly I:C in 
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THP-1 cells followed by culture at 37 °C for 24 hours. After 24 hours, the MxA protein 
levels were quantified using western blotting as described in Section 3.2.7.5.  
3.2.9 Mapping of continuous B-cell epitopes  
Analysis of continuous B-cell epitope mapping on IFN-β-1a Rebif™ protein was carried out 
using the Multipin Peptide Technology (PepSets) of Mimotopes (Victoria, Australia). The 
amino acid sequence of the IFN-β-1a Rebif™ protein was used to synthesise a complete set 
of overlapping (12 mer, 5 offset) peptides covalently attached to the surfaces of derivatised 
polyethylene pins in a format compatible with standard enzyme-linked immunosorbent assays 
(refer Figure 3.5). These overlapping peptides covered the entire sequence of the protein. The 
final PepSets consisted of a total of 31 peptides plus 2 control peptides. The reactivities of P3, 
P10, P13, P14 and P15 patient’s plasma samples containing anti-IFN-β-1a Rebif™ antibodies 
with the pin-bound peptides were detected by modified enzyme immunoassay.  
 
Figure 3.5: Schematic representation of continuous B-cell epitope mapping using 
multipin peptide technology (Step 1 photograph was taken from Mimotopes (Victoria, 
Australia). The pins were pre-coated for 1 hour at room temperature with 200 µL of pre-
coating buffer (0.01 M PBS pH 7.2 and 0.1 % v/v Tween 20) per well in the wells of a 
microtiter flat bottom plate. They were then incubated overnight at 4 °C with 200 µL of a 
1:1000 dilution of anti-IFN-β-1a Rebif™ antibodies positive plasma sample in pre-coating 
buffer. The plate containing the plasma was discarded, and the pin block was washed four 
times for 10 minutes each with PBS. Then, the peroxidase-conjugated secondary antibody 
goat anti-human IgG (H+L) F(ab')2 (Kirkegaard and Perry; Maryland, USA) at 1:2000 
dilution in conjugate buffer (0.01M PBS pH 7.2, 0.1 % v/v Tween-20 and 0.1 % w/v Sodium 
caseinate) was added to the wells of a microtiter plate and the pin block was inserted and 
incubated for 1 hour at room temperature. After being washed as before, the block was 
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inserted in a new microtiter plate containing 200 µL of 2,2'-Azinobis [3-
ethylbenzothiazoline-6-sulfonic acid]-diammonium salt (ABTS) substrate (Kirkegaard and 
Perry; Maryland, USA) per well and developed for 45 minutes with gentle agitation. The 
plate was read at 405 nm absorbance using a MRX microplate reader. To reuse the pin block, 
it was placed in an ultrasonic bath with disruption buffer (0.1 M PBS, 1 % w/v SDS and 0.1 
% v/v 2-mercaptoethanol pH 7.4) heated to 60 °C. The pin block was sonicated for 10 
minutes, rinsed and washed in deionised water with an initial temperature of 60 °C (twice for 
30 seconds each time and once for 30 minutes). The confirmation of antibody removal was 
checked by conjugate test. The test evaluates the reactivity of the conjugate with the peptides 
before actual epitope mapping test using patient’s plasma. When the pin block was not in use, 
the pins were air dried after immersion in 100 % methanol and stored at 4 °C.  
3.2.10 Linear binding epitope detection 
Liner binding epitopes in anti-drug antibodies against IFN-β-1a Rebif™ were detected using 
an in vitro competitive binding assay approach. The in vitro approach followed was 
combination of competition binding assay and ELISA. Peptides (12 amino acids long with 5 
amino acids overlap) for IFN-β-1a Rebif™ were custom synthesised (Mimotopes, Australia) 
for this assay (refer Table 3.3). A total of 32 lyophilised peptides (2.6 mg each) were 
dissolved in 1.6 ml of 100 % DMSO to yield an average of 1.7 moles per peptide. 
Concentrations of anti-drug antibodies in moles were determined based on anti-drug 
antibodies levels in serum as described in chapter 3 Figure 3.14a. Eight peptide pools were 
prepared by mixing 4 consecutive peptides for assessments (Pool 1: Peptide 1-4, Pool 2: 
Peptide 5-8, Pool 3: Peptide 9-12, Pool 4: Peptide 13-16, Pool 5: Peptide 17-20, Pool 6: 
Peptide 21-24, Pool 7: Peptide 25-28, Pool 8: Peptide 28-32). Peptides (8 pools) and anti-
drug antibodies containing serum n=8 were incubated at 37 °C for 1 hour. To facilitate 
maximum binding of the test peptides, saturating levels – 40 times: 2X (for IgG valency) + 
20X (excess), of peptides were added to the serum (1:20 dilution). The 100 µl of peptide: 
anti-drug antibodies mixture was added onto wells in an ELISA plate coated with IFN-β-1a 
Rebif™ (1.5 µg/ml; overnight incubation at 4 °C) and human IgG bound to IFN-β-1a Rebif™ 
was measured colorimetrically at 450 nm. Serum containing anti-drug antibodies (n=8) 
without peptides was used as controls for each anti-drug antibodies positive sample. A 
decrease in the optical density values in the peptide: anti-drug antibodies mixture compared 
to its corresponding anti-drug antibodies only category indicates reduced binding of the anti-
drug antibodies to the coated IFN-β-1a Rebif™. This indicates binding that the incubated 
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peptides to the anti-drug antibodies which prevents the binding of the anti-drug antibodies to 
the coated IFN-β-1a Rebif™. No change or slight increases in optical density values indicate 
lack of binding of the peptides to the anti-drug antibodies. Dr Swaminathan Sethu kindly 
conducted this experiment and analysed the data.  
1 MSYNLLGFLQRS 9 PEEIKQLQQFQK 17 ETIVENLLANVY 25 HLKRYYGRILHY 
2 LGFLQRSSNFQC 10 QLQQFQKEDAAL 18 NLLANVYHQINH 26 YGRILHYLKAKE 
3 RSSNFQCQKLLW 11 QKEDAALTIYEM 19 VYHQINHLKTVL 27 HYLKAKEYSHCA 
4 QCQKLLWQLNGR 12 ALTIYEMLQNIF 20 NHLKTVLEEKLE 28 KEYSHCAWTIVR 
5 LWQLNGRLEYCL 13 EMLQNIFAIFRQ 21 VLEEKLEKEDFT 29 CAWTIVRVEILR 
6 GRLEYCLKDRMN 14 IFAIFRQDSSST 22 LEKEDFTRGKLM 30 VRVEILRNFYFI 
7 CLKDRMNFDIPE 15 RQDSSSTGWNET 23 FTRGKLMSSLHL 31 LRNFYFINRLTG 
8 MNFDIPEEIKQL 16 STGWNETIVENL 24 LMSSLHLKRYYG 32 YFINRLTGYLRN 
Table 3.3: The amino sequences of thirty two 12mer 5offset overlapping IFN-β-1a 
Rebif™ peptides. The overlapping peptide libraries are important biological research tools 
used for screening of large number of peptides in order to discover critical bioactive peptides.  
3.2.11 Measurement of immune complex 
The formation of immune complex in vitro was induced by incubating IFN-β-1a Rebif™ 
with patient serum for 1 hour at 37 °C followed by quantification of IgG complexes bound to 
C1q using IMTEC-CIC IgG ELISA kit (Imtec, Human Gesellschaft für Biochemica und 
Diagnostica mbH, Germany).   
Hundred microliters of serum samples diluted at 1:100, standards and controls were added to 
C1q coated microtitre plate and incubated for 1 hour at room temperature. The plate was 
washed 3 times with wash buffer and 100 µL of conjugate solution was added and incubated 
for 30 minutes at room temperature. The plate was washed again and 100 µL of TMB 
solution was added and incubated for 10 minutes at room temperature. Following color 
development the reaction was stopped using addition of 100 µL of ready for use, 0.18 M 
H2SO4. The absorbance was read at 450 nm using a MRX microplate reader. 
3.2.12 Measurement of immune complex induced C3a and C5a  
The immune complex induced samples were analysed for activated complement factors, C3a 
and C5a using C3a and C5a ELISA kits (Hycult Biotech, Netherlands). Hundred microliters 
of immune complex induced samples (diluted at 1:4000 and 1:100 using dilution buffer for 
C3a and C5a respectively), standards and controls were added to microtitre plate coated with 
C3a or C5a specific antibody and incubated for 1 hour at room temperature. The plate was 
washed 4 times with wash buffer and 100 µL of biotinylated tracer antibody solution was 
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added to the microtitre plates and incubated for 1 hour at room temperature. The plate was 
washed again and 100 µL of streptavidin-peroxidase was added and incubated for 1 hour at 
room temperature. The wash procedure was repeated and then 100 µL of TMB solution was 
added and incubated for 20-30 minutes at room temperature. The reaction was stopped by 
addition of 100 µL of stop solution and the plate was read at 450 nm using a plate reader.  
3.2.13 Statistical analysis 
The data set for each group was tested for normality using the Shapiro-Wilk normality test. 
Descriptive statistical analysis was performed on each data group. For normal data sets, the 
mean and standard deviation (SD) was determined for each group. For non-normal data sets, 
the median and interquartile range was determined for each group. To determine statistical 
significance, comparisons were made using the Student’s t-test (for two parametric groups), 
the Mann Whitney U test (for two non-parametric groups), the ANOVA and ANOVA with 
Dunnett’s post hoc test (for more than two parametric groups) and the Kruskall-Wallis test 
for more than two non-parametric groups (Statsdirect; Cheshire, UK). The graphs were made 
using GraphPad Prism 5 software (GraphPad Saftware; CA, USA). Statistical significance 
was set at P < 0.05.  
3.3 Results 
3.3.1 Interferon beta 1a Rebif™ anti-drug antibodies are predominantly of the IgG1 
and IgG4 subclass 
The aim was to detect anti-drug antibodies against IFN-β-1a Rebif™ and to investigate the 
relative contribution of IgG subclasses in the formation of anti-drug antibodies. The 
distribution of IgG subclasses partially depends on the properties of antigen, with protein 
therapeutics normally eliciting IgG1 and IgG3 subclass specific response, whereas IgG2 
dominates with carbohydrate antigens (Ferrante, Beard & Feldman 1990; Siber et al. 1980). 
Therefore, we investigated the relative contribution of IgG subclasses to immunogenicity of 
IFN-β-1a Rebif™. In this study we found eight out of nineteen RRMS patients had detectable 
levels of IFN-β-1a Rebif™ specific IgG antibodies (refer Figure 3.6b). The donor P1 was 
discontinued due to poor health. The samples were classified as IFN-β-1a Rebif™ specific 
anti-drug antibody positive when the IFN-β-1a Rebif™ specific IgG concentrations were 
above the threshold value of the mean plus two times the standard deviation of the value in 
healthy control plasma. The IFN-β-1a Rebif™ specific IgG concentration ranged between 0.3 
µg/ml and 2.0 µg/ml in anti-drug antibodies positive samples. The data sets are non-
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parametric and hence the median and interquartile range was determined. No significant 
difference was noticed in the levels of total IgG 6.850 (4.575, 7.850) and 7.200 (6.200, 
9.400), total IgM 0.2650 (0.2025, 0.04925) and 0.3300 (0.2000, 0.5100) and IFN-β-1a 
Rebif™ specific IgM 43.56 (42.41, 53.91) and 45.01 (43.39, 51.27) between healthy donors 
and RRMS patients respectively (refer Figure 3.6a, 3.6c and 3.6d). IFN-β-1a Rebif™ specific 
IgG subclass revealed IFN-β-1a Rebif™ specific IgG1 and IgG4 in the plasma of eight anti-
drug antibodies positive patients and were significantly high when compared to IgG2 and 
IgG3 (refer Figure 3.7b). Distribution of IFN-β-1a Rebif™ specific IgG subclasses for each 
of the sample indicated IgG1 0.1550 (0.0950, 0.3325) and IgG4 0.2850 (0.0225, 0.4225) at 
varying levels predominantly contributed to the anti-drug antibodies followed by IgG3 
0.0200 (0.00575, 0.0200) and IgG2 0.0100 (0.0010, 0.0400) (refer Figure 3.7c). The donor 
P29 IFN-β-1a Rebif™ specific subclass IgG subclass profile was found to be primarily made 
up of IFN-β-1a Rebif™ specific subclass IgG1 and IgG3 with IFN-β-1a Rebif™ specific IgG 
subclass IgG4 being undetectable (refer Figure 3.7c). There were no significant differences in 
the total IgG subclass levels between healthy donors and RRMS patients (refer Figure 3.7a). 
Our data suggests that predominant Ig isotype of IFN-β-1a Rebif™ anti-drug antibodies is 
IgG and is dominated by IgG1/IgG4 subclass specific response in multiple sclerosis patients.        
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Figure 3.6: Immunoglobulin G and IgM of IFN-β-1a Rebif™ anti-drug antibodies. Total and 
IFN-β-1a Rebif™ specific IgG and IgM was quantified in plasma of healthy donors (n=10) and in 
RRMS patients (n=19) treated with IFN-β-1a Rebif™. Each open circle represents an individual 
total and IFN-β-1a Rebif™ specific IgG and IgM levels. Bars represent the IQR (25th and 75th 
percentiles) from the median (horizontal line). Figure A represents total IgG, the medians (25 th, 
75th percentiles) include 6.850 (4.575, 7.850) and 7.200 (6.200, 9.400) for the 2 groups 
respectively. Figure B represents IFN-β-1a Rebif™ specific IgG, the medians (25th, 75th 
percentiles) include 0.0750 (0.0525, 0.0950) and 0.0800 (0.0500, 1.500) for the 2 groups 
respectively. The anti-drug antibody positive samples circles are coloured in red, while negative 
samples circles are coloured in blue. Figure C represents total IgM, the median (25th, 75th 
percentiles) include 0.2650 (0.2025, 0.04925) and 0.3300 (0.2000, 0.5100) for the 2 groups 
respectively. Figure D represents IFN-β-1a Rebif™ specific IgM, the medians (25th, 75th 
percentiles) include 43.56 (42.41, 53.91) and 45.01 (43.39, 51.27) for the 2 groups respectively. 
The data point in each graph is a mean of triplicate measurements and is representative of three 
independent experiments. Statistically significant differences are shown in panels and 
comparisons were determined using Mann Whitney U test for two non-parametric groups.  
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Figure 3.7: Immunoglobulin G subclass (IgG1-IgG4) of IFN-β-1a Rebif™ anti-drug 
antibodies. Total IgG subclass was quantified in plasma of healthy donors and in RRMS 
patients. IFN-β-1a Rebif™ specific IgG subclass was determined in IFN-β-1a Rebif™ anti-
drug antibodies positive samples (n=8). Bars represent the IQR (25
th
 and 75
th
 percentiles) 
from the median (horizontal line). Figure A represents total IgG subclass (IgG1-IgG4), the 
medians (25
th
, 75
th
 percentiles) include 4.354 (3.814, 5.853) and 5.279 (4.484, 6.403) for 
IgG1, 1.878 (1.705, 2.104) and 1.748 (1.370, 2.067) for IgG2, 0.4680 (0.2563, 0.6425) and 
0.6400 (0.4520, 0.7460) for IgG3 and 0.1530 (0.08625, 0.2448) and 0.2040 (0.0910, 0.4100) 
for IgG4 in the 2 groups respectively. Figure B represents IFN-β-1a Rebif™ specific IgG 
subclass (IgG1 – IgG4) in anti-drug antibody positive samples. Each red circle represents an 
individual IFN-β-1a Rebif™ specific IgG subclass (IgG1 – IgG4). The medians (25th and 75th 
percentiles) include 0.1550 (0.0950, 0.3325), 0.0100 (0.0010, 0.0400), 0.0200 (0.00575, 
0.0200) and 0.2850 (0.0225, 0.4225) for IFN-β-1a Rebif™ specific IgG1, IgG2, IgG3 and 
IgG4 respectively. Figure C represents the proportion of IFN-β-1a Rebif™ specific IgG 
subclass (IgG1-IgG4) in each anti-drug antibody positive plasma samples P3, P10, P13, P14, 
92 
 
P15, P28, P29 and P30 respectively. The data point in each graph is a mean of triplicate 
measurements and is representative of three independent experiments. Statistically significant 
differences are shown in panels and comparisons were determined using Kruskall-Wallis test 
for more than two nonparametric groups. 
3.3.2 Neutralising potential of Interferon beta 1a Rebif™ anti-drug antibodies 
In order to assess the neutralising potential of IFN-β-1a Rebif™ anti-drug antibodies, we 
used IFN-β-1a Rebif™ induced intracellular MxA expression in human acute monocytic 
leukemic cells line, THP-1. Semi-quantitative assessment of neutralising potential of IFN-β-
1a Rebif™ anti-drug antibodies was performed using a bioassay based on IFN-β responsive 
MxA protein. MxA protein levels were measured by immunoblotting (refer Figure 3.8). 
Different concentrations of research grade IFN-β-1a and commercially available IFN-β-1a 
Rebif™ at 1U, 10U, 100U, 500U, 1000U and 5000U at different incubation times either 
overnight and 18 hours was also evaluated to induce interferon induced MxA protein. The 
decision was established to use 100U of IFN-β-1a Rebif™ and 18 hours of incubation time 
before preparation of protein lysates (refer Figure 3.9a).   
 
Figure 3.8: Schematic representation of in vitro bioassay using Type 1 IFN-receptor 
positive THP-1 cells.   
Our data indicate seven out of eight IFN-β-1a Rebif™ anti-drug antibodies positive samples 
had the potential to neutralise the IFN-β-1a Rebif™ induced MxA (refer Figure 3.8b). 
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However, donor P29 did not neutralise IFN-β-1a Rebif™ indicating the anti-drug antibodies 
were of non-neutralising type. None of the anti-drug antibodies negative samples and healthy 
donors neutralised IFN-β-1a Rebif™ induced MxA (refer Figure 3.9b). Our data was 
consistent with the data obtained from other neutralisation assays carried out independently at 
National Institute of Biological Standards and Control (NIBSC), UK (refer Appendix 7).  
 
Figure 3.9: Neutralisation potential of IFN-β-1a Rebif™ anti-drug antibodies. Figure A 
represents the western blot for MxA protein expression. THP-1 cells were treated with 
increasing doses of IFN-β-1a Rebif™ (1-5000 U) for 18 hours and whole cell lysates were 
prepared. The protein lysates (10 µg) were subjected to SDS-PAGE and the levels of MxA 
and the loading control protein β-actin were determined by western blot analysis. Figure B 
represents the western blot for IFN-β-1a Rebif™ induced MxA protein levels in THP-1 cells. 
100 U of IFN-β-1a Rebif™ was pre-incubated with 1:10 dilution of plasma samples of 
healthy controls and IFN-β-1a Rebif™ anti-drug antibody positive and negative samples for 1 
hour at 37 °C and was then added to THP-1 cells for 16 hours. Proteins from whole cell 
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lysates were separated by SDS-PAGE and western blotting was performed. The membranes 
were probed for human MxA and β-actin. Ctrl indicates the cell lysates prepared from cells 
without any treatment and IFNβ indicates the lysates from cells treated with 100U IFN-β-1a 
Rebif™ only. The images are representative of three independent experiments.     
3.3.3 Magnitude of neutralising potential of Interferon beta 1a Rebif™ anti-drug 
antibodies 
In order to determine the magnitude of neutralising potential in each of the IFN-β-1a Rebif™ 
anti-drug antibodies positive samples dose response neutralisation bioassay was performed 
(refer Section 3.3.2). The plasma samples were incubated for 1 hour at 37 °C with 100 U of 
IFN-β-1a Rebif™ at 1:10, 1:100, 1:1000, 1:10000, 1:100000 and 1:1000000 dilutions. Later, 
the mixture was added to THP-1 cells and incubated for 18 hours at 37 °C and MxA 
induction was measured. The Figure 3.10 represents the dose response neutralisation bioassay 
immunoblots for P3, P10, P13, P14, P15, P28, P29 and P20 samples.  The neutralisation 
capabilities for five samples P3, P10, P13, P14 and P15 was until 1:1000 dilutions (refer 
Figure 3.10Ai – v). However, P28 and P30 neutralisation capacity was until 1:100 dilutions 
(refer Figure 3.10Avi and viii). The donor P29 failed to neutralise IFN-β-1a Rebif™ induced 
MxA protein and therefore was classified as IFN-β-1a Rebif™ neutralising antibody negative 
sample (refer Figure 3.10vii). The remaining was classified as IFN-β-1a Rebif™ neutralising 
antibodies positive samples in this study.     
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Figure 3.10: Inter-individual variations in neutralisation potential of IFN-β-1a Rebif™ 
anti-drug antibodies. Western blots showing IFN-β-1a Rebif™ induced MxA protein levels 
in THP-1 cells. 100 U of IFN-β-1a Rebif™ was pre-incubated with increasing dilutions 1:10, 
1:100, 1:1000, 1:10000, 1:100000, 1:1000000 of plasma samples of IFN-β-1a Rebif™ anti-
drug antibody positive samples A. P3, B. P10, C. P13, D. P14, E. P15, F. P28, G. P29 and H. 
P30 for 1 hour at 37 °C and was then added to THP-1 cells for 18 hours. Proteins from whole 
cell lysates were separated by SDS-PAGE and western blotting was performed. The 
membranes were probed for human MxA and β-actin. C on the blots indicates the cell lysates 
prepared from cells without any treatment and 100 U on the blots indicates the lysates from 
cells treated with 100 U IFN-β-1a Rebif™ only. MxA protein bands were quantified by 
densitometry, expressed relative to β-actin and subsequently converted into ratio of MxA 
expression. The images are representative of three independent experiments.      
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3.3.4 IgG4 depletion for Interferon beta 1a Rebif™ anti-drug antibodies positive 
samples 
Our data suggests IgG1 and IgG4 contribute to IFN-β-1a Rebif™ anti-drug antibodies 
profile. The earlier studies have implicated IgG4 anti-drug antibodies have greater 
neutralisation potential compared to other IgG subclasses. Hence, IgG4 anti-drug antibodies 
was depleted in order to establish the correlation between IgG4 anti-drug antibodies and 
neutralising potential in all the IFN-β-1a Rebif™ anti-drug antibodies positive samples P3, 
P10, P13, P14, P15, P28 and P30. However, quantification of IgG subclasses revealed loss of 
IgG1, IgG2 and IgG3 in addition to the expected depletion of IgG4 (refer Table 3.4). Hence, 
adjustments of the samples were performed based on total IgG1 levels (refer Figure 3.11).    
A 
Samples 
Total plasma µg/ml 
Unadjusted IgG4 depleted fraction 
µg/ml 
IgG1 IgG2 IgG3 IgG4 IgG1 IgG2 IgG3 IgG4 
P3 13077.62 1016.59 1097.85 1084.32 5284.94 531.67 547.57 0.00 
P10 5849.32 1730.04 2089.52 543.62 3513.97 1046.30 1239.00 0.00 
P13 7652.09 2395.45 685.38 574.82 3718.17 1479.85 317.09 0.00 
P14 7422.87 2305.98 653.03 614.48 4517.56 1316.04 334.99 0.00 
P15 6246.60 1055.45 408.50 214.30 2926.98 572.36 278.20 0.00 
P28 8607.40 2040.60 2383.32 598.20 4460.91 1442.52 1348.33 0.00 
P30 7893.31 2052.79 621.70 46.78 4183.43 1206.12 343.56 0.00 
 
B 
Samples adjusted IgG4 depleted  fraction 
µg/ml 
IgG1 IgG2 IgG3 IgG4 
P3 11858.15 1168.02 1642.61 0.00 
P10 6917.24 1622.62 1889.80 0.00 
P13 7090.32 2823.06 722.88 0.00 
P14 7469.18 1980.21 467.45 0.00 
P15 9919.18 1101.80 578.74 0.00 
P28 7370.64 2092.88 2200.84 0.00 
P30 7692.11 1745.03 628.16 0.00 
 
Table 3.4: Quantification of total IgG subclasses in total plasma, adjusted and unadjusted 
IgG1-3 plasma samples.    
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Figure 3.11: Immunoglobulin G subclass (IgG1-IgG4) in total plasma, adjusted and 
unadjusted IgG1-IgG3 plasma samples. The total plasma, adjusted and unadjusted IgG1-3 
plasma samples from IFN-β-1a Rebif™ anti-drug antibody positive patients P3, P10, P13, 
P14, P15, P28 and P30 were analysed for total IgG subclass (IgG1-4) to assess the purity in 
obtained IgG1-3 fractions. Figure A represents total IgG1 levels in total, adjusted and 
unadjusted IgG1-3 plasma samples. Figure B represents total IgG2 levels in total, adjusted 
and unadjusted IgG1-3 plasma samples. Figure C represents total IgG3 levels in total, 
adjusted and unadjusted IgG1-3 plasma samples. Figure D represents total IgG4 levels in 
total, adjusted and unadjusted IgG1-3 plasma samples.       
3.3.5 Neutralising potential of IgG4 depleted Interferon beta 1a Rebif™ anti-drug 
antibodies  
In order to assess the neutralisation potential in total plasma and IgG4 depleted plasma 
(adjusted and unadjusted) the comparison was established using IFN-β induced MxA protein 
expression in THP-1 cells, using western blotting (refer Figure 3.12). Based on the results, 
depletion of IgG4 resulted in P3 donor 60-79 %, P10 donor 1-3 %, P14 donor 3-13 %, P14 
donor 3-18 %, P15 donor 13-14 %, P28 50 % and P30 56-64 % reduction in the neutralisation 
potential in both IgG4 adjusted and unadjusted plasma samples. Our observation from this 
study indicates that IgG4 may likely contribute to the neutralisation activity of IFN-β-1a 
Rebif™ specific anti-drug antibodies and this effect may vary between patients.  
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Figure 3.12: Neutralisation potential of IgG4 depleted IFN-β-1a Rebif™ anti-drug 
antibodies. Western blots showing variable differences in the potency of IFN-β-1a Rebif™ 
anti-drug antibody positive plasma samples with (total) and without (adjusted and 
unadjusted) IFN-β-1a Rebif™ specific IgG4 to neutralise IFN-β-1a Rebif™ induced MxA 
protein in THP-1 cells. IFN-β-1a Rebif™ 100 U pre-incubated with diluted plasma from 8 
IFN-β-1a Rebif™ anti-drug antibody positive samples (1:1000 for P3, P10, P13, P14 and P15 
and 1:10 for P28 an P30 with (total) and without (adjusted and unadjusted) IgG4 plasma 
samples for 1 hour at 37 °C and was then added to THP-1 cells for 16 hours. Proteins from 
whole cell lysates were separated by SDS-PAGE and western blotting was performed. The 
membranes were probed for human MxA and β-actin. C on the blots indicates the cell lysates 
prepared from cells without any treatment and 100 U on the blots indicates the lysates from 
cells treated with 100 U IFN-β-1a Rebif™ only. MxA protein bands were quantified using 
densitometry. Neutralisation % is the percentage based on densitometric analysis of western 
blots assessing IFN-β-1a Rebif™ induced MxA neutralisation by IFN-β-1a Rebif™ anti-drug 
antibody positive plasma samples with (total) and without (adjusted and unadjusted) IgG4 
relative to 100 U only category. The neutralisation % also indicates the difference in the 
neutralisation potential of IgG4 depleted plasma compared to its respective non-depleted 
fraction. The images are representative of three independent experiments.  
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3.3.6 Interferon beta 1a Rebif™ anti-drug antibodies cross reacts and neutralises the 
endogenous IFN-β induced bioactivity  
The aim of this experiment was to elucidate the potential for IFN-β-1a Rebif™ anti-drug 
antibodies on neutralisation of endogenous IFN-β. LPS and Poly (I: C) was used to induce 
IFN-β in THP-1 cells (refer Figure 3.13A). The production of IFN-β was determined using 
MxA protein expression. Eight IFN-β-1a Rebif™ anti-drug antibodies positive samples were 
tested for their cross-reactivity to endogenous IFN-β. Five donors P3, P10, P13, P14 and P15 
out of eight neutralised LPS and Poly I:C induced endogenous IFN-β at varying degrees 
(refer Figure 3.13B) P3 47.6 %, P10 77.5 %, P13 63 %, P14 60.5 % and P15 75 % reduction 
in the MxA protein expression to its positive control (Lane 2). The intensities of 
immunoreactive bands were quantified using densitometry. Our results indicate anti-drug 
antibodies generated in response to IFN-β-1a Rebif™ can neutralise endogenous IFN-β.   
 
Figure 3.13: IFN-β-1a Rebif™ anti-drug antibodies cross reacts and neutralises the 
endogenous IFN-β induced bioactivity. Figure A represents the schematic representation of 
the rationale and strategy for the cross reactivity studies. In brief the bioactivity of 
endogenous IFN-β was assessed by triggering IFN-β induced MxA protein by TLR4/3 
activation – LPS 1 µg/mL and Poly I:C 10 µg/mL. Cross reactivity of Rebif™ IFN-β-1a anti-
drug antibodies to endogenous IFN-β was studied by investigating the ability of the anti-drug 
antibodies to block or inhibit the induction of MxA protein. Figure B represents a western 
blot for MxA protein expression induced using LPS and Poly I:C stimulation for 24 hours in 
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THP-1 cells. Induction of MxA protein is a result of endogenous Type 1 Interferons, which 
includes IFN-β triggered by LPS and Poly I:C. The western blot also indicates the changes in 
the level of induced MxA protein when cells are co-incubated with 1:10 dilution of plasma 
samples from Rebif™ IFN-β-1a anti-drug antibody positive samples (P3, P10, P13, P14, P15, 
P28 and P30) along with LPS and Poly I:C. Proteins from whole cell lysates were separated 
by SDS-PAGE and western blotting was performed. The membranes were probed for human 
MxA and β-actin. Ctrl indicates the cell lysates prepared from cells without any treatment and 
LPS+PIC indicates the lysates from cells treated with LPS+PIC only. The images are 
representative of three independent experiments. 
3.3.7 Complement activation by Interferon beta 1a Rebif™ anti-drug antibodies 
immune complex 
The formation of immune complexes between a biologic and anti-drug antibody have the 
potential to activate complement system by first binding to complement component C1q, 
which then leads to induction of activated complement. Serum from -1a Rebif™ anti-
drug antibodies positive samples were used to investigate complements. Hence, we also 
quantified Rebif™ specific IgG in all anti-drug antibodies positive serum samples (refer 
Figure 3.14a).  The quantification was found comparable to plasma samples. Optimal C1q 
binding of the IFN-β-1a Rebif™ anti-drug antibodies and IFN-β-1a Rebif™ immune 
complex was observed at an antigen-antibody (IFN-β-1a Rebif™: anti-drug antibody) ratio 
5:1 (refer Figure 3.14b). Significant increase in immune complex formation was observed 
following IFN-β-1a Rebif™ incubation with IFN-β-1a Rebif™ anti-drug antibodies positive 
serum samples (refer Figure 3.14c). The magnitude of immune complex formation in 
individual samples was variable with values ranging from 0.2 to 2 fold increase from baseline 
(refer Figure 3.14d). Elevated C1q binding was accompanied by significant increase in the 
C3a levels in the serum samples incubated with IFN-β-1a Rebif™ (refer Figure 3.15a and b). 
However, no significant increase in C5a levels was observed (refer Figure 3.15c and d). Our 
data demonstrate IFN-β-1a Rebif™ anti-drug antibodies can form immune complexes with 
IFN-β-1a Rebif™ and therefore activate complement.    
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Figure 3.14: IFN-β-1a Rebif™ forms anti-drug antibody immune complexes that bind 
complement C1q. Figure A represents the IFN-β-1a Rebif™ specific IgG anti-drug 
antibodies in serum of P3, P10, P13, P14, P15, P28, P29 and P30 samples. Figure B 
represents Ag [IFN-β-1a Rebif™]:Ab [IFN-β-1a Rebif™ specific anti-drug antibody] ratio at 
which immune complexes were formed by incubating IFN-β-1a Rebif™ with serum 
containing IFN-β-1a Rebif™ specific IgG anti-drug antibodies for 1 hour at 37 °C. Figure C 
and D represents the levels of immune complex bound to C1q in 8 IFN-β-1a Rebif™ specific 
IgG anti-drug antibody positive P3, P10, P13, P14, P15, P28, P29 and P30 samples. Each 
open circle represents an individual immune complex bound to C1q. Bars represents the IQR 
(25
th
 and 75
th
 percentiles) from the median (horizontal line). The medians (25
th
, 75
th
 
percentile) include 20.20 (15.58, 23.65) and 30.80 (22.05, 50.65) for the 2 groups 
respectively. The data point in each graph is a mean of triplicate measurements and is 
representative of three independent experiments. Statistically significant differences are 
shown in panels and comparisons were determined using Mann Whitney U test for two 
nonparametric groups.     
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Figure 3.15: IFN-β-1a Rebif™ anti-drug antibody immune complex activates 
anaphylatoxins C3a and C5a. Figure A and B represent the subsequent changes in the C3a 
in 8 IFN-β-1a Rebif™ anti-drug antibody positive P3, P10, P13, P14, P15, P28, P29 and P30 
serum samples. Each open circle represents an individual immune complex induced C3a. 
Bars represent the IQR (25
th
 and 75
th
 percentiles) from the median (horizontal line). The 
medians (25
th
, 75
th
 percentile) include 5.662 (5.364, 6.887) and 10.54 (9.681, 11.22) for the 2 
groups respectively. Figure C and D represent the subsequent changes in the C5a in 8 IFN-β-
1a Rebif™ anti-drug antibody positive P3, P10, P13, P14, P15, P28, P29 and P30 serum 
samples. Each open circle represents an individual immune complex induced C5a. The 
medians (25
th
, 75
th
 percentile) include 32.63 (10.93, 478.1) and 60.40 (25.03, 473.9) for the 2 
groups respectively. The data point in each graph is a mean of triplicate measurements and is 
representative of three independent experiments. Statistically significant differences are 
shown in panels and comparisons were determined using Mann Whitney U test for two 
nonparametric groups.       
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3.3.8 Mapping of continuous antibody linear epitopes 
To identify the potential antibody linear epitopes, we analysed the binding of IFN-β-1a 
Rebif™ anti-drug antibodies in five positive P3, P10, P13, P14 and P15 plasma samples 
(refer Figure 3.17a), one negative N5 plasma sample (refer Figure 3.17b) and one healthy 
control H25 plasma sample (refer Figure 3.17c) to 32 12mer (5offset) overlapping peptides 
spanning 166 amino acid residues representing the amino acid sequence of IFN-β-1a Rebif™ 
molecule (refer 3.16a and b). The overlapping peptide library spanning IFN-β-1a Rebif™ 
protein was generated. The choice of appropriate peptide length and offset was determined 
based on previous studies. In general for antibody (or B-cell) epitope mapping, 5 – 20 amino 
acid length and 1 offset will be ideal. However, we used 12mer and 5 offset in our studies 
using multipin peptide technology. The binding was considered significant when the OD 
value was 25 % of the average of overall least OD values plus 2 times standard deviation. 
According to this type of analysis, significant binding was seen in P10, P13, P14 and P15 at 
amino acid residues 1-32, 40-62, 70-86, 106-112 and 136-166 respectively. No significant 
binding was observed either in negative and healthy control plasma samples.  
We also used an alternative approach to detect IFN-β-1a Rebif™ antibody linear epitopes 
using an in vitro competitive binding assay. This involves the combination of competitive 
binding assay and ELISA. In brief the anti-IFN-β-1a Rebif™ antibodies are incubated with 
IFN-β-1a Rebif™ peptides, the complexes are added to 96 well plate which are pre-coated 
with IFN-β-1a Rebif™, the unbound anti-IFN-β-1a Rebif™ antibodies are removed (peptide 
competition with anti-IFN-β-1a Rebif™ antibodies) , the secondary antibody specific to 
primary antibody which are conjugated with an enzyme is added and developed using 
chromogenic substrate. For this assay the higher the binding, the weaker is the eventual signal 
(Morris GE 2007). Therefore, there is IFN-β-1a Rebif™ peptide binding with anti-IFN-β-1a 
Rebif™ antibodies. The Figure 3.18 indicates no linear binding epitopes present against IFN-
β-1a Rebif™ or the method developed for detection of linear epitopes was not specific or 
sensitive to detect the linear binding IFN-β-1a Rebif™ epitopes.       
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A 
MSYNLLGFLQ RSSNFQCQKL LWQLNGRLEY CLKDRMNFDI PEEIKQLQQF QKEDAALTIY 
EMLQNIFAIF RQDSSSTGWN ETIVENLLAN VYHQINHLKT VLEEKLEKED FTRGKLMSSL 
HLKRYYGRIL HYLKAKEYSH CAWTIVRVEI LRNFYFINRL TGYLRN   
 
B 
1 MSYNLLGFLQRS 9 PEEIKQLQQFQK 17 ETIVENLLANVY 25 HLKRYYGRILHY 
2 LGFLQRSSNFQC 10 QLQQFQKEDAAL 18 NLLANVYHQINH 26 YGRILHYLKAKE 
3 RSSNFQCQKLLW 11 QKEDAALTIYEM 19 VYHQINHLKTVL 27 HYLKAKEYSHCA 
4 QCQKLLWQLNGR 12 ALTIYEMLQNIF 20 NHLKTVLEEKLE 28 KEYSHCAWTIVR 
5 LWQLNGRLEYCL 13 EMLQNIFAIFRQ 21 VLEEKLEKEDFT 29 CAWTIVRVEILR 
6 GRLEYCLKDRMN 14 IFAIFRQDSSST 22 LEKEDFTRGKLM 30 VRVEILRNFYFI 
7 CLKDRMNFDIPE 15 RQDSSSTGWNET 23 FTRGKLMSSLHL 31 LRNFYFINRLTG 
8 MNFDIPEEIKQL 16 STGWNETIVENL 24 LMSSLHLKRYYG 32 YFINRLTGYLRN 
 
Figure 3.16: The amino acid sequences. The Figure A represents the amino acid sequence 
of IFN-β-1a Rebif™ molecule. The Figure B represents 32 12mer 5offset overlapping IFN-β-
1a Rebif™ peptides.  
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Figure 3.17: Mapping of continuous B-cell linear epitopes using 32 12mer 5 offset overlapping 
peptides representing the amino acid sequence of the IFN-β Rebif™ molecule. Figure Ai, ii, iii, 
iv and v represents IFN-β Rebif™ anti-drug antibody positive plasma samples from P3, P10, P13, 
P14 and P15 for continuous B-cell epitope mapping using multipin peptide technology. Figures B 
and C represent IFN-β Rebif™ anti-drug antibody negative plasma sample from N5 and healthy 
control plasma sample from H24 as controls for B-cell epitope mapping. No significant binding 
was seen in N5 or H25 plasma samples. The plasma samples were diluted at 1:1000. The control 
peptides included negative peptide GLAQGGGG and positive peptide PLAQGGGG. However, the 
negative control peptide cannot truly be considered as negative control as the peptide is binding to 
the antibody. The OD was measured at 405nm.  
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Figure 3.18: Linear binding epitopes detection in anti-IFN-β-1a Rebif™ antibodies. In vitro competitive binding approach was designed and 
developed for detection of linear binding IFN-β-1a Rebif™ epitopes in anti-drug antibodies positive serum samples P3, P10, P13, P14, P15, P28, 
P29 and P30. Serum from respective anti-drug antibodies positive samples containing anti-drug antibodies without IFN-β-1a Rebif™ peptides 
was used as controls. One anti-IFN-β-1a Rebif™ negative donor N6 was also used as a control. The OD was measured at 450 nm.    
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3.4 Discussion 
The results presented in Figure 3.6 indicate the predominant immunoglobulin isotype of IFN-
β Rebif™ anti-drug antibodies is IgG isotype, with no detectable levels of IgM. However, the 
detection of IgM isotype after 3 months of IFN-β treatment has been reported, but this was 
gradually replaced by IgG after 6 months of treatment (Di Marco et al. 2006). In our studies 
the plasma samples were obtained from individuals who had been on IFN-β Rebif™ 
treatment for several years (refer to Table 3.1 for demographic and clinical features of 
patients enrolled for our studies). It is possible that IgM might have been part of early phase 
of an IFN-β-1a Rebif™ immunogenic response but have switched to IgG in our samples 
(Heyman 2000). The data presented in Figure 3.7 demonstrate the distribution of IFN-β 
Rebif™ IgG subclass specific anti-drug antibodies in anti-drug antibody positive plasma 
samples. The data also show the presence of both IgG1 and IgG4 anti-drug antibodies 
contributing to IFN-β-1a Rebif™ anti-drug antibody profiles. The studies have shown 
predominance of IgG4 anti-drug antibodies against IFN-β-1a formulations (Gibbs & Oger 
2007) and IgG2 and IgG4 anti-drug antibodies to IFN-β-1b formulation (Porter 2001). The 
observations are also similar to other treatments such as glatiramer acetate for multiple 
sclerosis where the predominant IgG subclass isotype was IgG4 anti-drug antibodies (Basile 
et al. 2006; Farina et al. 2002). It is also suggested that IgG4 anti-drug antibodies can be 
associated with increased neutralisation potential. Our studies in this chapter also attempt to 
demonstrate that IFN-β-1a Rebif™ IgG subclass specific anti-drug antibodies contribute to 
neutralisation potential.   
In order to assess the neutralisation potential in our plasma samples an IFN-β-1a Rebif™ 
induced MxA neutralisation bioassay was developed. Myxovirus resistance protein A (MxA) 
expression is the established biomarker for IFN-β bioactivity (Pachner et al. 2005). Figure 3.9 
demonstrates the immunoblots for neutralisation potential of IFN-β-1a Rebif™ anti-drug 
antibodies in all the plasma samples. Figure 3.10 demonstrates the inter-individual variation 
in neutralisation potential of IFN-β-1a Rebif™ anti-drug antibodies. The IgG4 was depleted 
from the IFN-β-1a Rebif™ anti-drug antibody positive plasma samples. The variations in the 
obtained plasma fractions were adjusted according to the IgG1 subclass. The neutralisation 
potential in total plasma, adjusted IgG4 depleted plasma and unadjusted IgG4 depleted 
plasma samples was determined using the IFN-β-1a Rebif™ induced MxA neutralisation 
bioassay. IgG4 antibodies have unique properties such as half-antibody exchange reactions 
because of two different Fabs arms rendering them bi-specific and hence functionally 
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monovalent for given antigen in circulation (Aalberse & Schuurman 2002). The evidence 
suggests that monovalent binding of IgG4 caused less neutralisation (Hofmeister Y et al 
2011). Hence, in our study these IgG4 antibodies might possess less neutralisation 
capabilities. The IgG4 structure and function implicates to exhibit diverse functional 
mechanisms in vitro and in vivo. The cytokines such as IL-4, IL-10 and IL-12 promote IgG4 
production and is dependent on the stimulating antigen (Nirula et al. 2011). Hence, evaluating 
cytokines can provide insights into immunogenicity reactions. The evidence also suggests 
prolonged exposure to allergens causes increase allergen-specific IgG4 response and shown T 
helper 2 cytokines such as IL-4, IL-5 and IL-13 in PBMCs cultures (Aalberse RC et al 1983, 
Akdis CA et al 1998). The densitometric analyses of the immunoblots show that the IgG4 
anti-drug antibodies are likely to be the major contributor to the neutralisation potential (see 
Figure 3.12). However, this has to be investigated further using increased number of samples 
and with purified IFN-β-1a Rebif™ specific IgG4. Furthermore, longitudinal studies are 
required to better understand the evolution of IgG subclass specific anti-drug antibodies and 
their neutralisation potential.  
The interaction of neutralising anti-drug antibodies against therapeutic proteins 
thrombopoietin and epoetin with endogenous protein has been studied (Bennett et al. 2004; Li 
et al. 2001). The data suggest that the antibodies have the ability to cross react with 
endogenous proteins and therefore compromise their normal physiological functions. The 
studies on therapeutic IFN-β have also shown cross reactivity with endogenous protein 
(Bertolotto et al. 2000; Khan & Dhib-Jalbut 1998). The recent reports also show IFN-β 
neutralising antibodies are able to neutralise fibroblast derived endogenous IFN-β (Shapiro et 
al. 2006; Sominanda et al. 2010). In our study we have shown in an in vitro model that IFN-
β-1a Rebif™ specific neutralising antibodies were able to neutralise the endogenous IFN-β 
bioactivity in THP-1 cells. The endogenous IFN-β activity was not completely neutralised 
when compared to therapeutic IFN-β, suggesting the amounts of endogenous IFN-β produced 
may be too high to be completely neutralised by their anti-drug antibodies. To test this 
possibility, the amounts of IFN-β produced by LPS/PIC activated THP-1 cells need to be 
quantified. The other possibility to explore is that the epitopes of both endogenous IFN-β and 
therapeutic IFN-β might differ in terms of recognition by neutralising anti-drug antibodies 
and this requires further investigation. The potential consequences of neutralisation of 
endogenous IFN-β include susceptibility to viral infections and an impact on the normal 
physiological functions of endogenous IFN-β in various organs including the CNS. This is of 
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particular importance considering the fact that the high titres of neutralising antibodies to 
IFN-β were found to last for many years after termination of IFN-β treatment (Hegen et al. 
2012; Sorensen et al. 2005b).   
The antigen-antibody based immune complex can initiate the classical complement activation 
cascade with the release of complement anaphylatoxins C3a and C5a. The data shown in 
Figure 3.14 and 3.15 demonstrates that the interaction of anti-drug antibodies with IFN-β-1a 
Rebif™ resulted in the formation of immune complex and activated complement cascade 
following binding of C1q and subsequently C3a and C5a. C3a and C5a are implicated in 
enhancing antigen processing and presentation and also in the maintenance of tolerance 
(Hegen et al. 2012; Strainic et al. 2008; Weaver et al. 2010). Complement activation 
enhances antigen uptake, processing and presentation and might be the major contributing 
factor in the initiation of the immunogenic response to biologics. Complement activation 
could also potentially favour the formation of anti-drug antibodies with increasing 
neutralising potential. The release of C3a and C5a enhance the function of DCs and generate 
Th1 cells. The effects are mediated via increased expression of co-stimulatory molecules 
CD80 and CD40 (Sacks & Zhou 2012). Furthermore, CD21 (complement receptor 2) 
expression on B cells enhances the processing of macromolecular antigens in immune 
individuals (Boackle, Holers & Karp 1997). One other important observation is that the 
incidence of anti-drug antibodies in subcutaneous Rebif™ and intramuscular Avonex™ is 
significantly different. The cause for this difference may be due to the ability of the immune 
complex between the injected Rebif™ and anti-drug antibodies to activate complements in 
the subcutaneous interstitium and gain access to antigen presenting cells such as Langerhans 
cells and dermal dendritic cells. The interactions between the immune complexes, activated 
complement and skin antigen presenting cells can enhance antigen processing and 
presentation of the therapeutic protein. This could also be the mechanism by which low 
affinity and non-neutralising antibodies lead to the development of neutralising antibodies 
through immune complex formation and antigen processing or presentation. In this study we 
also observe that patient P29, who had limited or no neutralising antibodies, was able to form 
immune complex and activated complement in presence of IFN-β-1a Rebif™. Based on this 
observation we also speculate that if a patient with non-neutralising antibodies continues to 
receive IFN-β treatment, immune complexes can be formed which through efficient antigen 
processing and presentation together with epitope spreading, may cause formation of 
neutralising antibodies. The complements are also altered in relapsing remitting multiple 
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sclerosis disease (Boos et al. 2004; Ingram et al. 2012). In our study we observed that 
complement activation by IFN-β-1a Rebif™ in anti-drug antibody positive samples increases 
the possibility that repeated administration of IFN-β-1a Rebif™ to anti-drug antibody 
positive patients can cause disturbed complement status. The impact of such complement 
activation on disease progression is still unclear and therefore requires further investigations.            
In order to further understand the binding patterns for IFN-β-1a Rebif™ anti-drug antibodies 
and receptor binding sites on IFN-β-1a Rebif™ molecule we also attempted to identify the 
binding regions on IFN-β-1a Rebif™ molecule and to examine if the neutralising antibody 
positive samples bind to the epitopes that are identical to the domains responsible for receptor 
binding. The B-cell epitope mapping was established in P3, P10, P13, P14 and P15 with 
differential amounts of IFN-β-1a Rebif™ anti-drug antibodies. Our preliminary data suggest 
the epitopes for antibodies against IFN-β-1a Rebif™ may be located on residues 1-32, 40-62, 
70-86, 106-112 and 136-166 respectively. However, the signals obtained in experimental 
results are not robust enough to make a definite conclusion. Immunoglobulin purification 
from serum or plasma before subjecting samples to the peptide pin assay may increase the 
signal. Human plasma is a mixture of many antibodies and hence we can expect to see 
binding to many peptides and therefore it is important to establish antibody specificity. In 
order to establish this specificity affinity purified antibodies are required. One other possible 
strategy is to use the peptide pins to affinity purify antibodies and then elute the antibodies 
from the pins that test each antibody for binding to the IFN-β-1a Rebif™ molecule. The 
major limitation of this set-up is that data are limited because of linear epitopes. It is difficult 
to establish evidence that antibodies binding to linear epitopes in the IFN-β Rebif™ molecule 
will recognise the same in endogenous IFN-β. The negative control peptide used in this set-
up cannot truly be considered as negative control as the peptide is binding to the antibody. An 
alternative strategy for identifying the binding patterns for IFN-β-1a Rebif™ anti-drug 
antibodies the in vitro competitive binding assay was also utilised. However, the data 
obtained indicate there are no linear binding epitopes in anti-IFN-β-1a Rebif™ antibodies or 
the method developed for the same was not specific or sensitive to achieve the objective. 
Further optimisation of peptide: anti-drug antibodies ratio mix (eg. using checkerboard 
titration) needs to be performed to rule this out as a potential cause for failure to reveal linear 
epitopes. Several studies have used peptide competitive binding assays to detect B-cell 
epitopes for examples Mycobacterium tuberculosis protein and fumonisin-a mycotoxin found 
in food (Yang H et al 2013, Liu X et al 2013). Some other epitope mapping techniques are 
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available to identify linear or conformational epitopes. X-ray crystallography (Amit et al. 
1986), nuclear magnetic resonance (Anglister et al. 1995) and electron microscopy (Belnap et 
al. 2003; Dore et al. 1988) can identify the contact amino acid residues on antibody-antigen 
complexes.     
In this study we characterised neutralising capabilities, the IgG subclass profile, cross-
reactivity to endogenous IFN-β and have also shown complement activation in multiple 
sclerosis patients. An attempt has also been made to identify the binding regions on the IFN-β 
Rebif™ molecule. Clear understanding of the evolution of anti-drug antibody formation and 
relevant immune responses can inform the development of better clinical approaches and 
regimens for biologics treatment.            
3.5 Conclusions 
o IgG4 and IgG1 contribute to IFN-β neutralising anti-drug antibodies profile.  
o Neutralising IFN-β anti-drug antibodies cross reacts and blocks endogenous IFN-β 
activity.  
o IFN-β anti-drug antibodies results in immune complex formation and complement 
activation.  
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Chapter 4: Role of T helper cells in anti-drug antibody development to Interferon beta 
in multiple sclerosis patients  
4.1 Introduction 
The previous chapter focused on humoral immune responses to therapeutic IFN-β. In this 
chapter we address the role of T helper cells in anti-drug antibodies development to IFN-β. 
Several studies have reported the clinical link between the existence of T helper cell epitopes, 
the titre and persistence of anti-drug antibodies for several therapeutic proteins (Barbosa et al. 
2006; Koren et al. 2007; Tatarewicz et al. 2007). For example as in the case of recombinant 
fusion protein FPX, which consists of two similar biologically active peptides bound to 
human Fc fragment and recombinant-methionyl human glial cell line-derived neurotrophic 
factor (r-metHuGDNF) (Koren et al. 2007; Tatarewicz et al. 2007). There has also been some 
indication that T helper cells are involved in anti-drug antibodies development to therapeutic 
IFN-β (Barbosa et al. 2006). The anti-drug antibodies that are of high-affinity, high titre and 
IgG class is usually indicative of T helper cell involvement (Baert et al. 2003; Casadevall et 
al. 2002; Li et al. 2001; Swanson et al. 2004). Protein therapeutics that contain within them 
MHC class II restricted helper T-cell epitopes are more likely to elicit anti-drug antibodies. In 
brief the protein therapeutic could be taken up by antigen presenting cell wherein they can be 
broken down into peptide fragments. The peptide fragments are then presented on the surface 
of antigen presenting cells (including B cells) as a complex with MHC class II molecules. T 
helper cells then interact with B cells presenting these peptides on appropriate MHC class II 
molecules, cause B cell activation and drive B cell maturation which then can secrete 
antibodies.  One of the important determinants of T-cell epitope immunogenicity is the fit or 
binding strength between T-cell epitope and MHC molecules (Lazarski et al. 2005). Evidence 
suggests only 2 % of peptide fragments derived from proteins have the exact amino acid side 
chains that fit into MHC class II binding groove (de Groot et al. 2009).  
Several computer algorithms for example Immune epitope database analysis resource (IEDB–
AR) (Zhang et al. 2008) are available to map the potential MHC class II restricted T-cell 
epitopes within proteins. MHC binding peptide prediction methods are classified into three 
major groups - motif based, statistical or mathematical expression and structure based 
methods. Structure based methods is considered as the gold standard method for MHC 
binding peptide prediction and this method calculates the binding energy of peptide – MHC 
complex and energetically favourable peptides are predicted as binders. The IEDB employs a 
consensus approach based on Sturniolo et al, automated generation and evaluation of specific 
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MHC binding predictive method (ARB) and stabilisation matrix align (SMM_align) (Bui et 
al. 2005; Nielsen, Lundegaard & Lund 2007; Sturniolo et al. 1999). ProPred is another server 
that employs quantitative matrices derived from the method described by Sturniolo et al. The 
server also can assist in locating promiscuous HLA-II binding regions on peptides. 
Promiscuous binding involves identification of antigen or region of antigen that can bind to 
several HLA alleles. Predicting promiscuous region is important for vaccine development 
(Singh & Raghava 2001). In silico predictions of T helper cell epitopes have been 
successfully applied to design vaccines (Ahlers et al. 2001; Reek et al. 2002). The IEDB 
analysis resource tool utilises consensus approach using NN–align (Nielsen & Lund 2009), 
SMM–align (Nielsen, Lundegaard & Lund 2007) and combinatorial library methods (Sidney 
et al. 2008 to predict MHC class II epitopes. Neural network based method (NN–align) is 
used to recognise the MHC class II binding core and the binding affinity. The stabilisation 
matrix align (SMM–align) is used to predict peptide: MHC binding affinities. The 
combinatorial library methods use a pool of peptides libraries to measure the contribution of 
each amino acid at each of the nine positions at the binding peptide. The IEDB exploits the 
features of the above three methods to predict T-cell epitopes. Propred use quantitative 
matrices which include all the fifty one human MHC class II alleles and predicts the 
promiscuous binding regions preferably for vaccine candidates {Sturniolo, 1999 #1237).  
The peptide libraries provide powerful tool in screening of large number of peptides that have 
a systemic arrangement of amino acids. The peptide libraries are ideal for T-cell assays and 
can be used for T-cell epitope mapping. Overlapping peptides are ideal for T-cell epitope 
mapping as T-cell epitopes are short linear peptides from the native protein sequence. The 
identified T-cell epitopes using in silico technologies should be successfully validated using 
functional T-cell assays.         
T-cell epitopes can be identified using several functional T-cell epitope mapping assays such 
as Carboxy Fluorescein Succinimidyl Ester (CFSE) T-cell proliferation assay, IFN-γ 
secretion using ELISpot, cytokine gene expression assay and tritiated thymidine 
incorporation (3HT) T-cell proliferation assay. Several studies suggest using naive primary 
T-cell proliferation assay for peptide epitope mapping which identifies the peptide epitope 
sequences that can elicit T helper cell proliferation (and therefore indicate the potential T 
helper cell involvement in anti-drug antibodies development). Human leukocyte antigen 
(HLA) proteins can present peptides for immune recognition (Leckband et al. 2013). Utilising 
HLA-genotyped PBMCs for T-cell assays can provide critical information of peptide binding 
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to different HLA haplotypes and identification of HLA allele responsible to elicit T helper 
cell proliferation. Numerous studies have identified HLA association in the development of 
anti-drug antibodies against biologics. HLA-DRB1*0401, HLA-DRB1*1601, HLA-
DRB1*0408 (Buck et al. 2011; Hoffmann et al. 2008), HLA-DRB1*0701 (Barbosa et al. 
2006), HLA-DR2, HLA-DQ6, DQB1*0602, HLA-DR15 (Stickler et al. 2004) for IFN-β, 
HLA-DQA1*0102, HLA-DR4.1, DQ4, DQA1*0301 (Ohta et al. 1999; Simonney et al. 
1985), HLA-DRA-DRB1*1104 (Ettinger et al. 2010) for factor VIII and HLA-DRB1*09-
DQB1*0309 for erythropoietin (Praditpornsilpa et al. 2009). Furthermore, Dendritic cell T-
cell assay can also be used to screen immunogenicity against biologics, especially when 
antigen modifies the function to T-cells.             
T regulatory cells (Tregs), subset of T-cells, play important role in immune regulation. 
Deficiencies in the number and function of Tregs are associated with several autoimmune 
diseases including multiple sclerosis. Tregs regulate autoantibody responses through receptor 
editing, anergy, follicular exclusion and lack of T-cell help. In addition, the autoreactive B 
cells can be controlled by Tregs. Several studies have identified the association of Tregs with 
anti-drug antibodies development to biologics (Cousens et al. 2013).  The evidence also 
suggests IFN-β treatment can restore Tregs function in multiple sclerosis (Korporal et al. 
2008).  
The aim of this study was to identify IFN-β-1a Rebif™ T helper cell epitopes using T-cell 
epitope prediction tools and functional assays. We utilised T-cells from multiple sclerosis 
patients, healthy volunteers and HLA genotyped cell archive from healthy volunteers. 
Furthermore, the study also investigated any protential correlation between the anti-drug 
antibody response to IFN-β-1a Rebif™ and the frequency and/or functional activity of Tregs 
cells.  
4.2 Methods 
The flow diagram of the methods employed in this chapter is shown in Figures 4.1 and 4.2.  
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Figure 4.1: The schematic representation of methods employed in T-cell study. 
Abbreviations: PBMCs – Peripheral blood mononuclear cells; EBV – Epstein-Barr virus; 
3HT – 3H-thymidine, IFN – Interferon; IEDB – Immune epitope database; HLA – Human 
leukocyte antigen; ELISpot – Enzyme-linked immunospot 
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Figure 4.2: The schematic representation of methods employed in  Treg study. 
Abbreviations: PBMCs – Peripheral blood mononuclear cells; Treg – Regulatory T-cells; 
Tresp – Responder T-cells, CD – Cluster of differentiation; PHA – Phytohemagglutinin; TT – 
Tetanus toxoid 
4.2.1 Chemicals and reagents 
Please refer to Section 3.2.1 for details. 
4.2.2 Whole blood samples 
Please refer to Section 3.2.2 for details. 
4.2.3 Human leukocyte antigen genotyped donor details 
Department of Molecular and Clinical Pharmacology, University of Liverpool, UK has an 
established HLA genotyped cell archive from 400 healthy volunteers (Alfirevic et al. 2012). 
This cell bank was generated from blood collected from the volunteers from which PBMCs 
and deoxyribonucleic acid (DNA) were isolated. The high-resolution sequence based HLA 
typing was performed from Histogenetic labs, NY, USA at the following loci                    
HLA – A, – B, – C, – DRB1 and – DQB1. Peripheral blood mononuclear cells from ten 
randomly chosen were used in IFN-β-1a Rebif™ study (refer Table 4.1).  
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Donor 
Identity 
Age Sex HLA–A HLA–B HLA–C HLA–DRB1 HLA–DQB1 
1 
 
 
45 F A*2402 
A*2601 
B*3503 
B*5501 
 
C*0303 
C*1203 
 
DRB1*0101 
DRB1*1401 
DQB1*0501 
DQB1*0503 
2 28 F A*0201 
A*2402 
B*0702 
B*2705 
C*0202 
C*0702 
 
DRB1*1501 
DRB1*0401 
DQB1*0301 
DQB1*0602 
3 29 F A*0201 
A*0301 
B*4001 
B*4001 
C*0304 
C*0304 
 
DRB1*0401 
DRB1*0401 
DQB1*0302 
DQB1*0302 
4 21 F A*0101 
A*1101 
B*0801 
B*4002 
C*0202 
C*0701 
 
DRB1*0301 
DRB1*1301 
DQB1*0201 
DQB1*0603 
5 25 M A*0302 
A*0301 
B*4001 
B*4402 
C*0304 
C*0501 
 
DRB1*0401 
DRB1*1001 
DQB1*0302 
DQB1*0501 
6 25 F A*0101 
A*3101 
B*0801 
B*3501 
C*0401 
C*0701 
 
DRB1*0103 
DRB1*1302 
DQB1*0501 
DQB1*0604 
7 43 M A*0301 
A*3101 
B*0702 
B*0702 
C*0702 
C*0702 
 
DRB1*1501 
DRB1*0801 
 
DQB1*0402 
DQB1*0602 
 
8 25 F A*1101 
A*2601 
B*0702 
B*4001 
C*0304 
C*0702 
DRB1*1601 
DRB1*0901 
 
DQB1*0303 
DQB1*0502 
9 27 F A*0301 
A*3301 
 
B*4403 
B*5101 
 
C*0202 
C*1502 
 
DRB1*0102 
DRB1*0402 
 
DQB1*0302 
DQB1*0501 
12 22 F A*0101 
A*0201 
B*1501 
B*4402 
C*0102 
C*0501 
 
DRB1*0401 
DRB1*0404 
DQB1*0302 
DQB1*0301 
11 57 F A*0201 
A*0101 
B*4403 
B*4402 
C*0704 
C*1601 
DRB1*0101 
DRB1*0701 
DQB1*0201 
DQB1*0501 
 
12 52 F A*0101 
A*0201 
B*0801 
B*4402 
 
C*0501 
C*0701 
DRB1*0301 
DRB1*0401 
DQB1*0201 
DQB1*0301 
13 21 F A*0201 
A*2501 
B*4402 
B*4402 
C*0501 
C*0501 
DRB1*0401 
DRB1*0401 
DQB1*0301 
DQB1*0301 
14 56 F A*1010 
A*0201 
B*0801 
B*4002 
C*0202 
C*0701 
DRB1*0401 
DRB1*0701 
DQB1*0302 
DQB1*0303 
 
15 19 F A*0201 
A*2402 
B*1501 
B*4402 
C*0102 
C*0501 
DRB1*0101 
DRB1*0301 
DQB1*0201 
DQB1*0501 
 
16 21 F A*0101 
A*0101 
B*0801 
B*1402 
C*0701 
C*0802 
DRB1*0301 
DRB1*0301 
DQB1*0201 
DQB1*0201 
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17 46 F A*0101 
A*0201 
B*1801 
B*3701 
C*0602 
C*0701 
DRB1*1501 
DRB1*1101 
DQB1*0301 
DQB1*0602 
 
18 18 M A*1101 
A*2402 
B*1502 
B*1502 
C*0801 
C*0801 
DRB1*1501 
DRB1*1201 
DQB1*0301 
DQB1*0601 
19 25 M A*0101 
A*2402 
B*3701 
B*4006 
C*0602 
C*1502 
DRB1*1501 
DRB1*1404 
DQB1*0503 
DQB1*0601 
 
20 24 F A*2402 
A*2901 
 
B*0705 
B*2707 
C*0702 
C*1502 
DRB1*1501 
DRB1*1101 
DQB1*0301 
DQB1*0301 
21 21 M A*0101 
A*0222 
B*1401 
B*5101 
C*1203 
C*1505 
DRB1*1104 
DRB1*0401 
DQB1*0301 
DQB1*0301 
 
22 19 F A*0201 
A*0201 
B*1501 
B*1801 
C*0303 
C*1203 
DRB1*1602 
DRB1*0401 
DQB1*0302 
DQB1*0502 
 
23 19 M A*0201 
A*0201 
B*1501 
B*1801 
C*0303 
C*1203 
DRB1*1602 
DRB1*0401 
DQB1*0302 
DQB1*0502 
 
24 24 F A*0101 
A*2601 
B*4001 
B*5701 
C*0304 
C*0602 
DRB1*0101 
DRB1*1301 
DQB1*0501 
DQB1*0603 
 
25 23 M A*0101 
A*0201 
B*0801 
B*2701 
C*0102 
C*0701 
DRB1*0103 
DBR1*0301 
DQB1*0201 
DQB1*0301 
 
26 27 N A*0301 
A*3101 
B*1501 
B*4403 
C*0304 
C*1601 
DRB1*0701 
DRB1*0901 
DQB1*0201 
DQB1*0303 
 
27 20  M A*0101 
A*0205 
B*5001 
B*5201 
C*0602 
C*1202 
DRB1*1502 
DRB1*1101 
DQB1*0301 
DQB1*0601 
 
28 58 M A*0101 
A*0301 
B*0801 
B*1402 
C*0701 
C*0802 
DRB1*0301 
DRB1*1302 
DQB1*0201 
DQB1*0609 
 
29 20 M A*2402 
A*6801 
B*0705 
B*1518 
C*0704 
C*0702 
DRB1*1501 
DRB1*0403 
DQB1*0302 
DQB1*0601 
 
30 24 F A*0101 
A*2601 
B*1518 
B*4006 
C*0704 
C*1502 
DRB1*1404 
DRB1*1404 
DQB1*0503 
DQB1*0503 
 
31 26 M A*0101 
A*0205 
B*0801 
B*5001 
C*0602 
C*0701 
DRB1*0301 
DRB1*1305 
DQB1*0201 
DQB1*0301 
 
32 27 M A*0201 
A*2402 
B*3501 
B*4402 
C*0401 
C*0501 
DRB1*0101 
DRB1*0103 
DQB1*0501 
DQB1*0501 
33 19 F A*0101 
A*0201 
B*0801 
B*3502 
C*0401 
C*0701 
DRB1*0301 
DRB1*1104 
DQB1*0201 
DQB1*0603 
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34 24 F A*0201 
A*0301 
B*1801 
B*4402 
C*0501 
C*0701 
DRB1*0401 
DRB1*0801 
DQB1*0301 
DQB1*0402 
 
35 19 M A*0201 
A*2501 
B*0702 
B*1801 
C*0702 
C*1203 
DRB1*0103 
DRB1*1501 
DQB1*0501 
DQB1*0602 
 
36 18 F A*0101 
A*0101 
B*0801 
B*5201 
C*0701 
C*1202 
DRB1*1502 
DRB1*0301 
DQB1*0201 
DQB1*0601 
 
37 36 F A*0101 
A*0201 
B*0702 
B*0801 
C*0701 
C*0702 
DRB1*1501 
DRB1*0301 
DQB1*0201 
DQB1*0602 
 
38 42 F A*0201 
A*2402 
 
B*0702 
B*3503 
C*0702 
C*1203 
DRB1*1501 
DRB1*0408 
DQB1*0304 
DQB1*0602 
39 24 M A*0224 
A*2601 
B*0702 
B*0702 
C*0702 
C*0702 
DRB1*1501 
DRB1*0701 
DQB1*0201 
DQB1*0603 
 
40 43 F A*0101 
A*0201 
B*0801 
B*3501 
C*0401 
C*0701 
DRB1*0101 
DRB1*0701 
DQB1*0201 
DQB1*0501 
 
Table 4.1: Human leukocyte antigen (HLA) and demographic features of 40 Healthy 
controls involved in this study. The total of 40 randomly selected healthy donors was used 
for this study. Abbreviation: HLA, human leukocyte antigen 
4.2.4 Separation of Peripheral blood mononuclear cells and Plasma 
Please refer to Section 3.2.3 for details. 
 4.2.5 T-cell proliferation assay 
Isolated PBMCs were plated in triplicate at a density of 1.5 x 10
5
 per well in 96-well U-
bottom plates (Nunc; Fisher Scientific, UK). The cultures were incubated with increasing 
concentration of heat inactivated IFN-β-1a Rebif™ at 37 °C under 95 % air 5 % CO2 for 5 
days. Tritiated-thymidine (0.5 µCi per well) was added for the last 16 hours of culture. IFN-
β-1a Rebif™ was heat inactivated by placing it at 100 oC for 30 minutes (Stickler et al 2004). 
Heat inactivation was performed to inhibit the suppressive effect on T-cell proliferation 
whilst retaining the antigenic properties of IFN-β-1a Rebif™. Cells were harvested onto filter 
mats using TomTec Mach III, CT, USA and counted in the scintillation counter (Microbeta 
Trilux, Perkin Elmer, MA, USA). The incorporation of tritiated-thymidine was measured as 
cpm and the data was processed to calculate the Stimulation index (SI). SI ≥ 1 was accepted 
as a cut off for antigen-induced proliferation. SI is calculated by dividing the mean cpm of 
stimulated cultures by the mean cpm of non-stimulated cultures.  
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4.2.6 Generation of Epstein-Barr virus transformed Lymphoblastoid Cell lines 
Lymphoblastoid cell lines were generated by Epstein-Barr Virus (EBV) transformation of the 
B-lymphocytes component within the peripheral blood lymphocyte population. The generated 
lymphoblastoid cell lines were used as antigen-presenting cells to evaluate antigen-specificity 
using T-cell proliferation assay as mentioned in Section 3.13.  
B95-8 (marmoset cell line) cells were used as a source of Epstein-Barr virus DNA which 
exists as circular episomes inside the nucleus of these infected cells 5-800 copies/cell. 5 mL 
of cell-free and filtered B95-8 supernatant was used to resuspend PBMCs. Cyclosporin-A 
(CSA) at 1 µg/mL was added to the cells to prevent T-cell growth and the tubes were cultured 
overnight 37
o
C, 5% CO2. After 16 hours, the cells were harvested using centrifugation for 5 
minutes at 300 g. Supernatant was discarded and cells were reconstituted in 2 mL of culture 
medium (RPMI-1640, 10 % v/v FBS, Penicillin 100 IU/mL, Streptomycin 100 µg/mL, 
HEPES buffer 25 mM, L-glutamine 2 mM) supplemented with 1 µg/mL CSA. Cells were 
then serially diluted in a 24-well plate; keeping the total volume per well at 1 mL. Cells were 
fed every 3 days with fresh medium containing CSA (1µg/mL). After 3 weeks the addition of 
CSA was stopped and cells were expanded using the same culture medium without CSA in 
25 cm
2
cell culture flasks according to their rate of growth. 
4.2.7 Generation of heat-inactivated Interferon beta 1a Rebif™ T-cell clones 
The isolated PBMCs from P3 and P10 patients at 1 x 10
6
 cells per well were incubated in 48-
well plate for 2 weeks in the presence of heat inactivated IFN-β-1a Rebif™.The cultures were 
incubated at 37
o
C and 5% CO2. The cells werefed on days 6 and 9 with complete medium 
supplemented with (Interleukin) IL-2 at 60 U/mL. 
On day 14, heat inactivated IFN-β-1a Rebif™treated cultures were pooled; cells were washed 
in culture medium (RPMI-1640, 10% v/v pooled heat-inactivated human AB-serum, 
Penicillin 100 IU/mL, Streptomycin 100 µg/mL, HEPES buffer 25 mM, L-glutamine 2 M, 
Transferrin 25 µg/mL) and counted using trypan blue dye exclusion. The cells were serially 
diluted by seeding them in 96-well U-bottom plates in three concentrations 0.3, 1 and 3 cells 
per well, in culture medium supplemented with IL-2 at 200 U/mL and PHA at 5 µg/mL. 
Forty five gray irradiated allogeneic lymphocytes were used as feeder cells and added to each 
well at the concentration of 5x10
4
 cells per well, 100 µL volume. Serial dilution cultures were 
incubated at 37
o
C, 5% CO2 for 2 weeks, fed every 48 hours with culture medium 
supplemented with IL-2 at 60 U/mL. 
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The cells in the serial dilution plates was restimulated using 45 Gy irradiated allogeneic 
lymphocytes as feeder cells at 5 x 10
4
 cells per well, IL-2 500 U/mL and PHA 10 µg/mL to 
maintain the T-cell expansion. The restimulated cultures were incubated at 37
o
C, 5% CO2 for 
2 weeks. The culture medium was supplemented with IL-2 60 U/mL every 48 hours. During 
this culture period, the well-growing cells were transferred into 96-well U-bottom plates and 
expanded when required.  
The generated T-cells were tested for antigen-specificity using T-cell proliferation assay. The 
T-cells were incubated in duplicates with and without heat-inactivated IFN-β-1a Rebif™ in 
presence of 60 Gy irradiated autologous EBV 10
4
 cells per well, as antigen presenting cells. 
Cultures were incubated for 48 hours at 37
o
C, 5% CO2 before the addition of 0.5 µCi/well 
tritiated-thymidine for the last 16 hours of the incubation. The cells were harvested on glass 
fibre filter mats and proliferation was detected as incorporated tritiated-thymidine using 
scintillation counter. The SI was calculated and SI ≥ 2 was accepted as an antigen-specific 
cell proliferation and the data was presented as cpm. T-cells shown to respond or proliferate 
in presence of antigen were further expanded to generate enough cells to further 
charaterisation. Expansion was carried out by expanding antigen specific cultures in 48-well 
plates by addition of 45 Gy irradiated allogeneic lymphocytes, IL-2 500 U/mL and PHA 10 
µg/mL total volume 1 mL. The cultures were maintained at 37
o
C, 5% CO2 and fed every 48 
hours with culture medium supplemented with IL-2 60 U/mL.  
4.2.8 T-cell epitope mapping 
In order to identify immunogenic epitopes of IFN-β-1a Rebif™, a combination of T-cell 
epitope prediction tools ProPred and Immune epitope database (IEDB) was used. ProPred is a 
MHC class-II binding peptide prediction server which can predict MHC class-II binding 
regions in an antigen sequence (Singh & Raghava 2001; Sturniolo et al. 1999). The prediction 
server will assist in locating promiscuous binding site i.e. region of an antigen that can bind 
to several HLA alleles. Immune epitope database include T-cell epitope prediction tool and 
employs a consensus method to predict MHC class-II epitopes built on Sturnilo, ARB and 
SMM_align (Nielsen, Lundegaard & Lund 2007; Peters et al. 2005).   The potential MHC 
class-II immunogenic sequence of 36 amino acids 
“HYLKAKEYSHCAWTIVRVEILRNFYFINRLTGYLRN” within IFN-β-1a Rebif™, was 
identified and overlapping (17mer, 5 offset) IFN-β-1a Rebif™ peptides were synthesised 
(Severn Biotech Ltd, UK). T-cell proliferation assay was performed using IFN-β-1a Rebif™ 
peptides as mentioned in Section 3.13. The IFN-β-1a Rebif™ peptides, PBMCs from P3, 
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P10, P13, P14 and P15 patients were co-cultured for 5 days with 0, 2.5, 5, 10 and 20 µM of 
IFN-β-1a Rebif™ peptides. T-cell proliferation was detected using tritiated-thymidine 
incorporation.     
4.2.9 Peptides quality checked by Liquid Chromatography-Mass Spectrometry analysis 
For LC-MS/MS analysis, aliquots of 1 µL (1 µM) IFN-β-1a Rebif™ peptides were analysed. 
Samples were delivered into a QSTAR™ Pulsar I-hybrid mass spectrometer (Applied 
Biosystems) by automated in-line liquid chromatography (integrated LCPackings System, 
5mm C18 nano-precolumn and 75 µm x 15 cm C18 PepMap column (Dionex, California, 
USA)) via a nano-electrospray source head and 10 µm inner diameter PicoTip (New 
Objective, Massachusetts, USA). A gradient from 5% ACN/0.05% TFA (v/v) to 48% 
ACN/0.05% TFA (v/v) in 60 minutes was applied at a flow rate of 300 nL/min, and MS and 
MS/MS spectra were acquired automatically in positive ion mode using information-
dependent acquisition (IDA; Analyst, Applied Biosystems). Survey scans of 1second were 
acquired for m/z 400-2000, and the 3 most intense ions were selected for MS/MS, with 
accumulation times of 1second and with a dynamic exclusion of 40seconds. The data were 
assessed manually to confirm the sequence of peptides. Dr Xiaoli Meng kindly carried out the 
processing and analysis of samples on LC-MS/MS.  
4.2.10 Measurement of Interferon gamma cytokine secretion  
ELISpot assays employ sandwich type ELISA technique. The monoclonal or polyclonal 
antibody specific for the chosen analyte is pre-coated onto a PVDF microtitre plate. The cells 
and the stimulants are added into the wells and the plate is placed into a humidified 37 
o
C 
CO2 incubator for a specific period of time. During incubation period the immobilised 
antibody in presence of secreting cells binds to secreted analyte. After washing the unbound 
cells and unbound substances, the biotinlyated antibody specific for the chosen analyte is 
added into the wells. Following a wash any unbound biotinylated antibody will be removed. 
Alkaline-phosphatase conjugated to steptavidin is added. Unbound enzyme is subsequently 
removed by washing and a substrate solution 4-bromo-5-chloro-indolyl phosphate/Nitro blue 
tetrazolium (BCIP/NBT) is added. The blue-black coloured precipitate forms and distinct 
spots appear at the sites of cytokine localisation, with each individual spot representing an 
individual analyte-secreting cell. The spots are counted using an automated ELISpot reader or 
using a stereomicroscope.   
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The ELISpot strips (Millipore; Watford, UK) were activated using 15 µL of 35 % (v/v) 
ethanol for 1 minute. The strips was washed five times using 250 µL of deionised water. IFN-
solution at 100 µL per well was added to ELISpot plate and incubated for 16 hours at 4 
o
C.   
Coating antibodies was removed and the plate was washed five times with sterile HBSS 200 
µL per well. 250 µL per well of culture medium was added and incubated for 30 minutes at 
room temperature. The culture medium was removed and the PBMCs (5 x 10
6
 cells/mL, 100 
µL) from P3, P10 and P15 were added. IFN-β-1a Rebif™ responsive peptides, PHA 5 µg/ml 
as positive control and medium alone of 100 µL was added as negative control. The plate was 
incubated in a 37 
o
C humidified incubator with 5 % CO2 for 24 hours. The cells were 
removed and the plate was washed for five times with 200 µL per well using sterile HBSS. 
The biotinylated detection antibody was diluted to 1 µg/mL in HBSS containing 0.5 % FBS. 
100µL/well of the detection antibody solution was added to each well and incubated for 2 
hours at room temperature. The plate was washed with HBSS 250 µL per well for five times. 
Streptavidin-ALP was diluted at 1:1000 in HBSS containing 0.5 % FBS 100 µL per well was 
added and incubated for 1 hour at room temperature. The plate was washed as described 
before. 100 µL per well of 5-bromo-4-chloro-3-indolyl-phosphate/nitro blue tetrazolium 
(BCIP/NBT) substrate solution was added and developed until distinct spots emerge. The 
colour development was stopped rinsing the plate extensively in tap water. The plate was left 
to dry for 16 hours and the spots was counted using ELISpot reader (Autoimmune 
Diagnostika GmbH; Strassberg, Germany). The ELISpot kit was obtained from Mabtech; 
Nacka Strand, Sweden.    
4.2.11 Global regulatory T-cells phenotyping  
Isolated PBMCs (0.2 x 10
6
 cells) was surface stained with CD4
FITC
, CD25
APC
 cocktail 
(eBioscience; Hatfield, UK) and CD127
PECy5
 (Biolegend, Cambridge, UK) anti-human 
monoclonal antibodies (mAbs) at 4 °C for 20 minutes in the dark. At the end of the 
incubation, the cells were washed using FACS buffer (PBS + 10 % v/v FCS + 0.02 % v/v 
sodium azide) followed by fixation and permeabilisation of cells for 45 minutes at 4 °C in the 
dark. The cells were washed again and intracellular staining was performed using Foxp3-PE 
and with the PE-isotype control for 45 minutes at 4 °C in the dark. At the end of this 
incubation, the cells were washed and resuspended in 0.5 mL FACS buffer, for flow 
cytometric analysis (FACS Calibur, BD Biosciences, UK). On average 60,000 events was 
captured for analysis. Data were processed using Cyflogic software. 
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4.2.12 Isolation of regulatory T-cells, responder T-cells and feeder cells 
Magnetic-activated cell sorting was used to isolate various cell populations depending upon 
their surface molecules. The technique allows cells to be separated by incubating with 
magnetic microbeads coated with antibodies against a particular surface molecule. The cells 
expressing the surface molecule attach to the magnetic microbeads. The cells solution is 
transferred on a column placed in a magnetic field. The cells with microbeads expressing the 
surface molecule stay on the column, while other cells not expressing the surface molecule 
flow-through. Using this method the cells can be separated positively or negatively. In 
positive selection the cells expressing surface molecules are attached in the magnetic column 
and are washed through in the different tube after removing the column from the magnet. 
Cells labeled with MACS microbeads can be positively selected using MS, LS and XS 
columns. In negative selection the cells expressing surface molecules which are attached in 
the magnetic column are not of interest and the flow-through is collected. Cells can be 
negatively selected efficiently using LD, CS and D columns.     
Isolated PBMCs were counted using Trypan blue dye exclusion. The cell suspension was 
centrifuged at 300 g for 10 minutes. The supernatant was discarded and the cell pellet was 
resuspended in 90 µL of Magnetic-activated cell sorting (MACS) buffer (HBSS + 5 % v/v 
BSA + EDTA 2 mM) per 10
7
 total cells. The cells were incubated with 10 µL of CD4
+
 T-cell 
biotin-antibody cocktail (Miltenyi Biotech; Surrey, UK) at 4 °C for 10 minutes. 20 µL of 
anti-biotin microbeads was added and incubated at 4 °C for 15 minutes. At the end of 
incubation, the cells were washed and resuspended in 0.5 mL of MACS buffer for magnetic 
separation. Using LD column (Miltenyi Biotech; Surrey, UK) non CD4
+ 
feeder cells and 
CD4
+
 cells were separated. CD4
+
 cells were centrifuged again at 300g for 10 minutes. The 
supernatant was discarded and the cells were incubated with 10 µL of CD25 microbeads. 
Using MS column (Miltenyi Biotech; Surrey, UK) Tregs (CD4
+
CD25
high
) and Tresp cells 
(CD4
+
CD25
low
) were separated. The separated cells were kept on ice until beforetheir 
addition to Tregs suppression assay (refer Section 3.21). The obtained cells fractions were 
surface stained for % of purity and were measured using facs. 
4.2.13 Regulatory T-cells suppression assay 
Isolated Tregs 5 x 10
4 
were co-cultured with 5 x 10
4
 Tresp cells at different ratios in the 
presence of stimulus. The stimulus includes phytohaemagglutinin (PHA) and Tetanus toxoid 
(TT). Tregs without stimulus shows hypoproliferative or anergic response. Tresp cells alone 
shows proliferative response to the stimuli. Co-culturing Tregs with Tresp cells results in 
126 
 
reduced proliferation of Tresp cells. The irradiated (45 Gy for 15 minutes) non-CD4
+
 feeder 
cells were added at 5 x 10
4
 cells per well followed by addition of stimulus. The addition of 
irradiated non-CD4
+
 feeder cells effectively stimulated T-cells to proliferate.  The cultures 
were incubated at 37 °C in humidified atmosphere of 95 % air 5 % CO2 for 3-5 days. Cells 
were pulsed with 0.5 µCi tritiated-thymidine per well for the last 16 hours of the incubation. 
The cells were harvested on filter mats and tritiated-thymidine incorporation was measured 
using scintillation counter. The incorporation of tritiated-thymidine was measured as counts 
per minute (cpm). The assay was performed with a dilution series ranging from a ratio of 1:1 
to 8:1 of Tresp cells: Tregs cells. As additional controls, the Tresp and Treg cells were 
cultured alone with and without addition of stimulus. The dilution series were carried out in 
triplicates. 
4.2.13 Statistical analysis 
Please refer to Section 3.2.13. 
4.3 Results  
4.3.1 Interferon beta 1a exhibits significant antiproliferative activity 
Interferons exhibit several immunomodulatory properties including antiproliferative activity. 
The studies also indicate interferons have an impact on different phases of mitotic cycle in 
particular causing G1 phase arrest (Tani et al. 1998).  
The overall aim was to investigate the antigenic determinant of IFN-β-1a Rebif™ on healthy 
donors PBMCs. However, the biologic effect of IFN-β on T-cells (antiproliferative) could 
prevent achieving this aim. In the first instance, we wished to assess the extent of the 
antiproliferative effect of IFN-β. We therefore used in vitro tetanus toxoid-stimulated T-cell 
proliferation assay to measure the antiproliferative effects. In this experiment the PBMCs are 
stimulated using fixed amount of Tetanus toxoid 0.5 µg/ml to elicit proliferation and different 
concentrations of IFN-β-1a Rebif™ ranging from 30 – 0.01 ng/ml was added to investigate 
the antigenic determinant of IFN-β-1a Rebif™ (refer Figure 4.3). The TT is used as routine 
positive control antigen for T-cell assays and exhibits both humoral and cellular responses in 
healthy controls. In this experiment we found IFN-β-1a caused antiproliferative effects in 
dose dependent manner in presence of TT and % of inhibition consisted of approx. 15 – 58 % 
for all the conditions respectively. The statistical differences were determined using ANOVA 
with Dunnett’s post hoc test. The 3H-Thymidine (3HT) was added to the culture on day 5 and 
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the proliferation was measured on day 6. Our data suggest IFN-β-1a Rebif™ exhibited 
significant dose dependent antiproliferative response at all the tested doses.  
 
Figure 4.3: IFN-β-1a exhibits significant antiproliferative activity. The Figure 4.3 
represents dose dependent proliferative responses of three healthy control PBMCs to research 
grade IFN-β-1a in presence of Tetanus toxoid. The statistical differences were determined 
using ANOVA with Dunnett’s post hoc test. Tetanus toxoid at 5 µg/ml was used a positive 
control. The different concentration of IFN-β is indicated on the X-axis and 3HT 
incorporation (cpm) is shown on the Y-axis. Results shown are mean cpm ± SD in presence 
and absence of antigenic stimulation. The graph is representative of three independent 
experiments.  
4.3.2 Heat inactivation for 30 minutes at 100 °C ablates antiproliferative effects of 
Interferon beta 1a Rebif™  
Heat inactivation of IFN-β-1a Rebif™ was performed to inhibit the antiproliferative effects 
on PBMCs whilst retaining the antigenic properties. In our previous experiments (refer 
Figure 4.3) IFN-β-1a was shown to exhibit antiproliferative properties. Hence, it was not 
possible to stimulate the PBMCs directly. However, heat inactivation was performed to 
investigate the relative antigenicity of IFN-β-1a molecule. 
In order to determine the ideal time interval for heat inactivation, IFN-β-1a Rebif™ was 
placed at 100 
o
C at 10, 20 and 30 minutes. The heat inactivated IFN-β-1a Rebif™ was used 
to measure the T-cell proliferation. The PBMCs from a healthy control was co-cultured with 
different concentrations 30 – 0.001 ng/ml of heat inactivated IFN-β-1a Rebif™ and with 
fixed amount of Tetanus toxoid 0.5 µg/ml. In Figure 4.4a, the response to 10 minutes heat 
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inactivated IFN-β-1a Rebif™ exhibited similar response to Figure 4.3 in dose dependent 
manner in presence of TT and % of inhibition consisted of approx. 20 – 80 % for all the 
conditions respectively. The maximum proliferation was observed at 0.003 ng/ml of heat 
inactivated IFN-β-1a Rebif™ plus 0.5 µg/ml TT. Therefore, suggesting the heat inactivation 
was not effective and has to be performed for longer time interval. The statistical differences 
were determined using ANOVA with Dunnett’s post hoc test. In Figure 4.4b and c the 
response to 20 and 30 minutes heat inactivated IFN-β-1a Rebif™ exhibited a variable 
antiproliferative activity. The 20 minutes heat inactivation exhibited approx. 30 – 80 % of 
inhibition for all the conditions respectively. The 30 minutes heat inactivation exhibited 
approx. 30 – 80 % of inhibition for all the conditions respectively. However, 30 minutes of 
heat inactivation of IFN-β-1a Rebif™ ablated the antiproliferative effects on PBMCs and was 
chosen ideal for establishing T-cell cloning experiments. In all of the experiments 3HT was 
added to the culture on day 5 and the proliferation was measured on day 6. Our data suggest 
heat inactivation of IFN-β-1a Rebif™ for 30 minutes at 100 °C ablates the antiproliferative 
effects on healthy donors PBMCs.       
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C 
 
Figure 4.4: Heat inactivated IFN-β-1a Rebif™ exhibit variable antiproliferative activity. 
The Figure 4.3a, b and c represents the antiproliferative responses of a healthy control 
PBMCs to IFN-β-1a Rebif™ and proliferative responses to Tetanus toxoid in combination 
with 10 minutes, 20 minutes and 30 minutes heat inactivated IFN-β-1a Rebif™. The 
statistical differences were determined using ANOVA with Dunnett’s post hoc test. Tetanus 
toxoid at 5 µg/ml was used a positive control. The different concentration of heat inactivated 
IFN-β-1a Rebif™ is indicated on the X-axis and 3HT incorporation (cpm) is shown on the Y-
axis. Results shown are mean cpm ± SD in presence and absence of antigenic stimulation. 
Each graph is representative of three independent experiments.  
4.3.3 Generation of heat inactivated Interferon beta 1a Rebif™ T-cell clones 
In an attempt to understand the cellular basis of IFN-β-1a Rebif™ T-cell responses the anti-
drug antibodies positive donors P3 and P10 were chosen for pilot T-cell cloning experiment. 
T-cell cloning provides the population of T-cells that derives from the same progenitor with 
unique phenotypic and functional characteristics. The obtained T-cell clone consists of cells 
with same phenotype and functions. The nature of T-cell response might provide useful 
insights of T-cells involvement in eliciting immune response. The T-cell cloning was 
executed using heat inactivated IFN-β-1a Rebif™ and no IFN-β-1a Rebif™ T-cell clones was 
generated for donor P3 but donor P10 provided two responsive T-cell clones (refer Figures 
4.5a and b). The IFN-β-1a Rebif™ T-cell clone 1 and 2 for donor P10 provided maximum 
proliferation of PBMCs at 0.5 µg/ml to heat inactivated IFN-β-1a Rebif™. The obtained T-
cell clones were expanded but failed to further respond and therefore dose dependent 
response to heat inactivated IFN-β-1a Rebif™ was not achieved. The obtained T-cell clones 
was tested using autologous B-LCLs as antigen presenting cells and 30 minutes heat 
inactivated IFN-β-1a Rebif™ was used. The data obtained suggests heat inactivated IFN-β-1a 
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Rebif™ T-cell clones can be generated and illustrates T-cell involvement in the formation of 
anti-drug antibodies.      
A  
 
B  
 
Figure 4.5: Heat inactivated IFN-β-1a Rebif™ specific T-cell clones. The Figures 4.5a and 
b represents the testing for 30 minutes heat inactivated IFN-β-1a Rebif™ specific T-cell 
clones obtained from donor P10. The statistical differences were determined using ANOVA 
with Dunnett’s post hoc test when compared to no stimulation. The different concentration of 
heat inactivated IFN-β-1a Rebif™ is indicated on the X-axis and 3HT incorporation (cpm) is 
shown on the Y-axis. Results shown are mean cpm ± SD in presence and absence of 
antigenic stimulation.  
4.3.4 Identification of Interferon beta 1a Rebif™ T-cell epitopes using in silico 
technologies 
Understanding the relevance of T-cell activation in anti-drug antibodies remains crucial for 
predicting and assessing immunogenicity. T-cell epitope is an amino acid or set of amino 
acids that are capable of being recognised from one or more T-cell receptors. The T-cells 
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recognise the linear peptides bound to MHC molecules. Several methods have been used to 
detect T-cell epitopes. In this study we focused on MHC class II molecules. CD4
+ 
T-cells 
recognise the peptides presented through MHC class II molecules that are expressed on 
antigen presenting cells. The structural features of MHC class II molecules and the peptides 
can predispose the T-cell responses. Steinitz et al has identified Factor VIII immunogenic 
peptides containing CD4
+ 
T-cell epitopes in humanised animal models (Steinitz et al. 2012). 
CD4
+ 
T-cells epitopes are short linear peptides spanning approx. 11 – 20 amino acids long. 
Hence, identification of CD4
+ 
T-cells epitopes is therefore considered a rational approach for 
assessing immunogenicity of the protein therapeutics.  
In silico technologies use computational algorithms to identify variant protein sequences that 
exhibits desired functional properties. The computer algorithms can also identify 
immunogenic T-cell epitopes. In our study in silico predictions were used to identify MHC 
class II IFN-β-1a Rebif™ T-cell epitopes using IEDB–AR (Zhang et al. 2008) and ProPred 
(Singh & Raghava 2001) in conjunction with the published articles (Barbosa et al. 2006) 
(refer Figures 4.6 and 4.7b). The screenshots represent the MHC class II IFN-β-1a Rebif™ 
binding sequence for HLA DRB1*1501 allele. However, the assessment of all the available 
HLA alleles in respective in silico prediction tools was carried out systematically. Low 
percentile rank in the IEDB–AR indicates good binders. In ProPred the blue colored amino 
acids indicate good binders whereas the red coloured amino acids suggest the possible 
promiscuous amino acids. The potential MHC class II immunogenic sequence of 36 amino 
acids “HYLKAKEYSHCAWTIVRVEILRNFYFINRLTGYLRN” within IFN-β-1a Rebif™ 
(position 130 – 166) was identified.  
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IEDB–AR MHC class II binding prediction results for IFN-β-1a Rebif™  
 
Figure 4.6: Screenshot of IEDB–AR MHC class II prediction tools. The Figure represents 
the IEDB–AR MHC class II binding results for IFN-β-1a Rebif™ molecule exclusively for 
HLA DRB1*1501 allele. Low Percentile Rank in the table indicates good binders. 
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ProPred MHC class II binding prediction results for IFN-β-1a Rebif™  
 
 
Figure 4.7: Screenshots of ProPred MHC class II binding prediction tools. The Figure 
represents the ProPred MHC class II binding results for IFN-β-1a Rebif™ molecule 
exclusively for HLA DRB1*1501 allele. The amino acids in blue colour indicate good 
binders and amino acids in red indicate the possible promiscuous amino acids.    
4.3.5 T helper cells responses to anti-Interferon beta 1a Rebif™ derived peptides with 
predicted immunogenic potential 
In order to assess the T-cell involvement in anti-IFN-β-1a Rebif™ antibody response, antigen 
specific responding T-cells in PBMCs, from anti-IFN-β-1a Rebif™ antibody positive donors, 
negative donors and healthy donors was investigated. The overlapping (17mer, 5 offset) IFN-
β-1a peptides from previously identified MHC class II immunogenic sequence were 
synthesised.  
Peptide 1  HYLKAKEYSHCAWTIVR 17mer 5 offset 
Peptide 2  KEYSHCAWTIVRVEILR 17mer 5 offset 
Peptide 3  CAWTIVRVEILRNFYFI 17mer 5 offset 
Peptide 4  VRVEILRNFYFINRLTG 17mer 5 offset 
Peptide 5  LRNFYFINRLTGYLRN 16mer 5 offset 
 
The synthesised IFN-β-1a Rebif™ peptides were dissolved in 50 % acetic acid in R9 medium 
as per instructions. Hence, the solubilisation and sequence of IFN-β-1a Rebif™ peptides were 
examined using LC–MS before executing T-cell proliferation assays (refer Appendix 8) for 
ion current chromatograms of identified IFN-β-1a Rebif™ peptides).  
In order to test for the reactivity against IFN-β-1a Rebif™ by in vivo primed T-cells, we used 
overlapping 17mer 5 offset peptides which were predicted to be immunogenic. The PBMCs 
isolated from donors were then incubated with these peptides and T-cell reactivity was 
determined using T-cell proliferation assay (measured by 3HT incorporation). No significant 
dose dependent T-cell activation was observed with PBMCs from anti-IFN-β-1a Rebif™ 
antibody negative donors N2, N4, N6, N16, N27 and in healthy donors H11, H18, H19, H20, 
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H21 (refer Figure 4.8). However, the donors N2, N16 and N27 exhibited significant 
proliferation of PBMCs to IFN-β-1a Rebif™ peptide 1 at 20 µM, 10 µM and 2.5 µM 
respectively and donor N2 exhibited significant proliferation of PBMCs at IFN-β-1a Rebif™ 
peptide 4 at 20 µM (refer Figures 4.8Bi, iv and v). Similarly, a healthy donor H18 exhibited 
significant proliferation of PBMCs to IFN-β-1a Rebif™ peptide 1 at 20 µM (refer Figure 
4.8Ai). In contrast, PBMCs from anti-IFN-β-1a Rebif™ antibodies positive donors exhibited 
variable T-cell activation in presence of IFN-β-1a Rebif™ peptide 1 (donors P3 at 20 µM, 
P10 at 10 µM and 20 µM and P15 at 20 µM), peptide 2 (donor P3 at 5 µM, 10 µM and 20 
µM) and peptide 5 (donors P10 at 2.5 µM, 5 µM, 10 µM and 20 µM, P14 at 2.5 µM and 20 
µM and P15 at 20 µM) respectively (refer Figures 4.8Ci, ii, iv and v). However, in donors 
P28, P29 and P30 no significant T-cell activation was observed (refer Figure 4.8). In all the 
datasets the incorporated 3HT was measured using beta particles as cpm. The cpm > negative 
control was considered of IFN-β-1a Rebif™ peptide specific. The dotted line on the graphs 
represents the minimum threshold for considering peptide specific T-cell activation. The 
stimulation index was calculated and represents the ratio of cpm between stimulated and 
negative control wells. The SI ≥ 1 was accepted as a cut-off for peptide induced proliferation 
(refer Figure 4.8D for healthy donors, Figure 4.8E for anti-IFN-β-1a Rebif™ antibodies 
negative donors and Figure 4.8F for anti-IFN-β-1a Rebif™ antibodies positive donors). Our 
data suggest the identified IFN-β-1a Rebif™ peptides are potentially immunogenic in anti-
IFN-β-1a Rebif™ antibodies positive donors P3, P10, P14 and P15. However, T-cell 
activation was also observed in anti-IFN-β-1a Rebif™ antibodies negative donors N2, N16 
and N27 and in a healthy donor H18.     
The ELISpots assays are well established for detection of T-cell activation against peptides 
(Mosmann et al. 1990). ELISpots can detect number of IFN-γ secreting T-cells. In order to 
further assess the T-cell involvement in anti-IFN-β-1a Rebif™ antibody response and to test 
the reactivity against IFN-β-1a Rebif™ by in vivo primed T-cells, PBMCs isolated from anti-
IFN-β-1a Rebif™ antibody positive donors P3, P10, P14 and P15 were incubated with the 
identified 17mer 5 offset IFN-β-1a Rebif™ peptides 1 and 5. The T-cell reactivity (measured 
by IFN-γ production) was determined with an ELISpot assay (refer Figures 4.9 and 4.10). 
The Figures 4.9a, b, c, d and 4.10a, b, c and d represents IFN-γ secretion to IFN-β-1a Rebif™ 
peptide 1 and 5 at 0 µM, 2.5 µM, 5 µM, 10 µM and 20 µM in anti-IFN-β-1a Rebif™ 
antibodies positive donors P3, P10, P14 and P15 respectively. The Figure 4.9e and 4.10f 
represents the quantification of IFN-γ spots in 500,000 PBMCs stimulated with IFN-β-1a 
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Rebif™ peptide 1 and 5 at different concentrations. The donor P3 (at 10 µM and 20 µM) 
exhibited significant IFN-γ spots to IFN-β-1a Rebif™ peptide 1. The donors P3 (at 10 µM 
and 20 µM) and P10 (at 5 µM, 10 µM and 20 µM) exhibited significant IFN-γ spots to IFN-
β-1a Rebif™ peptide 3. The donors P13, P28, P29 and P30 was excluded because no T-cell 
activation was seen in the previous T-cell proliferation assay (refer Figure 4.8c i – viii). Our 
data suggests the identified IFN-β-1a Rebif™ peptides are potentially immunogenic in 
antiIFN-β-1a Rebif™ antibodies positive donors P3 and P10 for IFN-β-1a Rebif™ peptides 1 
and 5 respectively.      
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Figure 4.8: T-cell epitope mapping in IFN-β-1a Rebif™ molecule. The Figures 4.8a (i – 
v), 4.6b (i – v), 4.6c (i – viii), 4.6d, 5.6e and 4.6f represents in vitro stimulation of PBMCs 
using  IFN-β-1a Rebif™ peptides in five healthy donors H11, H18, H19, H20 and H21, five 
anti-IFN-β-1a Rebif™ antibody negative donors N2, N4, N6, N16 and N27 and eight anti-
IFN-β-1a Rebif™ antibody positive donors P3, P10, P13, P14, P15, P28, P29 and P30. The 
IFN-β-1a Rebif™ peptide 1 elicited T-cell activation in donors P3, P10 and P15, peptide 2 
elicited T-cell activation in donor P3 and peptide 5 elicited T-cell activation in donors P10, 
P14 and P15. The dotted line on the graphs represents the minimum threshold for considering 
positivity of IFN-β-1a Rebif™ peptides specific T-cell activation. The statistical differences 
were determined using ANOVA with Dunnett’s post hoc test when compared to no 
stimulation. The phytohaemagglutinin at 5 µg/ml was used as a positive control. The different 
concentration of IFN-β-1a Rebif™ peptides is indicated on the X-axis and 3HT incorporation 
(cpm) is shown on the Y-axis. Results shown are mean cpm ± SD in presence and absence of 
antigenic stimulation. Each graph is representative of three independent experiments.        
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A  
Donor P3 
      
0µM 4 spots 2.5µM 7 spots 5µM 5 spots 10µM 18 spots 20µM 22 spots PHA 5µg/ml TNTC 
      
0µM 3 spots 2.5µM 7 spots 5µM 5 spots 10µM 24 spots 20µM 61 spots PHA 5µg/ml TNTC 
B 
Donor P10 
      
0µM 2 spots 2.5µM 1 spots 5µM 4 spots 10µM 5 spots 20µM 30 spots PHA 5µg/ml TNTC 
      
0µM 2 spots 2.5µM 1 spots 5µM 4 spots 10µM 5 spots 20µM 4 spots PHA 5µg/ml TNTC 
C 
Donor P14 
      
0µM 0 spots 2.5µM 1 spots 5µM 1 spots 10µM 0 spots 20µM 0 spots PHA 5µg/ml 45 
      
0µM 0 spots 2.5µM 1 spots 5µM 0 spots 10µM 1 spots 20µM 1 spots PHA 5µg/ml 43 
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D 
Donor P15 
      
0µM 0 spots 2.5µM 3 spots 5µM 12 spots 10µM 21 spots 20µM 37 spots PHA 5µg/ml TNTC 
      
0µM 5 spots 2.5µM 6 spots 5µM 0 spots 10µM 11 spots 20µM 12 spots PHA 5µg/ml TNTC 
E  
Figure 4.9: IFN-β-1a Rebif™ epitope mapping using an ELISpot assay. The PBMCs 
from anti-IFN-β-1a Rebif™ antibody positive donors P3, P10, P14 and P15 was stimulated 
for IFN-γ production in presence of identified 17mer 5 offset IFN-β-1a Rebif™ peptide 1. 
The Figures 4.9a, b, c and d represents IFN-γ secretion in PBMCs from donors P3, P10, P14 
and P15 in presence of IFN-β-1a Rebif™ peptide 1. The Figure 4.9d represents IFN-γ 
spots/500, 000 cells in donors P3, P10 and P15. The statistical differences were determined 
using ANOVA with Dunnett’s post hoc test when compared to no stimulation. The 
phytohaemagglutinin at 5 µg/ml was used as a positive control. The different concentration of 
IFN-β-1a Rebif™ peptide 1 is indicated on the X-axis and IFN-γ spots is shown on the Y-
axis.             
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A 
Donor P3 
      
0µM 17 spots 2.5µM 12 spots 5µM 36 spots 10µM 37 spots 20µM 46 spots PHA 5µg/ml TNTC 
      
0µM 13 spots 2.5µM 23 spots 5µM 34 spots 10µM 52 spots 20µM 84 spots PHA 5µg/ml TNTC 
B 
Donor P10 
      
0µM 29 spots  2.5µM 26 spots 5µM 67 spots 10µM 86 spots 20µM 113 spots PHA 5µg/ml TNTC 
      
0µM 25 spots 2.5µM 18 spots 5µM 62 spots 10µM 52 spots 20µM 82 spots PHA 5µg/ml TNTC 
C 
Donor P14 
      
0µM 4 spots 2.5µM 0 spots 5µM 2 spots 10µM 1 spots 20µM 0 spots PHA 5µg/ml 276 
      
0µM 0 spots 2.5µM 3 spots 5µM 4 spots 10µM 4 spots 20µM 7 spots PHA 5µg/ml 316 
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D 
Donor P15 
      
0µM 9 spots 2.5µM 22 spots 5µM 23 spots 10µM 23 spots 20µM 32 spots PHA 5µg/ml TNTC 
      
E 
Figure 4.10: IFN-β-1a Rebif™ epitope mapping using an ELISpot assay. The PBMCs 
from anti-IFN-β-1a Rebif™ antibody positive donors P3, P10, P14 and P15 was stimulated 
for IFN-γ production in presence of identified 17mer 5 offset IFN-β-1a Rebif™ peptide 5. 
The Figures 4.10a, b, c and d represents IFN-γ secretion in PBMCs from donors P3, P10, P14 
and P15 in presence of IFN-β-1a Rebif™ peptide 5. The Figure 4.10d represents IFN-γ 
spots/500, 000 cells in donors P3, P10 and P15. The statistical differences were determined 
using ANOVA with Dunnett’s post hoc test when compared to no stimulation. The 
phytohaemagglutinin at 5 µg/ml was used as a positive control. The different concentration of 
IFN-β-1a Rebif™ peptide 5 is indicated on the X-axis and IFN-γ spots is shown on the Y-
axis.  
Whilst performing T-cell proliferation assays in healthy controls we observed incidental T-
cell activation to IFN-β-1a Rebif™ peptide 1 in donor H18 (refer Figure 4.8Ai). T-cell 
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proliferation was also tested in healthy controls PBMCs H9, H22, H23, H24 and H25. The 
donors H9 (at 40 µM) and H25 (at 20 µM and 40 µM) exhibited significant proliferation of 
PBMCs to IFN-β-1a Rebif™ peptide 1 (refer Figure 4.11a and b). However, no T-cell 
activation was observed in donors H22, H23 and H25. The maximum stimulation for donor 
H9 and H25 was observed at 40 µM. Our data provide evidence for existence of potential 
IFN-β-1a Rebif™ T-cell epitopes in non-primed healthy donors.    
A  
 
B  
 
Figure 4.11:  IFN-β-1a Rebif™ molecule T-cell epitope mapping in healthy donors. The 
Figure 4.11 represents in vitro stimulation of PBMCs using IFN-β-1a Rebif™ peptide 1 in 
healthy donors H9 and H25. The IFN-β-1a Rebif™ peptide 1 elicited dose dependent T-cell 
activation in donors H9 and H25. The statistical differences were determined using ANOVA 
with Dunnett’s post hoc test when compared to no stimulation. The phytohaemagglutinin at 5 
µg/ml was used as a positive control. The different concentration of IFN-β-1a Rebif™ 
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peptide 1 is indicated on the X-axis and 3HT incorporation (cpm) is shown on the Y-axis. 
Results shown are mean cpm ± SD in presence and absence of antigenic stimulation.                    
4.3.6 Generation of Interferon beta 1a Rebif™ peptide responsive T-cell clones 
In an attempt to understand the cellular basis of IFN-β-1a Rebif™ peptide 1 and 5  T-cell 
responses the anti-drug antibodies positive donor P15 was chosen for pilot T-cell cloning 
experiments. T-cell cloning provides the population of T-cells that derives from the same 
progenitor with unique phenotypic and functional characteristics. The nature of T-cell 
response might provide useful insights of T-cells involvement in eliciting immune response 
against IFN-β-1a Rebif™ peptides. The choice of using donor P15 for T-cell cloning was 
based up on the T-cell proliferation data, IFN-γ production to IFN-β-1a Rebif™ peptides and 
also this donor exhibited highest amount of IFN-β-1a Rebif™ anti-drug antibodies. Hence, 
the donor P15 PBMCs was stimulated with 20 µM of each IFN-β-1a Rebif™ peptide 1 and 5 
and T-cell cloning experiment was performed. For IFN-β-1a Rebif™ peptide 1 two 
responsive T-cell clones and peptide 5 one responsive clone were generated (refer Figure 
4.12a, b and c). The IFN-β-1a Rebif™ peptide 1 T-cell clones 1 and 2 and IFN-β-1a Rebif™ 
peptide 2 T-cell clone 1 provided maximum proliferation of PBMCs at 5 µM of respective 
IFN-β-1a Rebif™ peptides. The obtained T-cell clones were expanded but failed to further 
respond. The obtained T-cell clones were tested using autologous B-LCLs as antigen 
presenting cells and IFN-β-1a Rebif™ peptide 1 and 5. The data obtained suggests IFN-β-1a 
Rebif™ peptide specific T-cell clones can be generated and illustrates potential T-cell 
involvement in the formation of anti-drug antibodies.  
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Figure 4.12: IFN-β-1a Rebif™ peptides specific T-cell clones. The Figures 4.12a and b 
represents the testing for IFN-β-1a Rebif™ peptide no. 1 specific T-cell clones obtained from 
donor P15. The Figure 4.12c represents the testing of peptide no. 3 specific T-cell clone 
obtained from donor P15. The statistical differences were determined using ANOVA with 
Dunnett’s post hoc test when compared to no stimulation. The different concentration of IFN-
β-1a Rebif™ peptides no. 1 and 5 are indicated on the X-axis and 3HT incorporation (cpm) is 
shown on the Y-axis. Results shown are mean cpm ± SD in presence and absence of 
antigenic stimulation.       
4.3.7 Identification of Interferon beta 1a Rebif™ T-cell epitopes in Human leukocyte 
antigens genotyped healthy donors  
The development of anti-IFN-β-1a IgG antibodies has been found to correlate with 
development of antigen specific T-cell responses. Several studies have identified the link 
between the human leukocyte antigens (HLA) with activation of antigen specific T-cells. For 
examples abacavir hypersensitivity was associated with HLA B*5701 (Mallal et al. 2002), 
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carbamazepine hypersensitivity in Caucasians and Japanese was associated with HLA 
A*3101 (McCormack et al. 2011; Ozeki et al. 2011), carbamazepine provoked Stevens 
Johnson syndrome in Han Chinese was associated with HLA B*1502 (Chung et al. 2004) and 
recently flucloxacillin induced liver injury was associated with HLA B*5701 (Monshi et al. 
2013).  
In order to investigate the HLA association with T helper cell activation to IFN-β-1a Rebif™ 
and development of IFN-β-1a Rebif™ anti-drug antibodies, the IFN-β-1a Rebif™ peptides 
identified earlier was examined for presence of T-cell epitopes using 30 HLA genotyped 
healthy donors. The proliferative response was measured using 3HT incorporation. The SI of 
≥ 2 was collated as positive responses to that peptide from that healthy donor (refer Figure 
4.13). Out of 30 donors tested for IFN-β-1a Rebif™ peptides – 3 donors at 2.5 µM, 6 donors 
at 5 µM, 2 donors at 10 µM and 2 donors at 20 µM elicited T helper cell activation to IFN-β-
1a Rebif™ peptide 1 (refer Figure 4.13a), 7 donors at 2.5 µM, 4 donors at 5 µM, 6 donors at 
10 µM and 4 donors at 20 µM elicited T helper cell activation to IFN-β-1a Rebif™ peptide 2 
(refer Figure 4.13b), 10 donors at 2.5 µM, 10 donors at 5 µM, 5 donors at 10 µM and 16 
donors at 20 µM elicited T helper cell activation to IFN-β-1a Rebif™ peptide 3 (refer Figure 
4.13c), 4 donors at 2.5 µM, 1 donor at 5 µM, 1 donor at 10 µM and 1 donor at 20 µM elicited 
T helper cell activation to IFN-β-1a Rebif™ peptide 4 (refer Figure 4.13d) and 3 donors at 
2.5 µM, 6 donors at 5 µM, 4 donors at 10 µM and 6 donors at 20 µM elicited T helper cell 
activation to IFN-β-1a Rebif™ peptide 5 (refer Figure 4.13d). Overall the maximum T helper 
cell activation was observed at IFN-β-1a Rebif™ peptide 3. However, the dose dependent T 
helper cell activation was observed in healthy donor 20 with HLA DRB1*1501 for IFN-β-1a 
Rebif™ peptides 1 and 5, healthy donor 24 with HLA DRB1*0101 for IFN-β-1a Rebif™ 
peptides 2 and 3, healthy donor 27 with HLA DRB1*1502 for IFN-β-1a Rebif™ peptide 2, 
healthy donor 28 with HLA DRB1*0301 for IFN-β-1a Rebif™ peptide 3, healthy donor 29 
with HLA DRB1*1501 for IFN-β-1a Rebif™ peptide 3, healthy donor 32 with HLA 
DRB1*0101 for IFN-β-1a Rebif™ peptide 4, healthy donor 36 with HLA DRB1*1502 for 
IFN-β-1a Rebif™ peptide 3, healthy donors 37, 38, 39 with HLA DRB1*1501 for IFN-β-1a 
Rebif™ peptide 3 respectively. Our data indicates the proliferative response to IFN-β-1a 
Rebif™ peptide 3 was associated with the presence of the HLA haplotype DRB1*1501 (refer 
Figure 4.14).   
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Figure 4.13: IFN-β-1a Rebif™ molecule T-cell epitope mapping. The Figure 4.13a, b, c, d 
and e represents in vitro stimulation of PBMCs and frequency of responses using identified 
IFN-β-1a Rebif™ peptides in 30 different HLA genotyped healthy donors. The IFN-β-1a 
Rebif™ peptides elicited differential T-cell activation in several healthy donors (indicated in 
red coloured circles). The phytohaemagglutinin at 5 µg/ml was used as a positive control. 
The different concentration of IFN-β-1a Rebif™ peptides is indicated on the X-axis and 
Stimulation index (SI) is shown on the Y-axis. The SI represents the ratio of cpm between 
stimulated and negative control wells. The dotted line on the graphs represents the minimum 
threshold for considering IFN-β-1a Rebif™ peptides specific T-cell activation.        
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Figure 4.14: T-cell activation to IFN-β-1a Rebif™ peptides in HLA-DRB1*1501 healthy 
donors. The Figure 4.14a, b, c, d and e represents in vitro stimulation of PBMCs using IFN-
β-1a Rebif™ peptide 1 and 3 in healthy donors 20, 29, 37, 38 and 39. The statistical 
differences were determined using ANOVA with Dunnett’s post hoc test when compared to 
no stimulation. The phytohaemagglutinin at 5 µg/ml was used as a positive control. The 
different concentration of IFN-β-1a Rebif™ peptides is indicated on the X-axis and 
Stimulation index (SI) is shown on the Y-axis.        
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4.3.8 Regulatory T-cells in anti-Interferon beta 1a Rebif™ antibodies development 
Regulatory T-cells (Tregs) are essential for control of adaptive immune responses and also 
constitutes tolerance to both self and non-self antigens (Sakaguchi et al. 2008). Tregs 
mediates regulation of B cells and promote tolerance against self antigens through contact 
dependent suppression or secretion of anti-inflammatory cytokines such as IL-10 and TGF-β. 
The studies suggests the role of Tregs in regulation of autoantibody responses through B cells 
either activating B cells directly or through T helper cells and antigen presenting cells (Bystry 
et al. 2001; Ludwig-Portugall et al. 2009; Ludwig-Portugall et al. 2008).  
In this set of experiments an attempt has been made to investigate the role of Tregs in 
regulation of anti-IFN-β-1a Rebif™ antibodies in MS patients. Tregs can be identified by the 
presence of cell surface markers, CD4
+
CD25
high
CD127
low
FoxP3
+
. The intracellular marker 
FoxP3 belongs to fork-head family of transcriptional factors and also considered as a master 
regulator of Tregs development and function (Hori, Nomura & Sakaguchi 2003; Khattri et al. 
2003). The gating strategy for identification of Tregs in peripheral blood is shown in Figure 
4.15). In this study we first investigated the frequency of Tregs in PBMCs of IFN-β-1a 
Rebif™ neutralising antibodies positive, negative and healthy donors (refer Figure 4.16). The 
Figures 4.16a and b represents percentage population of CD4
+
 T-cells, the medians (25th, 
75th percentiles) include 38.25 (29.21, 51.13) and 46.40 (37.67, 54.02) for two groups and 
38.25 (29.21, 51.13), 43.47 (37.71, 53.88) and 51.75 (37.53, 55.01) for three groups 
respectively. The Figure 4.16c and d represents percentage population of CD4
+
CD25
high
 T-
cells, the medians (25th, 75th percentiles) include 4.430 (2.525, 6.190) and 3.450 (2.800, 
5.000) for two groups and 4.430 (2.525, 6.190), 3.350 (2.270, 5.265) and 3.970 (2.808, 5.318) 
for three groups respectively. The Figures 4.16e and f represents percentage population of 
CD4
+
CD25
high
CD127
low
FoxP3
+
 T-cells, the medians (25th, 75th percentiles) include 2.870 
(1.250, 4.560) and 2.440 (1.790, 3.380) for two groups and 2.870 (1.250, 4.560), 2.575 
(2.158, 3.478) and 2.335 (1.408, 2.938) for three groups respectively. Our data suggests no 
significant differences in the frequency of Tregs in PBMCs of IFN-β-1a Rebif™ neutralising 
antibodies positive, negative and healthy donors respectively.  
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Figure 4.15: Global immunophenotyping of Tregs. The representation of gating strategy 
adopted for identification of Tregs in PBMCs using FACS. The Figure 4.15a represents dot 
plot for unstained cells as background control. The Figure 4.15b represents dot plot for cells 
stained with FITC conjugated anti-CD4, APC conjugated anti-CD25 and PE-Cy5 conjugated 
anti-CD127 antibodies. The Figure 4.15c represents dot blot for cells stained for FITC 
conjugated anti-CD4, APC conjugated anti-CD25, PE-Cy5 conjugated anti-CD127 and PE 
conjugated anti-FoxP3 antibodies. Isotype control antibodies were used for all cell surface 
staining. The dot plots were obtained using Cyflogic™, a FACS data analysis tool.      
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Figure 4.16: Frequency of CD4
+
CD25
high
CD127
low
FoxP3
+
 Tregs. Comparison of 
percentage of CD4
+ 
T-cells (refer Figures 4.16a and b), CD4
+
CD25
high
 T-cells (refer Figures 
4.16c and d) and CD4
+
CD25
high
CD127
low
FoxP3
+
 Tregs population (refers Figures 4.16e and 
f) in IFN-β-1a Rebif™ neutralising antibodies positive, negative and in healthy donors in the 
peripheral blood. Each open circle represents an individual percentage of defined T-cell 
population. Bars represent the IQR (25th and 75th percentiles) from the median (horizontal 
line). Statistical differences were not observed between differences in any groups and were 
determined using Mann Whitney U test for two non-parametric groups and Kruskall-Wallis 
test for more than two nonparametric groups.                      
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4.3.9 Evaluation of CD4
+
CD25
high
CD127
low
FoxP3
+ 
regulatory T-cells suppressive 
function  
In order to investigate whether there are differences in Tregs function between the different 
patient groups, Tregs suppression assay was used. The CD4+CD25
high
 Tregs were isolated 
and Tregs negative fraction CD4
+
CD25
low
 T-cells were used as responder T-cells (Tresp). 
The cells were stimulated using phytohaemagglutinin, irradiated non CD4
+ 
T-cells were used 
as feeder cells and different ratio of Tregs were added to the culture and the suppression was 
measured using 3HT incorporation. The obtained cells fractions were surface stained for % of 
purity and were measured using FACS (refer Figures 4.17a, b and c). The ideal concentration 
for polyclonal stimulation phytohaemagglutinin was optimised at 20 µg/ml and for antigenic 
stimulation Tetanus toxoid was optimised at 2 µg/ml and was determined using Tregs 
suppression assay. The maximum stimulation was observed for phytohaemagglutinin at 20 
µg/ml and for Tetanus toxoid at 2 µg/ml (refer Figures 4.18a and b). The functional activity 
of Tregs were measured in healthy donors H9, H11 and H18, IFN-β-1a Rebif™ positive 
donors P3 and P15 and negative donors N2, N4 and N12 using Tregs suppression assays 
(refer Figures 4.19). The no. of Tregs required to suppress Tresp was calculated which is 
illustrated in Figure 4.19j. Bars represent the IQR (25th and 75th percentiles) from the 
median (horizontal line). The medians (25th, 75th percentiles) include 16062 (14404, 17720), 
12216 (8592, 15840) and 15274 (11554, 16495) for three groups respectively. Our data 
suggests no significant differences in the Tregs functions of IFN-β-1a Rebif™ neutralising 
antibodies positive, negative and healthy donors respectively. 
However, during Tregs isolation we incidentally identified significantly difference in CD8
+
 
T-cells in healthy donors and IFN-β-1a Rebif™ neutralising antibodies positive and negative 
donors. Bars represent the IQR (25th and 75th percentiles) from the median (horizontal line). 
The medians (25th and 75th percentiles) include 21.35 (17.23, 27.72) and 10.77 (6.660, 
15.11) for two groups and 21.35 (17.23, 27.72), 7.620 (4.940, 10.77) and 15.36 (14.34, 16.24) 
for three groups respectively.  
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Figure 4.17: Assessing purity of Tregs. In order to ensure the quality of cells used for Tregs 
suppression assay, the identity and purity analysis was performed using cell surface staining. 
The Figure 4.17a represents the dot plot for unstained cells as background control. The panel 
also includes the histograms for PBMCs stained for PE conjugated anti-CD4, FITC 
conjugated anti-CD8 and PE conjugated anti-CD25 antibodies. The baseline percentages of 
cells were obtained at this stage. The isolated CD4
+
 T-cells were stained for PE conjugated 
anti-CD4 and non CD4
+
 T-cells were stained for PE conjugated anti-CD4, FITC conjugated 
anti-CD8 and PE conjugated anti-CD25 antibodies. The Figure 4.17b represents the dot plot 
for unstained cells as background control. The panel also includes the dot plots for PBMCs 
stained for FITC conjugated anti-CD4 and APC conjugated anti-CD25 antibodies. The 
isolated CD4
+
CD25
high 
Tregs are stained for FITC conjugated anti-CD4, APC conjugated 
anti-CD25, PE-Cy5 conjugated anti-CD127 and PE conjugated anti-FoxP3 antibodies. The 
Figure 4.17c represents dot plot for isolated CD4
+
CD25
low 
Tresp cells and are stained for PE 
conjugated anti-CD4 and PE conjugated anti-CD25 antibodies. Isotype control antibodies 
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were used for all cell surface staining. The dot plot was obtained using WinMDI 2.8, a FACS 
data analysis tool.                          
A  
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Figure 4.18: Validation of Treg suppression assay. The Figure 4.18a represents the 
proliferation of a healthy donor PBMCs to polyclonal stimulation phytohaemagglutinin. The 
CD4+CD25low T-cells were co cultured with irradiated non CD4+ T-cells at different 
concentrations of phytohaemagglutinin. The 3HT was added to the culture on day 3 and the 
proliferation was measured on day 4. The Figure 4.18b represents the proliferation of a healthy 
donor PBMCs to antigen stimulation Tetanus toxoid. The CD4+CD25low T-cells were co cultured 
with irradiated non CD4+ T-cells at different concentrations of Tetanus toxoid. The 3HT was 
added to the culture on day 5 and the proliferation was measured on day 6. The statistical 
differences were determined using ANOVA with Dunnett’s post hoc test when compared to no 
stimulation. The different concentrations of phytohaemagglutinin and Tetanus toxoid are 
indicated on the X-axis and 3HT incorporation (cpm) is shown on the Y-axis. Results are shown 
are mean cpm ± SD in presence and absence of phytohaemagglutinin and Tetanus toxoid.  
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Figure 4.19: In vitro Tregs suppression assays. In order to determine the functional activity 
of Tregs in vitro Tregs suppression assay was used to investigate Tregs function in healthy 
donors H9, H11, H18 (refer Figures 4.19a, b, c), IFN-β-1a Rebif™ neutralising antibodies 
positive donors P3, P15 (refer Figures 4.19d, e) and negative donors N2, N4, N12 (refer 
Figures 4.19f, g, h). Isolated CD4
+
CD25
high 
Tregs were co cultured with CD4
+
CD25
low
 Tresp 
in different ratios. The phytohaemagglutinin at 20 µg/ml was used to stimulate the cells. The 
controls CD4
+
CD25
high
 Tregs and CD4
+
CD25
low
 Tresp were cultured without 
phytohaemagglutinin. The proliferation was determined by measuring 3HT incorporation. 
The different ratios of T-cell fractions are indicated on the X-axis and 3HT incorporation 
(cpm) is shown on the Y-axis. Results shown are mean cpm ± SD in the presence and 
absence of stimulation. The Figure 4.19i represents the % suppression of Tregs using 
phytohaemagglutinin in all the three groups. The Figure 4.19j represents the number of Tregs 
required to suppress 50 % of Tresp in vitro. Each open circle represents an individual no. of 
Tregs required to suppress Tresp in vitro. Statistical differences were not observed between 
differences in any groups and comparisons were determined using Kruskall-Wallis test for 
more than two nonparametric groups.                     
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Figure 4.20: In vitro antigen specific Tregs suppression assay. In order to demonstrate the 
antigen specific Tregs suppression assay isolated CD4
+
CD25
high 
Tregs were co cultured with 
CD4
+
CD25
low
 Tresp in different ratios. In this experiment Tetanus toxoid 2 µg/ml was used 
to stimulate the cells. The proliferation was determined by measuring 3HT incorporation. The 
different ratios of T-cell fractions are indicated on the X-axis and 3HT incorporation (cpm) is 
shown on the Y-axis. Results shown are mean cpm ± SD in the presence and absence of 
antigenic stimulation.        
 
Figure 4.21: Frequencies of CD8
+
 T-cells. The PBMCs were stained for CD8
+
 T-cell 
surface marker whilst isolating Tregs. The Figures 4.21a and b represents the frequencies of 
CD8
+
 T-cells in healthy donors and IFN-β-1a Rebif™ neutralising antibodies positive and 
negative donors in relapsing forms of multiple sclerosis. Each open circle represents an 
individual percentage of CD8
+
 T-cells from the peripheral blood PBMCs. Statistically 
significant differences are shown in panels and comparisons were determined using Mann 
Whitney U test for two non-parametric groups and Kruskall-Wallis test for more than two 
nonparametric groups.  
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4.4 Discussion 
The main area of interest was to identify T helper cell responses to IFN-β-1a Rebif™ and any 
particular peptide epitopes that are involved. Heat inactivation was chosen as a method to 
ablate the therapeutic protein IFN-β-1a Rebif™ because it may not be possible to stimulate 
PBMCs directly as the protein modifies the function of responding T-cells. IFN-β-1a Rebif™ 
exhibit anti-proliferative activities and using the protein directly on PBMCs will always 
suppress T-cell proliferative responses. Stickler et al measured T-cell activation in healthy 
donors using heat inactivated IFN-β. The Figure 4.3 demonstrates IFN-β-1a exhibits 
significant anti-proliferative function. Therefore, Stickler et al heat inactivation protocol for 
heat inactivating IFN-β-1a was pursued and found using 30 minutes of heat inactivation was 
sufficient to stimulate the PBMCs. In order to understand the cellular basis of heat inactivated 
IFN-β-1a Rebif™ T-cell responses the donors P3 and P10 PBMCs were attempted for T-cell 
cloning. The T-cell cloning will provide a platform to understand and analyse the 
functionalities of immune mechanisms for example mediated by T-cells, antigen presentation, 
the nature and mode of action of cytokines, the cell surface molecules and also provide 
insights into signalling molecules that orchestrate T-cell activation. However, may not 
represent the whole population of T-cells in in vivo settings. The antigen specific T-cells can 
be detected after in vitro stimulation with the antigen of interest. Steinitz KN et al generated 
Factor VIII specific T-cell clones to assess Factor VIII peptides specificity (Steinitz et al. 
2012) in humanised mouse models. Furthermore, Jacquemin M et al have identified T-cell 
epitopes of Factor VIII recombinant protein using CD4
+
 T-cell clones which are isolated 
from Haemophilia A patient (Jacquemin et al. 2003). Identification of CD4
+ 
T-cells epitopes 
is considered as a rational approach for assessing immunogenicity of the protein therapeutics. 
In our study the T-cell cloning experiment provided several T-cell lines and after initial 
stimulation with heat inactivated IFN-β-1a Rebif™ two responsive clones was generated. 
Unfortunately, after expansion of these responsive cells, the cells failed to respond further in 
a dose dependent manner indicating non specificity. The EBV-transformed lymphoblastoid 
cell line was used to stimulate the obtained IFN-β-1a Rebif™ T-cell lines. The evidence also 
indicates stimulation with protein loaded monocyte-derived dendritic cells is more effective 
in expanding antigen specific T-cell population (Ho et al. 2006). Such approaches could be 
adopted to increase the efficiency of generating T-cells clones. Further investigations into the 
obtained IFN-β-1a Rebif™ T-cell lines for example TcR vβ repertoire to determine T-cell 
clonality (Bonfigli et al. 2003; Gennery & Cant 2007; van den Beemd et al. 2000)could 
provide additional insights.  
167 
 
In order to further investigate the presence of IFN-β-1a Rebif™ T-cell epitopes in silico 
methods were utilised due to limited number of patient PBMCs. In silico predictions are of 
advantage to the extent especially in pharmaceutical industry but the servers also indicate for 
further in vitro assessments. The ideal situation is to examine IFN-β-1a Rebif™ overlapping 
peptides of the entire sequence for T-cell activation. In order to overcome the limited number 
of cells the PBMCs could have been stimulated with IFN-β-1a Rebif™ peptides pools. 
However, the PBMCs were stimulated using the identified IFN-β-1a Rebif™ 17mer 5 offset 
peptides because of limited number of PBMCs. The dataset indicates the different degree of 
T-cell activation and also compatible to the previously published data (refer Figures 4.8). 
Several T-cell activation assays are available to identify T-cell epitopes such as CFSE T-cell 
proliferation assays and this enables accurate measurements of proliferating CD
+
 T-cells. 
ELISpots detects the secretion of cytokine at a single cell level and therefore using ELISpots 
for T-cell epitope identification can be more sensitive. In this study ELISpots for IFN-γ was 
used to validate the IFN-β-1a Rebif™ peptides identified (refer Figures 4.9 and 4.10). In 
order to further understand the cellular basis of IFN-β-1a Rebif™ peptides T-cells responses 
the donor P15 was used for T-cell cloning. The T-cell cloning experiment provided several T-
cell lines and after initial stimulation with respective IFN-β-1a Rebif™ peptides three 
responsive clones was generated (refer Figures 4.12). The expansion of cells caused T-cell 
clones to become non-responsive. In our T-cell cloning experiments B-LCLs was used as 
antigen presenting cells to stimulate the cells obtained. In order to establish maximum 
stimulation DC T-cell assays are found to be beneficial, sensitive and versatile which 
measures if the protein can induce T-cell proliferation. For example, Ho et al generated high 
avidity T-cell clones against WT1 (tumour associated antigen) using protein loaded 
monocyte-derived dendritic cells (Ho et al. 2006).    
The evidences also suggest link between the HLA and activation of antigen specific T-cells. 
Therefore, the identified IFN-β-1a Rebif™ peptides were tested in 50 randomly selected 
healthy donors of whom for 30 donors the HLA genotyped PBMCs were used from the cell 
archive. Using 30 randomly selected healthy donors represent or mimic the HLA allele 
frequencies found in global population. Initial stimulation using IFN-β-1a Rebif™ peptides 
revealed proliferative responses to IFN-β-1a Rebif™ peptide no. 1 (refer Figure 4.13). 
However, executing T-cell proliferation assays in 30 donors revealed proliferative responses  
to IFN-β-1a Rebif™ peptide 3 in HLA-DRB1*1501 haplotype (refer Figures 4.13 and 4.14). 
The HLA-DRB1*1501 represents an important locus for several diseases for example  Type I 
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diabetes, rheumatoid arthritis and multiple sclerosis (Davies et al. 1994; Nepom & Erlich 
1991; Todd et al. 1988). Studies on DRB1*1501 with antigenic peptides has been 
investigated for example using human MBP to study multiple sclerosis and concludes this 
allele is characterised by hydrophobic P4 pocket in presence of alanine at DRβ71 position 
(Smith et al. 1998). The major anchor residue for human MBP peptide (residue 85-99) was 
phenylalanine. Understanding and identification of the antigenic anchor residues could also 
reveal those residues that may be important for TCR contact. In our studies we speculate 
hydrophobic amino acids in IFN-β-1a Rebif™ peptide CAWTIVRVEILRNFYFI might 
participate in T-cell activation and these amino acids are in the predicted positions for HLA-
DRB1*1501 binding. The hydrophobic amino acids in IFN-β-1a Rebif™ peptide sequence 
are coloured in red.  Steinitz KN et al 2012 has also identified Factor VIII peptide regions 
presented by HLA-DRB1*1501 in humanised haemophilic mouse model. However, the 
identified IFN-β-1a Rebif™ peptide presented by HLA-DRB1*1501 by healthy donors can 
be cross examined using available in silico technologies. The clear understanding of peptide 
binding affinities to specific HLA haplotype can determine the molecular interactions 
involved in the aetiology of diseases and also assist in development of effective drugs. Chang 
et al reports identification of peptide binding repertoires can provide effective development of 
epitope-based vaccines (Chang et al. 1997). In our studies we identified HLA-DRB1*1501 
association in IFN-β-1a Rebif™ peptide. However, the evidence provided here requires 
further characterisation. The possible studies include generation of IFN-β-1a Rebif™ peptide 
specific T-cell clones using HLA-DRB1*1501 PBMCs and characterising the obtained T-cell 
clones. The clones can also be used to define the functional epitopes on HLA-DRB1*1501 
molecule (Goronzy, Weyand & Waase 1985). The potential association between HLA 
haplotype and T-cell response to IFN-β-1a Rebif™ peptide indicate a potential risk factor for 
development of antibodies against IFN-β-1a Rebif™. Interestingly, the identified HLA 
DRB1*1501 has been associated with increased susceptibility to multiple sclerosis (Alcina et 
al. 2012). 
The frequency of circulating Treg cells subpopulation in relapsing forms of multiple sclerosis 
with IFN-β-1a Rebif™ treatment and in healthy donors was also evaluated. The Figures 4.16 
suggest there was no significant difference in the global Tregs frequencies and function. 
Feger U et al has determined increased frequencies of Tregs in the CSF of multiple sclerosis 
patients (Feger et al. 2007). The evidence also suggests the deficit in Tregs suppressive 
function in multiple sclerosis patients (Frisullo et al. 2009). Namder et al suggests IFN-β 
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treatment in multiple sclerosis may restore Tregs function (Namdar et al. 2010). The data 
obtained in our studies indicate no significant difference in the Tregs function between IFN-
β-1a Rebif™ neutralising antibodies positive, negative and in healthy donors. The use of 
IFN-β-1a Rebif™ or peptides in Tregs suppression assays to determine the antigen specific 
Treg function could provide more meaningful data. However, to achieve this, antigenic 
epitopes within IFN-β need to be determined. Venkan et al has shown the difference in naïve 
and memory Tregs in patients and in healthy controls. The naïve Tregs was defined as 
CD4
+
CD25
high
CD127
low
CD45RA
+
 (nTregs) and memory Tregs was defined as 
CD4
+
CD25
high
CD127
low
CD45RA
–
 (mTregs) (Venken et al. 2008). Constantino et al has 
shown no difference in Treg frequency and function from untreated patients and in healthy 
controls. The Tregs was defined as CD4
+
CD25
high
 T-cell population (Costantino, Baecher-
Allan & Hafler 2008). Our results are in agreement with Constantino et al as possibly due to 
the fact that we focus on at CD4
+
CD25
high
 T-cell population. A finer resolution of Treg 
subpopulations might uncover any potential differences.  
4.5 Conclusions  
o Using T-cell epitope prediction tools (IEDB–AR and ProPred) and T-cell functional 
assays we identified an immunogenic sequence of 36 amno acids within IFN-β molecule 
(position 130-166). 
o The data also suggest one IFN-β peptide within this sequence is a potential T-cell 
immunogenic epitope. 
o Identified possible association of one of the IFN-β peptide with HLA haplyotype 
DRB1*1501. 
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Chapter 5: Final discussion  
Unwanted immunogenic responses such as anti-drug antibodies to protein therapeutics can 
cause decrease in efficacy, hypersensitivity reactions, anaphylaxis, induction of 
autoimmunity and cross reactivity to endogenous proteins. Interferon beta (Rebif™, 
Avonex™, Betaseron/Betaferon™) is approved for chronic administration to relapsing forms 
of multiple sclerosis. Immunogenicity resulting from IFN-β-1a Rebif™ administration is 
significant complication associated with protein therapeutics. The mechanisms of 
development of anti-IFN-β antibodies are poorly understood. The overall aim of the work 
was to characterise the immunogenic responses to therapeutic IFN-β-1a Rebif™.  
As part of the thesis work, a systematic review was conducted and findings from which 
suggest 1.22 – 19.44 % of patients developed neutralising antibodies to Avonex™, 15.20 – 
33.25 % of patients developed neutralising antibodies to Rebif™ and 27.38 – 58.79 % of 
patients developed neutralising antibodies to Betaseron/Betaferon™. Overall the 
development of neutralising antibodies was less in IFN-β-1a Avonex™, moderate in IFN-β-
1a Rebif™ and high in IFN-β-1b Betaseron/Betaferon™. Based on this review IFN-β-1a 
Avonex™ 30 µg IM should be the drug of choice for patients suffering from relapsing forms 
of multiple sclerosis. An attempt was made to capture all the factors affecting the 
development of neutralising antibodies. Therefore where necessary data are available the 
meta-analysis was executed. Our review managed to perform the comparison of neutralising 
antibodies against IFN-β-1a Avonex™ 30 µg and 60 µg, IFN-β-1a Rebif™ 22 µg and 44 µg 
and IFN-β-1a and IFN-β-1b. However, due of limited number of studies and variability in 
reporting we could not able to perform the relevant analysis for example frequency of 
administration for the contribution of development of neutralising antibodies.  
In experimental chapters I have characterised anti-drug antibodies in a cohort of MS patients, 
have explored the neutralising capabilities of IgG subclass specific antibodies, tested the 
potential of ADAs to form immune complexes and activate complement, and have addressed 
the role of T-cells in development of anti-drug antibodies.  
5.1 Do IgG subclass specific anti-drug antibody responses to Interfeon beta 1a Rebif™, 
have differential neutralising capabilities? 
The work conducted was to characterise anti-IFN-β-1a Rebif™ antibodies against therapeutic 
IFN-β-1a Rebif™ in a cohort of IFN-β-1a Rebif™ treated patients and to determine the 
relative contribution of anti-IFN-β-1a Rebif™ antibodies in neutralising IFN-β bioactivity.  
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The analyses of plasma samples identified that ADAs were predominantly of IgG1 and IgG4 
antibodies. IgG4 antibodies are implicated in greater neutralisation potential compared to 
other IgG subclasses. Out data showed IgG4 antibodies are likely to be the major contributor 
to the neutralisation by anti-IFN-β-1a Rebif™ antibodies. But, this need further investigation 
perhaps increasing sample size and investigating using purified forms of IgG4 antibodies for 
investigating differential neutralising capabilities are beneficial . The longitudinal studies are 
required to investigate the evolution of IgG4 antibodies.  
The role of IgG1 antibodies also needs to be further explored. Clearly, IgG1 antibodies also 
contribute towards the neutralising potential. Hence, isolating IgG1 antibodies and 
investigating for neutralising potential could answer important questions relevant to 
immunogenicity. In order to further elucidate the evolution of IgG subclasses in anti-IFN-β 
antibodies, clearly defined longitudinal analysis are required which can provide insights into 
development of anti-drug antibodies.   
The evidence suggests IgG subclasses patterns vary in IFN-β-1b treated compared to IFN-β-
1a treated patients. In IFN-β-1b treated patients the IgG1 and IgG3 antibodies peaked within 
first 6 months followed by progressive decline, whilst IgG4 antibodies increased later after 24 
months. In contrast, in IFN-β-1a treated patients IgG1, 2 and 4 peaked after 18 months 
thereafter with progressive decline whilst IgG4 antibodies begin to increase. IgG4 antibodies 
were prominent in neutralising antibodies positive patients. However, correlations on the 
implications of different IgG subclass antibodies with clinical outcomes are difficult to make. 
There is some evidence in the case of other biologics that neutralising antibodies may tend to 
disappear or be reduced on prolonged treatment (Hegen et al. 2012b; Pungor et al. 1998; Rice 
et al. 1999). However, in the case of IFN-β, anti-drug antibodies can persist for a long time 
even after cessation of treatment, which could still impact patient safety. In terms of 
persistence of different subclasses, IgG1, IgG2 and IgG4 antibodies exhibits 21 – 23 days of 
half life whereas IgG3 antibodies exhibit 7 – 8 days of half life. Because of long survival the 
IgG1, 2 & 4 antibodies may give rise to immune complex formation and persist in circulation 
for indefinite period of time (Suen et al. 2003). However, the importance of IFN-β specific 
IgG subclasses half-life in neutralisation potential remains to be investigated. The 
development of anti-drug antibodies against other biologics for example IFN-α, 
erythropoietin, Factor VIII, IX, insulin, GM-CSF, anti-TNF alpha has also resulted in 
compromised therapeutic efficacy. The IgG subclass profiling for IFN-α indicated all four 
IgG subclasses were involved IgG1 35 %, IgG2 10 %, IgG3 27 % and IgG4 28 % (Gregorek 
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et al. 2000). The detailed investigation of IgG subclass profiling for anti-erythropoietin 
antibodies indicate anti-EPO IgG1 antibodies in all clinical patients but neutralising 
antibodies were associated with anti-EPO IgG4 antibodies (Barger et al. 2012). The distinct 
characteristics of IgG subclass profiling for anti-factor VIII antibodies indicate both IgG1 and 
IgG4 antibodies in patients with FVIII inhibitors however IgG4 antibodies was absent in 
healthy controls (Whelan et al. 2013). Orstavik et al reports anti-factor IX antibodies contain 
all the IgG subclasses except IgG3 antibodies (Orstavik 1990). The IgG subclass response in 
anti-insulin antibodies involves IgG1, IgG3 and IgG4 and the anti-insulin antibodies also 
vary with type of diabetes. The evidence suggests the variations in IgG subclass profiles exist 
depending on the protein therapeutic. Sometimes development of anti-drug antibodies caused 
life threatening conditions.  
5.2 Do neutralising antibodies neutralise both exogenous and endogenous Interferon 
beta? 
Investigation of neutralising IFN-β-1a Rebif™ antibodies on endogenous IFN-β revealed 
varying degrees of neutralisation of endogenous IFN-β. High titre neutralising antibodies can 
persist for years and may impede IFN-β signalling and impacts the immune system. Potential 
consequences include susceptible to viral infections. It has been indicated neutralisation of 
endogenous proteins may potentially impact fetal development when such a response is 
generated during pregnancy or whilst breast feeding (Guidance document on immunogenicity 
assessment for proteins drugs issued from U.S Department of Health and Human Services 
http://www.fda.gov/downloads/Drugs/.../Guidances/UCM338856.pdf assessed February 
2013). Furthermore, the evidence also indicates red cell aplasia due to anti-erythropoitin 
antibodies (Casadevall et al. 2002), thrombocytopenia due to anti-thrombopoietin antibodies 
(Li et al. 2001b) are a result of cross reactivity to endogenous protein counterpart.  
5.3 Does Interferon beta 1a Rebif™ specific anti-drug antibodies form immune 
complexes with Interferon beta 1a Rebif™ and can such complexes activate the classical 
complement pathway? 
Our data demonstrated the IFN-β-1a Rebif™ specific anti-drug antibodies formed immune 
complexes with IFN-β-1a Rebif™ and activated complements. Delayed hypersensitivity 
reactions are those mediated through immune complexes and T-cells (Hunley et al. 2004). 
The clinical signs and symptoms of immune complex deposition include flu like symptoms, 
rash, arthralgia, myalgia, proteinuria, hematuria and so on. There is some evidence in the 
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form of a case report on IFN-β-1b treated patient developing severe vasculitis like skin 
reaction (delayed severe cutaneous reaction) after 9 months of treatment (Cohen, Greenberger 
& Saini 1998). Some of the signs are suggestive of immune complex formation has also been 
shown in patients undergoing tolerance induction treatment using Factor IX and alpha-
glucosidase (Hunley et al. 2004).   Immune complexes can activate complement through 
classical pathway. The evidence indicates development of anti-drug antibodies can lead to 
complement activation with subsequent production of anaphylatoxins such as C3a and C5a 
and release of mediators from mast cells (Vultaggio, Maggi & Matucci 2011).  
The release of C3a and C5a are implicated in enhancing antigen processing and presentation 
and also in maintenance of tolerance (Hegen et al. 2012b; Strainic et al. 2008; Weaver et al. 
2010). The evidence suggests C3a and C5a enhance function of DCs and generate T helper 1 
cells. The role of C3a and C5a in immunogenicity needs to be fully explored.  The activated 
complements C3a and C5a influence antibody responses through modulating DCs, T-cells 
and B-cells function. The antigen presenting cells express complement receptors, the 
complement regulatory proteins for optimal maturation and T-cell activation (Hashimoto et 
al. 2010; Kerekes et al. 2001; Weaver et al. 2010; Zhou et al. 2006). Primary APC T-cell 
assays in conjunction with targeting of complement receptors (by genetic and 
pharmacological means) need to be performed to assess the role of complements in T-cell 
activation (Strainic et al. 2008).   
5.4 Could antibody-binding sites on Interferon beta 1a Rebif™ be identified? 
An attempt was made to investigate the potential antibody linear epitopes. The multipin 
peptide technology revealed significant binding residues 1–32, 40–62, 70–86, 106–112 and 
136–166 on IFN-β-1a Rebif™ molecule and the in vitro competitive binding assay indicated 
no linear binding epitopes on IFN-β-1a Rebif™ molecule. The identification of antibody 
epitopes can potentially lead to strategies to avoid immunogenicity.  It is conceivable that 
reengineering of IFN-β-1a Rebif™ molecule such as substitutions or deletions of amino acids 
within predicted epitope regions might reduce the incidence of development of anti-drug 
antibodies. However, such a reengineering should not result in compromise in IFNb 
functional or receptor binding activities. Formation of neoepitopes through reengineering is 
also a possibility and needs to be taken into consideration.   
5.5 Could T helper cells specific for Interferon beta 1a Rebif™ epitopes be identified in 
anti-drug antibodies positive patients? 
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In order to understand the role of T helper cells in immunogenicity of IFN-β, we identified T-
cell epitopes using T-cell prediction tools and overlapping (17mer, 5 offset) IFN-β-1a 
Rebif™ peptides in cells from patients, healthy donors and HLA genotyped cell archive from 
healthy donors. 
T-cell prediction tools IEDB–AR and ProPred was used to predict MHC class II bindig 
sequence of 36 amino acids within IFN-β-1a Rebif™ (position 130 – 166). The overlapping 
(17mer, 5 offset) IFN-β-1a Rebif™ peptides were synthesised. The reactivities of in vivo 
primed cells using T-cell proliferation assays and IFN-γ ELISpots suggest the identified IFN-
β-1a Rebif™ peptides are relatively immunogenic in some ADA positive donors. However, 
T-cell activation was also observed in some ADA negative and healthy cells. Such T-cell 
responses in healthy subjects have also been observed in the case of other biologics, for 
example EPO (Barger et al. 2012).  
In order to address the HLA association with T helper cell activation to IFN-β-1a Rebif™ 
and development of anti-drug antibodies, the identified IFN-β-1a Rebif™ peptides was 
investigated for the presence of T-cell epitopes in 30 HLA genotyped healthy donors. The 
data indicates IFN-β-1a Rebif™ peptide 3 was associated with the presence of HLA 
DRB1*1501 allele. Several associations between the specific HLA and diseases (for e.g. 
HLA-DRB1*0401 is associated with Type 1 Diabetes, HLA-DRB1*1501 is associated with 
multiple sclerosis, HLA-DRB1*5701 and DRB1*3501 is associated with HIV infections), 
specific HLA and activation of T-cells (for e.g. HLA B*5701 is associated with abacavir 
hypersensitivity, HLA A*3101 is associated with carbamazepine hypersensitivity, HLA 
B*1502 is associated with carbamazepine provoked Stevens Johnson syndrome, HLA 
B*5701 is associated with flucloxacillin induced liver injury) and specific HLA and 
immunogenicity against biologics (for e.g. HLA-DRB1*0401, HLA-DRB1*1601, HLA-
DRB1*0408, HLA-DRB1*0701, HLA-DR2, HLA-DQ6, DQB1*0602, HLA-DR15 is 
associated with formation of anti-IFN-β antibodies, HLA-DQA1*0102, HLA-DR4.1, DQ4, 
DQA1*0301, HLA-DRA-DRB1*1104 is associated with formation of anti-Factor VIII 
antibodies, HLA-DRB1*09-DQB1*0309 is associated with anti-erythropoietin antibodies) 
have been discovered. It is possible that stratifying individuals for treatment according to 
HLA can reduce risk for development of anti-drug antibodies against biologics. Additionally, 
strategies that can be employed to decrease immunogenicity is by eliminating T-cell epitopes 
(Jones et al. 2009). Depleting T-cell epitopes from therapeutic proteins has been confirmed to 
reduce immunogenicity and several deimmunised proteins are in clinical trials for example 
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antibody drug conjugates such as Brentuximab vedotin SGN-35 for Hodgkin lymphoma, 
Inotuzumab ozogamicin for non-Hodgkin lymphoma and Trastuzumab-DM1 for breast 
cancer (Alley, Okeley & Senter 2010; Baker & Jones 2007).  
5.6 Does a difference in regulatory T-cells frequencies and subsequent 
immunosuppressive function lead to Interferon beta 1a Rebif™ immunogenicity? 
In order to investigate the role of Tregs in immunogenicity the frequency of Tregs in PBMCs 
of IFN-β-1a Rebif™ neutralising antibodies positive, negative and healthy donors were 
investigated. The data suggest no significance in global Tregs. The functionalities of Tregs 
were assessed using Tregs suppression assay and no significant differences were found. Our 
Tregs project has number of limitations. Tregs from PBMCs were isolated and it was 
challenging to retain the functionalities of isolated Tregs. Furthermore, phytohaemagglutinin 
was used to stimulate Tregs in Tregs suppression assay. The use of antigenic stimulation for 
example using antigenic IFN-β-1a Rebif™ or peptides to stimulate the Tregs is more 
appropriate to understand the role of Tregs in immunogenicity. There is a potential strategy 
that can induce tolerance to biologics by expanding Tregs. Expanding induced Tregs ex vivo 
and injecting the same can be an option for inducing donor specific tolerance (Nesburn et al. 
2007). The studies on mice with interferons have shown anti-IFN IgG antibodies are inhibited 
by oramucosal administration (Meriter et al. 2001).  Nagal – Anderson C et al concludes the 
induction of tolerance in oromucosal administration is dependent on tolerising dendritic cells 
and Tregs (Nagler-Anderson & Shi 2001).  
Furthermore, T-cell epitopes which are associated with Tregs and termed as Tregitopes are 
being investigated for suppressing immunogenicity (Nakatsui, Wong & Groot 2008).  
5.7 Concluding remarks 
In conclusion, the work described in this thesis has sought to understand immunogenicity to 
IFN-β-1a Rebif™ in relapsing forms of multiple sclerosis through characterisation of 
humoral and cellular immune responses to IFN-β-1a Rebif™. 
The work detailed in this thesis has provided new information on the subclass profile of IFN-
β ADAs, the potential involvement of T helper cells and possible antibody epitopes within 
IFN-β. Future studies should be aimed at providing finer detail on the evolution of the ADA 
response and identify strategies to remove immunogenic determinants from IFN-β and other 
biologics.    
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Appendices  
Appendix 1 List of Biologics 
Biologic Type & Mechanism of action Indications Immune related adverse events 
Abatacept Fusion protein (CTLA4-Fc-IgG1) which binds 
to CD80 and/or CD86 to prevent interaction 
with CD28 and so inhibits selective T-cell co-
stimulation 
RA, JIA No boxed or product label 
warning issued 
 
Abciximab 
 
Is a glycoprotein (GP) IIb/IIIa receptor 
inhibitor that binds to GP IIb/IIIa receptor on 
the platelet, blocking interaction of fibrinogen 
with GP IIb/IIIa receptor which is a final 
pathway for aggregation of platelets  
Used as adjunct to percutaneous 
coronary intervention (a procedure to 
open the blocked arteries in the heart) 
Anaphylaxis (Guzzo & Nichols 
1999) 
Warning for thrombocytopenia 
on product label 
Adalimumab Human mAb which binds to TNF and blocks 
its interaction with its receptors 
RA, JIA, PsA, AS, CD Boxed warning for serious 
infections (tuberculosis and 
invasive fungal infections) and 
malignancy (lymphoma and 
leukaemia)  
Immunogenicity reported 
(Bartelds et al. 2011) 
Warnings for cytopenias: 
pancytopaenia, lymphopaenia and 
thrombocytopaenia on product 
label 
1
7
6
 
 
1
3
9
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Aflibercept Fusion protein (VGEF receptors 1 and 2 
extracellular domains:Fc-IgG1) which  
inhibits the binding and activation of cognate 
VEGF receptors 
Neovascular AMD, macular edema 
following CRVO  
Warnings for neutropenia and 
neutropenic complications on 
product label  
Agalsidase beta rh α-galactosidase enzyme that catalyze the 
hydrolysis of glycosphigolipids 
Fabry disease Warnings for anaphylactic and 
allergic reactions on product label 
Aldesleukin rhIL-2 which mimics endogenous IL-2 Metastatic renal cell carcinoma Boxed warning for capillary leak 
syndrome and infections 
Alefacept Fusion protein (soluble LFA-Fc-IgG1) that 
binds to CD2 and inhibits the interaction 
between CD2 and LFA3 during lymphocyte 
activation 
Adult moderate to severe chronic 
plague psoriasis 
Infections and malignancy 
reported in post marketing studies 
 
Alemtuzumab Humanised mAb that binds to CD52 on 
leukocytes and initiates antibody-dependent 
cellular-mediated lysis 
B-CLL Boxed warnings for cytopenias, 
infusion reactions and infections. 
Autoimmunity (Investigators et 
al. 2008) and immunogenicity 
(Somerfield et al. 2010) is also 
reported 
Abciximab Lysosomal glycogen-specific enzyme and 
provides exogenous source of α-glucosidase 
Pompe disease Boxed warning for anaphylaxis 
and allergic reactions 
 
1
7
7
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Anakinra rh IL-1RA derived from E Coli binds to IL-
1Rα and prevents the interaction between IL-1 
and IL-1R1 
RA No  boxed or product label 
warning issued 
 
Asparaginase 
erwinia 
chrysanthemi 
Asparagine specific enzyme which inhibits 
asparagine synthetase activity 
ALL who have developed 
hypersensitivity to E Coliderived 
asparaginase 
Warnings for serious 
hypersensitivity reactions on 
product label  
Basiliximab 
 
Chimeric mouse human mAb that binds to IL-
2Rα and prevents the interaction between IL-2 
and IL-2R 
Renal transplant rejection Warnings for hypersensitivity and 
anaphylaxis on product label 
Immunogenicity reported 
(Baudouin et al. 2003) 
Becaplermin rh platelet derived growth factor (GF) and 
promote chemotactic recruitment and 
proliferation of cells involved in wound repair 
Lower extremity diabetic neuropathic 
ulcers  
Warnings for increased rate of 
mortality secondary to 
malignancy on product label 
Bevacizumab rh monoclonal IgG1 antibody that binds to 
human vascular endothelial growth factor 
(VEGF) preventing interaction of VGEF to its 
receptors on the endothelial cells 
mCRC, non-small cell lung cancer, 
Gliobalstoma, mRCC 
Warnings for arterial and venous 
thromboembolic events on 
product label 
 
Belatacept Fusion protein (CTLA-4-Fc-IgG1) that binds to 
CD80 and/or CD86 to prevent the interaction 
with CD28 and therefore inhibits selective T-
cell co-stimulation 
Renal transplant rejection Boxed warning for post-
transplant lymphoproliferative 
disease (PTLD), malignancy and 
infections 
1
7
8
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Belimumab Human mAb that inhibits BLyS/BAFF SLE No  boxed or product label 
warning issued 
Hypersensitivity and anaphylaxis 
reported in post marketing studies 
Brentuximab 
vedotin 
Chimeric mouse-human mAb that forms 
antibody-drug conjugate CD30-specific mAb 
conjugated to monomethyl auristatin (MMAE) 
which induce cell cycle arrest and cause 
apoptosis 
Hodgkin lymphoma, and systemic 
anaplastic large cell lymphoma 
Boxed warning for PML 
Warnings for neutropenia and 
infection on product label (Gopal 
et al. 2012) 
Canakinumab Human mAb which binds to human IL-1β to 
prevent the interaction with IL-1R 
CAPS, FCAS, MWS Warnings for risk of infection on 
product label 
Catumaxomab Rat-mouse hybrid mAb bispecific antibody 
which binds to CD3-EpCAM and forms the 
bridge between cancer cells and T-cells 
Cancer and malignant ascites Boxed warnings for CRS and or 
SIRS 
Immunogenicity reported (Ruf et 
al. 2010) 
Capromab 
pendetide 
Murine mAb IgG1k directed against prostrate 
specific membrane antigen (PMSA)  
Tissue diagnosis of prostate cancer  Warnings for risk of anaphylaxis 
and allergic reactions on product 
label 
 
 
 
1
7
9
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Certolizumab 
pegol 
Pegylated Fab’ humanised mAb that binds to 
TNF and blocks its interaction with TNFR 
CD, RA Boxed warnings for serious 
infections and malignancy 
Warnings for significant 
cytopenia such as leukopenia, 
pancytopenia and 
thrombocytopenia on product 
label  
Severe skin reactions reported in 
post marketing studies 
Cetuximab EGFR antagonist and binds to EGFR and 
competitively inhibits binding of EGF and 
other ligands such as TGF-α (Kirkpatrick P et 
al 2004) 
Head and neck cancer, colorectal 
cancer 
Warnings for serious infusion 
reactions on product label 
Collagenase 
clostridium 
histolyticum 
Proteinases that can hydrolyse collagen 
resulting in lysis of collagen deposits.  
Dupuytren’s disease Warnings for injection site 
reactions on product label 
Daclizumab 
(withdrawn due to 
non-safety 
reasons) 
Humainsed mAb binds to IL-2 receptor and 
prevents the interaction between IL-2 and IL-
2R 
Renal transplant rejection No  boxed or product label 
warning issued 
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Denileukin diftitox Fusion protein (IL-2 and Diptheria toxin) 
which binds to CD25 of IL-2R and triggers 
toxin-induced cell death 
T-cell lymphoma Boxed warnings for severe 
infusion reactions and capillary 
leak syndrome 
Denosumab Human mAb prevents RANKL binding to 
receptors that inhibits osteoclast formation, 
function and survival 
Osteoporosis No  boxed or product label 
warning issued  
Hypersensitivity reactions 
reported in post marketing studies 
Dornase alfa rh DNase which cleaves extracellular DNA 
reduces the viscocity of purulent lung 
secretions 
CF No  boxed or product label 
warning issued 
Ecallantide  Plasma kallikrein inhibitor and binds to 
plasma kallikrein and blocks the binding site 
inhibiting conversion of kininogen to 
bradykinin.  
 
Acute attacks of hereditary 
angioedema 
Boxed warnings for anaphylaxis 
 
Eculizumab Humanised mAb that binds to complement 
complex C5 and inhibits its cleavage to C5a 
and C5b and prevents the formation of 
terminal complement complex C5b-9 
PNH, aHUS Boxed warnings for serious 
meningococcal infections  
Epoetin alfa Erythropoiesis-stimulating agent that mimics 
endogenous erythopoietin   
Treatment of anaemia due to CKD and 
chemotherapy in patients with cancer 
Warnings for immunogenicity on 
product label 
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Etanercept Fusion protein (TNFR2-IgG1) which binds to 
TNF and blocks its interaction with TNFR 
RA, JIA, AS, Psoriasis Boxed warnings for serious 
infections and malignancy 
Filgrastim Recombinat methionyl human G-CSF that 
mimics endogenous G-CSF 
AML, bone marrow transplant in 
cancer, blood progenitor cell 
collection and therapy, chronic 
neuropenia 
No boxed or product label 
warning issued 
Risk of splenic rupture and 
ARDS indicated in product label 
Galsulfase  Hydrolytic lysosomal glycosaminoglycan 
(GAG)-specific enzyme replacement  
Mucopolysaccharidosis VI (MPS VI; 
Maroteaux-Lamy syndrome) 
Risk of infusion reactions 
indicated on product label 
Golimumab Human mAb binds to TNF and blocks its 
interaction with TNFR 
RA, psoriatic arthritis and AS Boxed warnings for serious 
infections and malignancy  
Glucarpidase  Recombinant bacterial enzyme which causes 
hydrolyses of carboxyl-terminal glutamate 
residue from folic acid and methotrexate and 
converts methotrexate to inactive metabolites.  
Toxic plasma methotrexate 
concentrations in impaired renal 
function patients.   
 
Risk of serious allergic reactions 
indicated on product label  
Ibritumomab 
tiuxetan 
Mouse mAb, the Fab segment of the antibody 
targets CD20 on B-cells, allowing covalently 
linked radioactive yttrium, which emits a β 
particle to destroy the cell 
Follicular NHL Boxed warnings for acute 
infusion reactions, severe 
cutaneous and muco-cutaneous 
reactions and prolonged and 
severe cytopenia 
Anaphylaxis and immunogenicity 
reported (Jankowitz, Joyce & 
Jacobs 2008) 
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Idursulfase Recombinant human iduronate-2-sulfatase and 
provides exogenous substitute   
Hunter syndrome 
(Mucopolysaccharidosis II) 
Boxed warning for anaphylaxis  
Infliximab Chimeric mouse human mAb which binds to 
TNF and blocks its interaction with TNFR 
CD, paediatric CD, UC, paediatric 
UC, RA, AS 
Boxed warnings for serious 
infections and malignancy  
PML reported (Kumar, Bouldin 
& Berger 2010) 
Immunogenicity reported (Baert 
et al. 2003) 
Severe thrombocytopenia 
reported (Mocciaro et al. 2013) 
Interferon alpha rh IFN alpha that mimics endogenous 
interferon alpha 
Chronic hepatitis C, hairy cell 
leukemia, hairy cell leukemia, AIDS-
related Kaposi’s sarcoma, CML 
Boxed warnings for autoimmune 
reactions and infections 
Risk of cytopenia indicated in 
product label 
Immunogenicity reported (Strayer 
& Carter 2012) 
Interferon beta-1a hu IFN-β-1a that mimics endogenous 
interferon beta 
RRMS No boxed or product label warnings  
Anaphylaxis reported post marketing 
studies  
Immunogenicity reported 
(Strayer & Carter 2012) 
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Interferon beta-1b hu IFN-β-1b that mimics endogenous 
interferon beta 
RRMS No boxed warnings  
Risk of lymphopenia indicated on 
product label 
Immunogenicity reported (Strayer 
DR et al 2012) 
Interferon gamma rh IFN gamma that mimics endogenous 
interferon gamma 
Chronic granulomatous disease and 
osteopetrosis 
No boxed or product label 
warnings issued 
Ipilimumab Human mAb which binds to CTLA-4 to block 
the interaction of CTLA4 with its ligands 
CD80 and CD86 
Unresectable and/or metastatic 
melanoma  
Boxed warning for immune-
mediated adverse reactions  
Laronidase Endogenous enzyme that replaces the missing 
or deficient lysosomal enzyme in MPS-1, 
alpha-L-iduronidase. 
Hurler and Hurler-Scheie forms of 
MPS-1 
Boxed warning for anaphylaxis 
Muromonab-CD3 Mouse mAb which kills CD3 positive cells by 
inducing antibody-dependent cell mediated 
toxicity and complement-dependent 
cytotoxicity 
Organ transplant rejection Boxed warnings for CRS and 
anaphylactic reactions  
Warnings for infections and 
malignancy on product label  
Immunogenicity reported (Jaffers 
GJ et al 1986) 
 
 
1
8
4
 
185 
 
Natalizumab Humanised mAb that binds to α4-subunit of 
α4β1 and α4β7 integrins and inhibits α4 
integrin-mediated adhesion of leukocytes 
(except for neutrophils) to their counter-
receptors 
RRMS and CD Boxed warnings for serious 
infections in particular PML 
Immunogenicity reported 
(Sorensen et al. 2011) 
Nofetumomab Fab fragment of IgG2a murine mAb used for 
diagnostic evaluation of fresh human tumors 
Detection of untreated small cell lung 
cancer  
Warnings for allergic and 
anaphylaxis reactions on product 
label 
Ofatumumab Human mAb that targets CD20 and facilitates 
cell lysis due to complement-dependent cell-
mediated cytotoxicity and antibody-dependant 
cell-mediated cytotoxicity of B-cells 
CLL No boxed or product label 
warnings issues 
Infections reported (Coiffier et al. 
2008) 
Omalizumab binds to IgE 
and prevents IgE-mediated activation of mast 
cells and basophils 
Asthma Boxed warnings for anaphylaxis 
parasitic (Helminth) infections 
reported (Cruz et al. 2007) 
Oprelvekin  
 
Recombinant IL-11 a thrombotic GF which 
stimulates megakaryocytopoiesis and 
thrombopoiesis 
Severe thrombocytopenia in adults  Boxed warnings for allergic 
reactions including anaphylaxis  
Panitumumab Epidermal growth factor receptor antagonist 
that inhibits the binding of ligands for the 
receptors 
mCRC  Boxed warnings for dermatologic 
toxicity and infusion reactions 
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Palifermin Mucocutaneous epithelial human GH and 
enhance the growth of epithelial cells 
Severe oral mucositis in patients with 
hematologic malignancies 
No boxed or product label 
warnings issues 
Palivizumab Humanised mAb with anti-RSV activity Serious lower respiratory tract disease 
in children 
No boxed warnings  
Warnings for anaphylaxis and 
serious hypersensitivity reactions 
including immunogenicity on 
product label 
PEGinterferon 
alfa-2a 
rh IFN alpha that mimics endogenous 
interferon alpha 
 Chronic hepatitis C  Boxed warnings issued for 
autoimmune reactions and 
infections. 
Risk of cytopenia indicated in 
product label 
PEGinterferon 
alfa-2b 
rh IFN alpha that mimics endogenous 
interferon alpha 
Chronic hepatitis C Boxed warnings issued for 
autoimmune reactions and 
infections. 
Risk of cytopenia indicated in 
product label 
PEGloticase PEGylated recombinant uricase which 
catalyze the oxidation of uric acid to allantoin 
and therefore decreases the serum uric acid 
Chronic gout in adults Boxed warnings issued for 
anaphylaxis and infusion 
reactions 
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Pertuzumab HER2 receptor antagonist and inhibits ligand-
initiated intracellular signalling which results 
in cell growth arrest and apoptosis 
HER2-positive metastatic breast 
cancer 
Risk of infusion associated 
reactions, hypersensitivity 
reactions or anaphylaxis are 
indicated on product label 
Rasburicase Recombinant urate-oxidase which catalyze the 
enzymatic oxidation of soluble uric acid into 
inactive and more soluble metabolite 
Management of plasma Uric acid 
levels in children and adults suffering 
from Leukemia, lumphoma and solid 
tumour malignancies. 
Boxed warning issued for 
anaphylaxis 
 
Ranibizumab VGEF inhibitor and binds to biologically 
active VGEF110 hence reducing endothelial 
cells  proliferation, vascular leakage and new 
blood vessel formation 
Neovascular AMD, macular edema 
following RVO and DME 
No boxed or product label 
warnings issues 
Rilonacept Fusion protein IL-IR-Fc-IgG1 which binds to 
IL-1β and neutralises its activity by blocking 
its intersection with IL-1R 
CAPS No boxed or product label 
warnings issues 
Rituximab Chimeric mouse human mAb that binds to 
CD20 on B-cells and triggers B-cell lysis by 
complement-dependent and antibody-
dependent cell-mediated cytotoxicity. 
NHL, CLL, RA, Wegener’s 
granulomatosis and microscopic 
polyangiitis 
Boxed warnings for acute 
infusion reactions and/or CRS, 
TLS, severe mucocutaneous 
reactions and PML  
Romiplostim TPO receptor agonist that activates TPO 
receptor and increases the platelet production 
Thrombocytopenia in patients with 
chronic ITP 
No boxed or product label 
warnings issues 
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Sargramostin rh GM-CSF that mimics endogenous GM-CSF Cancer, bone marrow transplant and 
neutropenia 
No boxed or product label 
warnings issues 
Tenecteplase Recombinant tPA binds to fibrin rich clot and 
cleaves the bonding and hence exerts the 
thrombolytic effect 
Acute MI and lysis of intracoronary 
emboli 
No boxed or product label 
warnings issues 
Tositumomab Mouse mAb which binds to CD20 positive 
cells and cause cell death  through ionising 
radiation when it is radiolabelled and also 
induces complement-dependent and antibody-
dependent cell-mediated cytotoxicity 
Non-Hodgkin’s lymphoma (CD20 
positive, follicular)  
Boxed warnings for severe 
allergic reactions and/or 
anaphylaxis, adn prolonged and 
severe cytopenia  
Malignancy warning on product 
label  
Immunogenicity reported 
(Buchegger et al. 2006) 
Trastuzumab Is a mediator of antibody-dependent cellular 
cytotoxicity and inhibit the proliferation of 
human tumour cells that overexpress HER2 
HER2 overexpressing breast cancer, 
HER2-overexpressing metastatic 
gastric or gastroesophageal junction 
adenocarcinoma 
Boxed warnings for infusion 
reactions 
Hypersensitivity and infections 
reported on post marketing 
studies 
Ustekinumab Human mAb which blocks the function of IL-
12 and IL-23 by binding to the p40 subunit of 
these cytokines 
Psoriasis No boxed or product label 
warnings issued 
Allergy and/or hypersensitivity 
reported in post marketing studies 
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Appendix Table 1: The comprehensive list of FDA and EU approved biologics products. Abbreviations: AE – Adverse events; aHUS – 
Atypical haemolytic-uremic syndrome; AIDS – Acquired immune deficiency syndrome; ALL – Acute lymphoblastic leukemia; AMD – Acute 
myeloid leukemia; AMD – Age related macular degeneration; AS – Alkylosing spondylitis; BAFF – B-cell activating factor; B-CLL – B-cell 
chronic lymphocytic leukemia; CAPS – Cryopyrin associated periodic syndrome; CD – Crohn’s disease; CD – Cluster of differentiation; CF – 
Cystic fibrosis; CKD – Chronic kidney disease; CML – Chronic myeloid leukaemia; CRVO – Central retinal vein occlusion; CTLA – Cytotoxic 
T-lymphocyte antigen; DME – Diabetic macular edema; DNA – Deoxy ribonucleic acid; EGFR – Endothelial growth factor receptor; EpCAM – 
Epithelial cell adhesion molecule; FCAS – Familial cold autoinflammatory syndrome; GF – Growth factor; GM-CSF – Granulocyte macrophage 
colony-stimulating factor; HER – Human epidermal growth factor receptor; IFN – Interferon; IL – Interleukin; JIA – Juvenile idiopathic 
arthritis; LFA – Lymphocyte function associated protein; MAb – Monoclonal antibody; mCRC – metastatic colorectal carcinoma; MI – 
Myocardial infarction; MMP – Matrix metalloproteinase; MPS – Mucopolysaccharidosis; mRCC – metastatic renal carcinoma; MWS – Muckle-
Wells syndrome; NHL – Non-Hodgkin lymphoma; PEG – Polyethylene glycol; PML – Progressive multifocal leukoencephalopathy; PNH – 
Paroxysmal nocturnal hemoglobinuria; PsA – Psoriatic arthritis; RA – Rheumatoid arthritis; RANKL – Receptor activator of nuclear factor 
kappa B ligand; rh – recombinant; r-methu G-CSF – recombinant methionyl human granulocyte colony-stimulating factor; RRMS – Relapsing 
remitting multiple sclerosis; RSV – Respiratory syncytical virus; RVO – Retinal vein occlusion; SJIA – Systemic juvenile idiopathic arthritis; 
SLE – Systemic lupus erythematosus; TLS – Tumor lysis sundrome; TNF – Tumor necrosis factor; TNFR – Tumor necrosis factor receptor; 
TPO – Thrombopoietin; tPA – Tissue plasminogen activator; VEGF – Vascular endothelial growth factor. 
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Appendix 2 Search Strategies 
MEDLINE on Ovid 
Search: ((((((((((((((((((((("Multiple Sclerosis, Relapsing-Remitting"[Mesh]) OR 
"Demyelinating Diseases"[Mesh:noexp]) OR "Demyelinating Autoimmune Diseases, 
CNS"[Mesh:noexp])) OR "relapsing remitting multiple sclerosis"[Title/Abstract]) OR 
"multiple sclerosis"[Title/Abstract]) OR "remitting relapsing multiple 
sclerosis"[Title/Abstract]) OR "acute relapsing multiple sclerosis"[Title/Abstract]) OR 
"demyelinating disease"[Title/Abstract]) OR "demyelinating disorders"[Title/Abstract])))) 
OR ((("Encephalomyelitis"[Mesh:noexp]) OR "Encephalomyelitis, Acute 
Disseminated"[Mesh]) OR "Optic Neuritis"[Mesh])) OR (((("encephalomyelitis 
adem"[Title/Abstract]) OR "encephalomyelitis"[Title/Abstract]) OR "optic 
neuritis"[Title/Abstract]) OR "transverse myelitis"[Title/Abstract])) OR ("Myelitis, 
Transverse"[Mesh:noexp]))))) AND (((((((((((((((((("Interferon Type I"[Mesh]) OR 
"Interferon-beta"[Mesh]) OR "interferon beta 1a"[Supplementary Concept]) OR "interferon 
beta-1b"[Supplementary Concept])) OR "avonex"[Title/Abstract]) OR 
"rebif"[Title/Abstract]) OR "betaferon"[Title/Abstract]) OR "betaseron"[Title/Abstract]) OR 
"extavia"[Title/Abstract]) OR Beta-Seron[Title/Abstract])) AND 
(((("Antibodies/blood"[Mesh:noexp]) OR "Immunoassay"[Mesh:noexp]) OR ("Interferon-
beta/immunology"[Mesh]) AND ("Interferon-beta/antagonists and inhibitors"[Mesh] OR 
"Interferon-beta/therapeutic use"[Mesh])) OR "Neutralization Tests"[Mesh])))))) OR 
"immunogenicity/antibody"[Title/Abstract] OR "immunogenicity"[Title/Abstract])) AND 
((((("Antibodies/blood"[Mesh:noexp]) OR "Immunoassay"[Mesh:noexp]) OR ("Interferon-
beta/immunology"[Mesh]) AND ("Interferon-beta/antagonists and inhibitors"[Mesh] OR 
"Interferon-beta/therapeutic use"[Mesh])) OR "Neutralization Tests"[Mesh]))) AND 
((((((((("Randomized Controlled Trial"[Publication Type]) OR "Controlled Clinical 
Trial"[Publication Type])) OR (((((((((("Randomized Controlled Trial"[Publication Type]) 
OR "Controlled Clinical Trial"[Publication Type])) OR "drug therapy"[Title/Abstract]) OR 
"randomized"[Title/Abstract]) OR "randomised"[Title/Abstract]) OR 
"randomly"[Title/Abstract]) OR "placebo"[Title/Abstract]) OR "trials"[Title/Abstract]) AND 
"groups"[Title/Abstract])))) OR "longitudinal study"[Title/Abstract])) OR ("Longitudinal 
Studies"[Mesh])) 
EMBASE on Ovid  
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#43       #18 AND #28 AND #33 AND #42 AND [humans]/lim 
#42        #34 OR #35 OR #36 OR #37 OR #38 OR #39 OR #40 OR #41 
#41       'longitudinal study':ab,ti 
#40       'longitudinal study'/exp 
#39        'trials':ab,ti 
#38       'placebo':ab,ti 
#37       'randomly':ab,ti 
#36      'randomised':ti 
#35      'controlled clinical trial'/exp 
#34       'randomized controlled trial'/exp 
#33      #29 OR #31 OR #32 
#32      'neutralizing antibodies':ab,ti 
#31     'nabs':ab,ti 
#29      'neutralizing antibody'/exp 
#28      #19 OR #20 OR #21 OR #22 OR #23 OR #24 OR #25 OR #26 OR #27 
#27      'extavia':ab,ti 
#26      'betaseron':ab,ti 
#25     'betaferon':ab,ti 
#24      'rebif':ab,ti 
#23     'avonex':ab,ti 
#22     'interferon beta 1b'/mj 
#21     'interferon beta 1a'/mj 
#20     'interferon beta'/mj 
#19     'interferon type i'/mj 
#18      #2 OR #3 OR #4 OR #5 OR #6 OR #7 OR #8 OR #9 OR #10 OR #11 OR #12 OR 
#13 OR #14 OR #15    OR #16 OR #17 
#17     'myelitis transverse'/mj 
#16    'transverse myelitis':ab,ti 
#15    'optic neuritis':ab,ti 
#14    'encephalomyelitis':ab,ti 
#13    'encephalomyelitis adem':ab,ti 
#12    'optic neuritis'/mj 
#11    'encephalomyelitis acute disseminated'/exp 
#10    'encephalomyelitis'/mj 
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#9     'demyelinating disorders':ab,ti 
#8     'demyelinating disease':ab,ti 
#7     'acute relapsing multiple sclerosis':ab,ti 
#6     'multiple sclerosis':ab,ti 
#5     'relapsing remitting multiple sclerosis':ab,ti 
#4     'demyelinating autoimmune diseases, cns'/mj 
#3     'demyelinating diseases'/mj 
#2     'multiple sclerosis relapsing remitting'/exp 
CENTRAL on The Cochrane Library 
Search: ((((((((((((((((((((("Multiple Sclerosis, Relapsing-Remitting"[Mesh]) OR 
"Demyelinating Diseases"[Mesh:noexp]) OR "Demyelinating Autoimmune Diseases, 
CNS"[Mesh:noexp])) OR "relapsing remitting multiple sclerosis"[Title/Abstract]) OR 
"multiple sclerosis"[Title/Abstract]) OR "remitting relapsing multiple 
sclerosis"[Title/Abstract]) OR "acute relapsing multiple sclerosis"[Title/Abstract]) OR 
"demyelinating disease"[Title/Abstract]) OR "demyelinating disorders"[Title/Abstract])))) 
OR ((("Encephalomyelitis"[Mesh:noexp]) OR "Encephalomyelitis, Acute 
Disseminated"[Mesh]) OR "Optic Neuritis"[Mesh])) OR (((("encephalomyelitis 
adem"[Title/Abstract]) OR "encephalomyelitis"[Title/Abstract]) OR "optic 
neuritis"[Title/Abstract]) OR "transverse myelitis"[Title/Abstract])) OR ("Myelitis, 
Transverse"[Mesh:noexp]))))) AND (((((((((((((((((("Interferon Type I"[Mesh]) OR 
"Interferon-beta"[Mesh]) OR "interferon beta 1a"[Supplementary Concept]) OR "interferon 
beta-1b"[Supplementary Concept])) OR "avonex"[Title/Abstract]) OR 
"rebif"[Title/Abstract]) OR "betaferon"[Title/Abstract]) OR "betaseron"[Title/Abstract]) OR 
"extavia"[Title/Abstract]) OR Beta-Seron[Title/Abstract])) AND 
(((("Antibodies/blood"[Mesh:noexp]) OR "Immunoassay"[Mesh:noexp]) OR ("Interferon-
beta/immunology"[Mesh]) AND ("Interferon-beta/antagonists and inhibitors"[Mesh] OR 
"Interferon-beta/therapeutic use"[Mesh])) OR "Neutralization Tests"[Mesh])))))) OR 
"immunogenicity/antibody"[Title/Abstract] OR "immunogenicity"[Title/Abstract])) AND 
((((("Antibodies/blood"[Mesh:noexp]) OR "Immunoassay"[Mesh:noexp]) OR ("Interferon-
beta/immunology"[Mesh]) AND ("Interferon-beta/antagonists and inhibitors"[Mesh] OR 
"Interferon-beta/therapeutic use"[Mesh])) OR "Neutralization Tests"[Mesh]))) AND 
((((((((("Randomized Controlled Trial"[Publication Type]) OR "Controlled Clinical 
Trial"[Publication Type])) OR (((((((((("Randomized Controlled Trial"[Publication Type]) 
193 
 
OR "Controlled Clinical Trial"[Publication Type])) OR "drug therapy"[Title/Abstract]) OR 
"randomized"[Title/Abstract]) OR "randomised"[Title/Abstract]) OR 
"randomly"[Title/Abstract]) OR "placebo"[Title/Abstract]) OR "trials"[Title/Abstract]) AND 
"groups"[Title/Abstract])))) OR "longitudinal study"[Title/Abstract])) OR ("Longitudinal 
Studies"[Mesh])) 
Clinicaltrials.gov 
Search: Neutralising antibodies and multiple sclerosis 
Appendix 3 Study Eligibility Screening Form 
Study ID: Reviewer: Date: 
Question 1: Did some or all of the 
participants received IFN-β 
Avonex™ or Rebif™ or 
Betaferon/Betaseron™ or 
Extavia™? 
If no: EXCLUDE 
If yes: go to Question 2 
If unsure: go to Question 2 
Question 2: Are some or all of the 
participants 
Adults >18 years undergoing 
treatment for multiple sclerosis and 
fulfilling Poser (Poser CM et al 
1983) or McDonald criteria 
(McDonald WI et al 2001) or 
defined by the study authors? 
If no: EXCLUDE 
If yes: go to Question 3 
If unsure: go to Question 3 
Question 3: Does the paper report a 
randomised controlled trial or a non-
randomised study which included 
>20 patients? 
If no: EXCLUDE 
If yes: INCLUDE 
In unsure: INCLUDE 
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Appendix 4 Data collection form for randomised studies 
 
 
 
Paper ID: Reviewer: Date: 
Study Characteristics 
Number of participants  
Number of participants in each treatment 
group 
 
Year completed  
Setting  
Inclusion criteria  
Definition of neutralising antibody positivity  
Length of follow up  
Participants 
Age  
Gender  
Underlying disease  
Indication for  IFN-β  treatment  
Treatment 
No. of treatment groups  
Avonex™ and/or Rebif™ and/or 
Betaferon/Betaseron™ and/or Extavia ™ 
 
Dosage   
Route of administration  
Frequency of treatment  
Outcomes 
Status of neutralising antibodies   
Method used to detect neutralising antibodies  
Additional data relating to neutralising antibodies 
Additional data on neutralising antibodies  
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Appendix 5 Data collection form for non-randomised studies 
 
 
 
Paper ID: Reviewer: Date: 
Study Characteristics 
Number of participants  
If there were two treatment groups, number 
of participants in each treatment group 
 
Year completed  
Setting  
Inclusion criteria  
Definition of neutralising antibody positivity  
Length of follow up  
Participants 
Age  
Gender  
Underlying disease  
Indication for  IFN-β  treatment  
Treatment 
Avonex™ and/or Rebif™ and/or 
Betaferon/Betaseron™  
and/or Extavia™ 
 
Dosage   
Route of administration  
Frequency of treatment  
Outcomes 
Status of neutralising antibodies   
Method used to detect neutralising antibodies  
Additional data relating to neutralising antibodies 
Additional data on neutralising antibodies  
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Appendix 6 Elements adapted from McHarm Scale 
1. Was NAb positivity pre-defined using standardised or precise definitions? 
2. Was the mode of NAb data collection specified as active? 
3. Did the study specify the baseline, timing and frequency of the NAb data 
collection? 
4. Did the authors use standard scales(s) or checklist(s) for NAb data collection? 
5. Is there a possibility of selective outcome reporting? 
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Appendix 7 
 NIBSC Hertfordshire CDSS Liverpool 
Samples IFN--aRebif™ 
antibodies detected 
NAbs titres Screening Screening NAbs 
titres 
IFN--aRebif™ 
antibodies detected 
Neutralisation 
assay 
Neutralisation assay EC50 Binding 
assay 
Neutralisation 
assay 
EC50 IFN--aRebif™ 
antibodies detected 
MxA 
MxA assay MxA assay ECL assay ECL assay ECL assay ELISA  ng/ml Immunoblot 
P1 Yes 
 
200 Yes Yes 25 Discontinued 
P3 Yes 
 
>1000 Yes Yes 240  Yes 1186 Yes 100% 
P7 Yes 
 
<10 No No    No  50 No 
P10 Yes 
 
>1000 Yes Yes 700  Yes 1094 Yes 100% 
P13 Yes 
 
>1000 Yes Yes 380  Yes 1137 Yes 100% 
P14 Yes 
 
>1000 Yes Yes 1000  Yes 1013 Yes 100% 
P15 Yes 
 
>1000 Yes Yes 780  Yes 1217 Yes 100% 
P28 Yes 
 
850 Yes Yes 35  Yes 213 Yes >75% 
P29 Yes 
 
80 Yes Yes 8  Yes 782 Yes <10% 
P30 Sample not available for analysis   Yes 725 Yes >75% 
Appendix Table 2: Comparision of NIBSC, Hertfordshire and CDSS, Liverpool binding and neutralising antibodies data.
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Appendix 8 
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Appendix Figure 1: LC-MS ion current chromatograms for predicted IFN-β-1a Rebif™ 
peptides. The appendix Figures 1a, b, c, d, e, f, g, h, i and j indicates the molecular mass of 
each IFN-β-1a Rebif™ peptides 1, 2, 3, 4 and 5 and characteristic fragments are shown in 
arrows for the individual amino acids.  
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